Title of Invention

"THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY"

Abstract To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I): [wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: -CONR5R6 (in which any one of R5 and R6 is a hydrogen atom) ] .
Full Text Technical Field
[0001]
The present invention relates to thienopyrazole derivatives,
pharmaceutically acceptable salts and solvates thereof, having selective
PDE 7 (phosphodi.esterase VII) inhibiting effect. Further, the present
invention relates to an intermediate compounds for preparing said theino-
pyrazole derivatives and a process for producing them. These compounds
are effective compounds for treating various kinds of diseases such as
allergic diseases, inflammatory diseases and immunological diseases.
Background Art
[0002]
Cyclic AMP (cAMP) or cyclic GMP (cGMP), which is an intracellular
second messenger substance, is decomposed and inactivated by
phosphodiesterases (PDE 1 to PDE 11) . The PDE 7 selectively decomposes
cAMP, and is characterized as an enzyme which is not inihibited by rolipram.
Rolipram is a selective inhibitor of PDE 4, which decomposes cAMP similarly.
[0003]
It is suggested that PDE 7 plays an important role for activating
T cells (Beavo, et al., Science, 283, 848 (1999)), and is well known that
activation of 0-cell is concerned with the exacerbation of allergic
diseases, inflammatory diseases or immunological diseases. These
diseases are for example bronchial asthma, chronic bronchitis, chronic
obstructive pulmonary disease, allergic rhinitis, psoriasis, atopic
dermatitis, conjunctivitis, osteoarthritis, rheumatoid arthritis,
multiple sclerosis, systemic lupus erythematosus, inflammatory bowel
disease, hepatitis, pancreatitis, encephalomyelitis, sepsis, Crohn's
disease, rejection reaction in transplantation, graft versus host disease
(GVH disease), and restenosis after angioplasty [J. Allergy Clin.

Immunol., 2000 Nov; 106(5 Suppl.) : .3221-6; An. J. Respir. Crit. Care Med.,
1996 Feb; 153(2): 629-32; Am. J. Respir. Crit. Care Med. , 1999 Nov; 160(5
Pt 2): S33-7; Clin. Exp. Allergy, 2000 Feb; 30(2): 242-54; Hosp. Med.,
1998 Jul; 59(7): 530-3; Int. Arch. Allergy Immunol., 1998 Mar; 115(3):
179-90; J. Immunol., 1991 Feb 15; 146(4) : 1169-74; Osteoarthritis Cartilage,
1999 Jul; 7 (4) : 401-2; Rheum. Dis. Clin. North Am., 2001 May; 27 (2) : 317-34;
J. Autoimmun., 2001 May; 16(3): 187-92; Curr. Rheumatol. Rep., 2000 Feb;
2(1) : 24-31; Trends Immunol., 2001 Jan; 22 (1) : 21-6; Curr. Opin. Immunol.,
2000 Aug; 12(4):: 403-8; Diabetes Care, 2001 Sep; 24(9): 1661-7; J.
Neuroimraunol., 2000 Nov 1; 111(1-2): 224-8; Curr. Opin. Immunol., 1997
Dec; 9(6) : 793-9; JAMA, 1999 Sep 15; 282(11) :1076-82; Semin. Cancer Biol.,
1996Apr; 7(2) : 57-64; J. Interferon Cytokine Res., 2001 Apr; 21(4) : 219-21] .
Therefore, it is considered that a compound having PDE 7 inhibiting
effect is useful for treating various kinds of diseases such as allergic
diseases, inflammatory diseases or immunological diseases concerned with
T cells..
[0004]
There has been proposed that many compounds selectively inhibit
PDE 7. There can be mentioned the examples such as imidazopyridine
derivatives (Parent Document 1) , dihydropurine derivatives (Patent
Document 2) , pyrrole derivatives (Patent Document 3) ,
benzothiopyranoimidazolone derivatives (Patent Document 4) , heterocyclic
compounds (Patent Document 5; Patent Document 6) , quinazoline and
pyridopyrimidine derivatives (Patent Document 7), spiro tricyclic
compounds (PatentDocument 8) , thiazole andoxathiazolederivatives (Patent
Document 9), sulfonamide derivatives (Patent Document 10), hetero-
biarylsulfonamicle derivatives (Patent Document 11) , dihydroisoquinoline
derivatives (Patent Document 12) , guanine derivatives (Non-Patent Document
1), benzothiadiazine derivatives and benzothienothiadiazine derivatives
(Non-Patent Document 2, and Non-Patent Document 3) . However, no curative
medicines having PDE 7 inhibiting effect as main pharmacological mechanism
have developed up to now.
[0005]

Though some compounds having thienopyrazole skeleton have been
known (Patent Documents 13 - 24; Non-Patent Documents 4-8), there is
no suggestion that these compounds have PDE 7 inhibiting effect. Further,
the method for producing the thienopyrazole derivatives of the present
invention has been reported (Won-Patent Documents 9 - 11) ; however, the
substituents on ;he thienopyrazole skeleton are different from those of
the present invention.
[0006]
Patent Document 1: International Patent Publication WO 01/34,601
Patent Document 2: International Patent Publication WO 00/68,203
Patent Document 3: International Patent Publication WO 01/32,618
Patent Document 4: DE Patent 19,950,647
Patent Document 5: International Patent Publications WO 02/88,080
Patent Document 6: International Patent Publications WO 02/87,513
Patent Document 7: International Patent Publication WO 02/102,315
Patent Document 8: International Patent Publication WO 02/74,754
Patent Document 9: International Patent Publication WO 02/28,847
Patent Document 10: International Patent Publication WO 01/98,274
Patent Document 11: International P£itent Publication WO 01/74,786
Patent Document 12: International Patent Publication WO 02/40,450
Patent Document 13: International Patent Publication WO 02/100,403
Patent Document 14: International Patent Publication WO 02/79,146
Patent Document 15: International Patent Publication WO 02/66,469
Patent Document 16: International Patent Publication WO 01/90,101
Patent Document 17: U.S. Patent No. 6,022,307
Patent Document 18: International Patent Publication WO 03/024,962
Patent Document 19: International Patent Publication WO 03/029,245
Patent Document 20: International Patent Publication WO 03/040,096
Patent Document 21: International Patent Publication WO 03/097,617
Patent Document 22: International Patent Publication WO 03/099,821
Patent Document 23: International Patent Publication WO 97/27,200
Patent Document 24: U.S. Patent No. 3,649,641
[0007]

Non-Patent Document 1: Bioorg. Med. Cham. Lett., 11(2001), 1081
Non-Patent Document 2: J. Med. Cnem., 43(2000), 683
Non-Patent Document 3: Eur. J. Med. Chem., 36(2001), 333
Non-Patent Document 4: Russ. J. Org. Chem., 39(2003), 893
Non-Patent Docuir.ent 5: Aknos Consulting and Solutions GmbH Co., Catalog:
Akos samples
Non-Patent Document 6: Phosphorus, sulfur and silicon and related Elements,
157(2000), 107
Non-Patent Document 7: Zhurnal Organisheskoi Khimii., 9(1973), 2416
Non-Patent Document 8: Zhurnal Organisheskoi Khimii., 5(1969), 1498
Non-Patent Document 9: Phosphorus, sulfur and s ilicon and related Elements,
157(2000), 107
Non-Patent Document 10: Chinese Chemical Letters, 10(3), (1999). 189
Non-Patent Document 11: Indian Journal of Chemistry, Section B: Organic
Chemistry Including Medicinal Chemistry, 35B(7), (1996), 715
Disclosure of Invention
The Problem to be Solved in The Invention
[0008]
The purpose of the present invention is to provide novel compounds
having PDE 7 inhibiting activity, and PDE 7 inihibitors containing said
inhibitors as an active ingredient. Further, the present invention
provices useful intermediate compounds for manufacturing the
above-mentioned novel compounds.
[0009]
The compounds of the present invention inhibit PDE 7 selectively,
and therefore, enhance cellular cAMP level. Consequently, the compounds
of the present invention are useful for treating various kinds of diseases
such as allergic diseases, inflammatory diseases or immunological diseases
by inhibiting the activation of T-cells.
[0010]
For example, the compounds of the present invention are useful for
treating or preventing the diseases such as bronchial asthma, chronic

bronchitis, chronic obstructive pulmonary disease, allergic rhinitis,
psoriasis, atopic dermatitis, conjunctivitis, osteoarthritis, rheumatoid
arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory
bowel disease, hepatitis, pancreatitis, encephalomyelitis, sepsis,
Crohn's disease, rejection reaction in transplantation, GVH disease,
restenosis after angioplasty.
Means to Solve The Problem
[0011]
Through extensive investigations of researching compounds having
the capabilities of inhibiting PDE 7, the present inventors discovered
that the compounds having thienopyrazole skeleton in the molecule
represented by the formula (I) mentioned below possess potent and selective
PDE 7 inhibiting effect, and thus, completed the present invention.
[0012]
Accordingly, as one aspect of the present invention, it is provided
thienopyrazole compounds represented by the following formula (I):
[0013]
[Formula 1]
wherein :
R1 is substituted or unsubstituted C3-C8 alkyl group, substituted
or unsubstitiuted cycloalkyl group or substituted or unsubstituted
heterocycloalkyl group;
R2 is a hydrogen atom or substituted or unsubstituted C1-C3 alkyl
group;
R3 is a hydrogen atom, substituted or unsubstituted C1-C3 alkyl group,
or a halogen atom;
R4 is substituted or unsubstituted aryl group, substituted or

unsubstituted heteroaryl group, or a group -CONR5R° or -C02R7;
R and R6 are, same or different from each other, a hydrogen atom;
C1-C6 alkyl group which may be substituted by a halogen atom, substituted
or unsubsituted aryl group, substituted or unsubsituted heteroaryl group,
substituted or unsubsituted heterocycloalkyl group, substituted or
unsubstitutedcycloalkyl group, agroup-NR7COR8, -COR8, -NR9R10; substituted
or unsubstituted cycloalkyl group; substituted or unsubstituted
heterocycloalkyl group; substituted or unsubstituted aryl group;
substituted or unsubstituted heteroaryl group; or substituted or
unsubstituted heterocycloalkyl group in which the ring is formed together
with the nitrogen atom binding R5 and R6;
R7 is a hydrogen atom, or substituted or unsubstituted C1-C3 alkyl
group;
R8 is substituted or unsubstituted heterocycloalkyl group, or a
a group -OH, -OR7 or -NR9R10;
R9 and R10 are, same or different from each other, a hydrogen atom,
substituted or unsubstituted C1-C3 alkyl group, substituted or
unsubstituted heterocycloalkyl group; substituted or unsubsituted acyl
group; a group -S02R7, or substituted or unsubstituted heterocycloalkyl
group in which the ring is formed together with the nitrogen atom binding
R5 and R6;
or pharmaceutically acceptable salts or solvates thereof.
[0015]
Another aspect of the present invention, it is provided PDE 7
inhibiting composition containing the thienopyrazole compounds mentioned
above, or pharmaceuticalY acceptable salts or solvates thereof as an
active ingredient.
[0016]
Still another aspect of the present invention, it is provided a
method for preparing the thienopyrazole compounds represented by the
formula (I) .
In particular, the method is comprised by chlorination of
pyrazole-5-one derivative represented by the formula (VI):

7

wherein, R1 and R2 have the same meanings as defined above;
5 and then, by an electrophilic substitution reaction of the resulting
compound without separation to give the pyrazole derivative of the formula
(IV):
[0018]
10
wherein, R1, R2 and R3 have the same meanings as defined above;
then, by reacting the resulting pyrazole derivative of formula (IV) with
the compound of the formula (III) in the presence of base:
[0019]

wherein, R4 has the same meanings as defined above;
to give the compound of the formula (II):
[00201

wherein, R1, R2, R3 and R4 have the same meanings as defined above;
and then, by treating the resulting compound of formula (II) with base

to give thienopyrazole compound of the formula (I):
[0021]

i wherein, R1, R2, R3 and R4 have the same meanings as defined above.
[0022]
Additionally, the intermediate compound of the formula (IV) can
be obtained by electrophilic substitution reaction of chloropyrazole
compound of the formula (V):
I [Formula 7]
wtierem, iC ana R2 have the same meanings as defined above.
[0023]
Furthermore, the compound of the formula (I) can be obtained by
> one pot synthesis from the compound of the formula (IV) without separation
of the intermediate compound of the fromula (II) . In paticurally, it is
provided the manufacturing method for the compound of the formula (I),
in which R3 is a hydrogen atom.
) Effects of The Invention
[0024]
The compounds of the present invention inhibit PDE 7 selectively,
and therefore, the compounds of the present invention are useful for
treating or preventing the diseases such as bronchial asthma, chronic
) bronchitis, chronic obstructive pulmonary disease, allergic rhinitis,
psoriasis, atopic dermatitis, conjunctivitis, osteoarthritis, rheumatoid
arthritis, multiple sclerosis, systemic lupus erythematosus, inflammatory

bowel disease, hepatitis, pancreatitis, encephalomyelitis, septicemia
sepsis, Crohn's disease, rejection reaction of transplantation, GVHdisease,
restenosis after angioplasty.
Further, rhe compounds of the formula (II) and (IV) are important
intermediate compounds for synthesis of the present compound of formula
(I) , and therefore, by using these intermediates, the compounds of the
present invention represented by the formula (I) can be obtained by simple
and easy way.
Best Mode for Carrying Out The Invention
[0025]
The present invention will now be explained more specifically as
following.
The term "Cn-Cm alkyl group" of the present invention includes a
straight or a branched-chained alkyl group having n to m carbon atoms.
The term "cycloalkyl group" means cycloalkyl group having 3 to 8 carbon
atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclooctyl and the like. The term "heterocycloalkyl group"
may be 3 to 7 membered monocyclic or polycyclic heterocyclic group
containing the same or different 1 to 4 hetero atom(s) such as oxygen,
nitrogen or sulfur atom(s), and examples may include piperidinyl,
pyrrolidinyl, piperazinyl, tetrahydrofuryl, tetrahydropyranyl,
morpholinyl, azetidinyl, imidazolidinyl, oxazolidinyl,
hexahydropyrrolidinyl, octahydroindolidinyl, octahydroquinolidinyl,
octahydroindolyl, and oxo-derivatives thereof.
[0026]
The "halogen atom" includes chlorine, fluorine, bromine and iodine.
The term "aryl group" may be aromatic hydrocarbon group, which consists
of mono-benzene ring, or binding or condensed benzene ring, such as phenyl,
naphthyl, biphenyl and the like; and dicyclic or tricyclic group, which
consists of benzene ring condensed with cycloalkyl or heterocyclic ring,
such as 1,2,3,4-tetrahydronaphthalene, 2,3-dihydroindene, indoline,
coumarone and the like.

The term "heteroaryl group" may be 5 to 7 menibered monocyclic
heteroaryl group or polycyclic heteroaryl group, and having 2 to 8 carbom
atoms with 1 to 4 hetero atom(s) such as oxygen, nitrogen, sulfur atom(s),
in which the polycyclic heteroaryl group has condensed ring system by
the same or different nomocyclic heteroaryl or benzene ring each other;
or polycyclic group which is consited of heteroaryl group condensed with
cycloalkyl or heterocycloalkyl ring.
The examples include pyrrole, furyl, thienyl, imidazolyl, thiazolyl,
pyrazinyl, indolyl, indolinyl, quinolinyl, isoquinolinyl, tetrazolyl,
pyridinyl, pyrc.zolyl, pyridazinyl, pyrimidinyl, benzothiophenyl,
isoxazolyl, indazolyl, benzoimidazolyl, phthalazinyl, triazolyl,
benzooxazolyl, benzothiazolyl, dihydrocyclopentapyridinyl, dihydro-
pyrropyridinyl and the like.
[0027]
Examples o f suitable substituent of the present inventionmay include
straight, branched-chained or cyclic C1-C8 alkyl group, which may be
substituted by cne or more methyl, ethyl, propyl, isopropyl, n-butyl,
t-butyl, cyclohexyl, cycloheptyl, methoxymethyl, hydroxymethyl,
trifluoromethyl, C1-C3 alkoxy group, halogen atom, and hydroxyl group;
hydroxy! group; cyano group; substituted or unsubstituted alkoxy group
such as methoxy, ethoxy group; amino group which may be substituted by
C1-C6 alkyl group or acyl group such as amino, methylamino, ethylamino,
dimethylamino, acylamino and the like; carboxylic group; substituted or
unsubstituted ester group; phosphate group; sulfonic group; substituted
or unsubstituted aryl group; substituted or unsubstituted heteroaryl
group; saturated or unsaturated hererocycloalkyl group which may be
substituted; substituted or unsubstituted carbamoyl group; substituted
or unsubstituted amide group; substituted or unsubstituted thioamide
group; halogen atom; nitro group; substituted or unsubstituted sulfone
group; substituted or unsubstituted sulfonylamide group; oxo group;
substituted or unsubstituted urea group; straight, branched-chained or
cyclic alkenyl group such as ethenyl, propenyl, cyclohexenyl and the like.
[0028]

Examples of suitable substituent of "C3-C8 alkyl group which may
be substituted" in the group of R1 may include hydroxyl group, halogen
atom, alkoxy grouo and the like, and examples of suitable substituent
of "cycloalkyl group which may be sunstituted" in the group of R1 include
hydroxyl group, alkoxy group, oxo group, C1-C3 alkyl group such as methyl
group. Examples of suitable substituent of "heterocyclo alkyl group which
may be substituted" in the group of R1 may include C1-C3 alkyl group such
as methyl group.
[0029]
Examples of suitable substituent of "C1-C3 alkyl group which may
be substituted" in the group R2 may include hydroxyl group, alkoxy group,
halogen atom such as fluorine atom. Further, examples of suitable
substituent of C1-C3 alkyl group which may be substituted" in the group
R3 include hydroxyl group, alkoxy group, halogen atom such as fluorine
atom.
Examples of suitable substituent of "aryl group which may be
substituted" and "heteroaryl group which may be substituted" in the group
R4 may include hydroxyl group, halogen atom, heterocycloalkyl group which
may be substituted by C1-C6 alkyl group.
[0030]
Examples of suitable substituent of "cycloalkyl group which may
be substituted" in the groups R5 and R6 may include hydroxyl group; oxo
group; carboxyl group; carboxyl ester group; cyano group; C1.-C6 alkyl group
(in which said C1-C6 alkyl group may be substituted by C1-C3 alkoxyl group,
hydroxyl group, amino group which may be substituted by C1-C6 alkyl group,
arylsulfonyloxy group, heterocycloalkyl group (in which said
heterocycloalkyl group may be substituted by hydroxyl group, C1-C6 alkyl
group, oxo group or acetyl group) }; amide group (in which said amide group
may be substituted by cycloalkyl group or C1-C6 alkyl group which may be
substituted by hydroxyl group); heterocycloalkylamide group which may
be substituted by C1-C6 alkyl group; heterocycloalkylamide group which
may be substituted by hydroxyl group; amino group (in which said amino
group may be substituted by C1-C6 alkyl group which may be substituted

by C1-C3 alkoxy croup and acyl group); heterocycloalkyl group {in which
said heterocycloalkyl group may be substituted by C1-C6 alkyl group (in
which said alkyl group may be substituted by hydroxyl group) , oxo group,
acyl group, hydroxyl group, amino group which may be substituted by C1-C6
alkyl group, amino group which may be substituted by acyl group, C1-C3
alkoxy group, alkoxycarbonyl group, carboxyl group, aminocarbonyl group
which may be substituted by C1-C6 alkyl group, or sulfonyl group which
may be substituted by C1-C6 alkyl group}.
Examples of suitable substituent of "heterocycloalkyl group which
may be substituted" may include benzyl group; acyl group; oxo group;
heterocycloalkyl group (in which said heterocycloalkyl group may be
substituted by C1-C6 alkyl group, acyl group, sulfonyl group which may
be substituted by C1-C6 alkyl group or alkoxycarbonyl group); C1-C6 alkyl
group which may be substituted by carboxyl group or carboxylic ester group;
amido group which may be substituted by C1-C6 alkyl group;
heterocycloalkylamide group which may be substituted by C1-C6 alkyl group;
sulfonyl group which may be substituted by C1-C6 alkyl group; sulfonamide
group which may be substituted by C:L-C6 alkyl group; cycloalkyl group which
may be substituted by oxo or hydroxyl group; alkoxycarbonyl group, and
the like.
[0031]
Further, examples of suitable substituent of "aryl group which may
be substituted" in the group of R6 and R6 may include halogen atom; nitro
group; cyano group; acyl group; amino group which may be substituted by
acyl group; amide group (in which said amide group may be substituted
by C1-C6 alkyl group which may be substituted by C1-C3 alkoxy group or C1-C6
alkyl group which may be substitute by hydroxyl group) ; alkoxycarbonylamino
group; alkoxycarbonyl group; alkoxy group (in which said alkoxy group
may be substituted by carboxyl group, carboxylic ester group, or amide
group); carbonyl group; carboxyl group; carboxylic ester group; carbamoyl
group; sulfonic group; sulfonamide group; aminosulfonyl group; C1-C6 alkyl
group (in which said alkyl group may be substituted by C1-C3 alkoxy group,
hydroxyl group cr hetrocycloalkyl group which may be substituted by C1-C6

alkyl group); heterocycloalkylamide group which may be subustituted by
C1-C6 alkyl group; heterocycloalkyl group which may be substituted by
hydroxyl grop; acetic acid group; acetic acid amide group; or
heterocycloalkyl group (in which said heterocycloalkyl group may be
substituted by hydroxyl group, oxo group, acyl group, C1-C6 alkyl group,
amino group which may be substituted by C1-C6 alkyl group, amino group
which may be substituted by acyl group, C1-C3 alkoxy group, alkoxycarbonyl
group, and the like).
Examples of suitable substituent of "heteroaryl group which may
be substituted" in the group of R5 and R6 may include halogen atom; acyl
group; amide group {in which said amide group may be substituted by C1-C6
alkyl group (in which said alkyl group may be further substituted by amino
group which may be substituted by C1-C6 alkyl group or hydroxyl group) };
cycloalkyl group which may be subustituted by hydroxyl group;
cycloheteroalkyl group which may be substituted by C1-C6 alkyl group or
acyl group; heterocycloalkylamide group which may be substituted by C1-C6
alkyl group; heterocycloalkylamide group which may be substituted by
hydroxyl group; oxo group; acylamino group; C1-C6 alkyl group (in which
said alkyl group may be substituted by cycloheteroalkyl group which may
be substituted by hydroxyl group, acyl group or cycloheteroalkyl group
which may be substituted hydroxyl group) ; carboxyl group; carboxylic ester
group; sulfonyl group; heterocycloalkyl group (in which said
heterocycloalkyl group may be substituted by hydroxyl group, oxo group,
acyl group, C1-C6 alkyl group, amino group which may be substituted by
C1-C6 alkyl group, amino group which may be substituted by acyl group,
C1-C3 ailkoxy group, alkoxycarbonyl group, and the like) .
Examples of suitable substituent of "substituted or unsubstituted
heterocycloalkyl group which is formed said ring system together with
nitrogen atom which they are bonded" may include acyl group; amide group;
C1-C6 alkyl group or C1-C3 alkoxy group; carbonyl group; carboxyl group;
carboxylic ester group; hydroxyl group; carbamoyl group; sulfonamide
group; aminosulfonic group; oxo group; and the like.
[0032]

Examples of suitable substituent of "C1-C3 alkyl group which may
be substituted" in the group R7 may include hydroxyl group, alkoxy group,
halogen atom such as fluorine atom, and the like.
[0033]
Examples cf suitable substituent of "heterocycloalkyl group which
may be substituted" in the group R8 may include hydroxyl group, alkoxy
group, oxo group, acyl group, C1-C6 alkyl group, C1-C3 alkoxy group, carboxyl
group, amide grcup, and the like.
[0034]
In the groups R9 and R10, examples of suitable substituent of "C1-C3
alkyl group which may be substituted" may include hydroxyl group, alkoxy
group and the like. Further, examples of suitable substituent of
"heterocycloalkyl group which may be substituted" may include C1-C6 alkyl
group, hydroxyl group, alkoxy group, oxo group, acyl group and the like,
and examples of suitable substituent of "acyl group which may be
substituted" may include C1-C6 alkyl group, hydroxyl group, alkoxy group
and the like.
Examples of suitable substituent of "substituted or unsubstituted
heterocycloalkyl group which is formed said ring system together with
nitrogen atom which they are bonded" include acyl group, amide group,
C1-C6 alkyl group, C1-C3 alkoxy group, carbonyl group, carboxyl group,
carboxylic ester group, hydroxyl group, carbamoyl group, sulfonamide
group, aminosulfonic group, and the like.
[0035]
Preferable compounds of the formula (I) of the present invention
may include the compounds wherein R1 is cyclohexyl group, cycloheptyl group
or tetrahydropyranyl group; R2 is methyl group; R3 is a hydrogen atom;
and R4 is the group -NR5R6 (in which one of these R5 and R6 is a hydrogen
atom) .
[0036]
It is understood that when the compounds of the formula (I) of the
present invention exist in the tautomeric mixtures, each tautomeric isomers
per se, as well as the mixture thereof. Furthermore, the radiolabelled

compound of the formula (I) shall be included within the scope of the
compounds of the present invention.
[0037]
The compounds of the present invention may contain one or more
asymmetric carbon atom and therefore, the compounds of the present invention
may exist as optically isomer of (R)-form or (S)-form, racemic forms,
as well as diastereomers. Further, the compounds of the present invention
may exist as geometrical isomer such as (Z)-form or (E)-form due to the
double bond in the substituent. Therefore, the compounds of the present
invention should include these isomers per se as well as the isomeric
mixtures thereof.
[0038]
The compounds of the present invention may form acid additional
salt thereof with various acids. Examples of the acid additional salt
include the salts with inorganic acid such as hydrochloric acid, hydrobromic
acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and
the like; salts with organic acid such as formic acid, acetic acid,
propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid,
maleic acid, lactic acid, malic acid, citric acid, tartaric acid, benzoic
acid, picric acid, methanesulfonic acid, toluenesulfonic acid,
benzenesulfonic acid, trichloroacetic acid, trifluoroacetic acid,
asparaginic acid, glutamic acid and the like.
[0039]
The compounds of the present invention may form pharmaceutically
acceptable salts by treating with various kinds of metal, especially alkali
metal or alkali earth metal. These salts may include sodium salt,
potassium salt, calcium salt and the like. Further, the compounds of the
present invention may include hydrate thereof or solvate with ethanol
or isopropanol thereof, and polymorphisms thereof.
[0040]
The following compounds are preferable thienopyrazole compounds
of the formula (I) of the present invention.
[0041]

Ethyl l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylare;
N-Benzyl-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
l-CyclohexyI-3-methyl-N-phenyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
N-{4-[Acetyl(methyl) amino]phenyl}-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]py::azole-5-carboxamide;
N-[4-(Acetylamino)-3-methoxyphenyl]-l-cyclohexyl-3-methyl-lH-
thieno [2, 3-c]py::azole-5-carboxamide;
N-(l-Acetyl-2,3-dihydro-lH-indol-5-yl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}phenylcarbamate;
tert-Eutyl 5-{[;i-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl) -carbonyl] am:Lno}-l-indolinecarboxylate;
1-Cyclohexyl-N-(2,3-dihydro-lH-indol-5-yl)-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-(lH-indol-5-yl)-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
l-Cyclohexyl-3-raethyl-N-[4-(4-morpholinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-(3-nitrophenyl)-IH-thieno[2,3-c]-
pyrazole-5-carboxamide;
N-(3-Aminophenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
[0042]
N-[3-(Acetylamino)phenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]py;razole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{4-[(methylamino)carbonyl]phenyl}-1H-
thieno[2, 3-c]py:cazole-5-carboxaimde;
l-Cyclohexyl-3-methyl-N-(l-propionyl-2,3-dihydro-lH-indol-5-
yl) -lH-thieno[2,. 3-c]pyrazole-5-carboxamide;
Ethyl 5-{[(l-cyclohexyl-3-methyi-lH-thieno[2,3-c]pyrazol-5-yl)-

carbonyl] amino}-l-indolinecarboxylate;
1-Cyclohexyl-N-(l-isobutyryl-2,3-dihydro-lH-indol-5-yl)-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-(l-Butyryl-2,3--dihydro-lH-indol-5-yl)-l-cyclohexyl-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-[l-(2,2-dimethylpropanoyl)-2,3-dihydro-lH-
indol-5-yl]-3-methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-(2-oxo-2,3-dihydro-lH-indol-S-yl)-1H-
thieno[2,3-c]pyrazole-5-carboximide;
N-[4-(Acetylamino)-3-chlorophenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[(ethylamino)carbonyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-[4-(methoxymethyl)phenyl]-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-(hydroxymethyl)phenyl]-3-methyl-lH-thieno-
[2,3-c]pyrazole-5-carboxcamide;
[0043]
l-Cyclohexyl-3-irethyl-N-[4-(4-morpholinylcarbonyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{4- [ (4-methyl-l-piperazinyl) carbonyl] -
phenyl} -lH-thier.o [2, 3-c] pyrazole-5-carboxamide;
l-Cyclohexyl-3-niethyl-N-{4-[(methylsulfonyl) amino]phenyl}-lH-
thieno[2,3-c]pyrazole-5-carboxiamide;
l-Cyclohexyl-3-methyl-N-{4-[(methylamino)sulfonyl]phenyl}-lH-
thieno [2, 3-c]pyi:azole-5-carboxamide;
N-{1-[(l-Cycloh€;xyl-3-methyl-lH-thieno[2/3-c]pyrazol-5-yl)-
carbonyl] -2, 3-d:.hydro-lH-indol-5-yl}acetamide;
l-Cyclohexyl-3-nethyl-N-{4-[(4-methyl-l-piperazinyl)sulfonyl]-
phenyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclchexyl-N-(4-{[(2-methoxyetnyl)amino]carbonyl}phenyl)-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
N-(4-Acetylphenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-

pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[(dimethyl amino)carbonyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}benzoate;
4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)carbonyl]-
amino}benzoic acid;
1-Cyclohexyl-N-(2-methoxy-4-nitrophenyl)-3-methyl-lH-thieno-
[2, 3-c]pyrazole-5-carboxamide;
[0044]
N-(4-Amino-2-methoxyphenyl)-l-cyclohexyl-3-methyl-lH-thieno-
[2,3-c]pyrazole~5-carboxamide;
N-[4-(Acetylamino)-2-methoxyphenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2, 3-c]pyi:azole-5-carboxamide;
1-Cyclonexyl-N-i 4-[(isopropylamino)carbonyl]phenyl}-3-methyl-lH-
thieno[2, 3-c]pyi:azole-5-carboxamide;
1-Cyclohexyl-N- (4.-{ [ (2-hydroxyethyl) amino] carbonyl}phenyl) -3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[6-(Acetylamino)-3-pyridinyl]-l-cyclohexyl-3-methyl-lH-
thieno [2, 3-c] py2:azole-5-carboxamide ;
1-Cyclohexyl-N-(4-methoxyphenyl)-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
l-Cyclohexyl-N-c;yclopentyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
N,l-Dicyclohexy---3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{4-[(tert-butylamino)carbonyl]phenyl}-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-{5-[(isopropylamino)carbonyl]-2-pyridinyl}-3-methyl-
lH-thieno[2, 3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-(formylamino)phenyl]-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
tert-Butyl 4-[(4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}phenyl)sulfonyl]-1-piperazinecarboxylate;

[0045]
l-Cyclohexyl-3-methyl-N-[4-(1-piperazinylsulfonyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(4-morpholinylsulfonyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4- (methylsulfonyl)phenyl]-lH-thieno-
[2, 3-c]pyrazole-!5-carboxamide;
1-Cyclohexyl-N-[1-(cyclopropylcarbonyl)-2,3-dihydro-lH-indol-5-
yl]-3-methyl-lH-rhieno[2,3-c]pyrazole-5-carboxaimde;
l-Cyclohexyl-3-methyl-N-[1-(methylsulfonyl)-2,3-dihydro-lH-indol-5-
yl]-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N- (l-Acetyl-lH-indol-5-yl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
l-Cyclohexyl-N-cyclopropyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
N-(l-Benzyl-4-piperidinyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
l-Cyclohexyl-3-ir.ethyl-N- (4-piperidinyl) -lH-thieno [2, 3-c]pyrazole-
5-carboxamide;
N-(l-Acetyl-4-piperidinyl)-l-cyclohexyl-3-methyl-lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
Ethyl (4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}phenoxy)acetate;
(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}phenoxy)acetic acid;
[0046]
l-Cyclohexyl-3-nethyl-N-{4-[2-(methylamino)-2-oxoethoxy]phenyl }-
lH-thieno[2,3-c^ pyrazole-5-carboxamide;
Ethyl (4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl] amino}phenyl)acetate;
(4-{[(l-Cyciohexyl-3-methyl-lH-tnieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}phenyl)acetic acid;
l-Cyclchexyl-3-methyl-N-{4-[2-(methylamino)-2-oxoethyl]phenyl}-

lH-thieno[2,3-c]pyrazole-5-carboxamide;
tert-Butyl 4-(4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}phenyl)-1-piperazinecarboxylate;
l-Cyclohexyl-3-rr.ethyl-N- [4- (1-piperazinyl) phenyl] -lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
N-[4-(4-Acetyl-l-piperazinyl)phenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-(trans-4-hydroxycyclohexyl)-3-methyl-lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-rr.ethyl-N- (4-oxocyclohexyl) -lH-thieno [2, 3-c] -
pyrazole-5-carbcxamide;
l-Cyclohexyl-3-methyl-N-{4-[2-(4-methyl-l-piperazinyl)-2-
oxoethoxy]phenyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[2-(dimethylamino)-2-oxoethoxy]phenyl}-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
2-{4-[4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}phenyl]sulfonyl}-1-piperazinyl}ethyl acetate;
1-Cyclohexyl-N-(4-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}-
phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0047]
N-[fcrans-4-(Acetylamino)cyclohexyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N,3-dimethyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl l-cyclopentyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylate;
N-[4-(Acetylamino)phenyl]-l-cyclopentyl-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
Ethyl l-cycloheptyl-3-methyl-lH--hieno[2,3-c]pyrazole-5-carboxylate;
N-[4-(Acetylamino)phenyl]-l-cycloheptyl-3-methyl-lH-thieno-
[2, 3-c]pyrazole--5-carboxamide;
1-Cyclohexyl-N,3-dimethyl-N-phenyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
l-Cyclohexyl-3-methyl-N-(4-pyridinyl)-lH-thieno[2,3-c]pyrazole-5-
carboxamide;

l-Cyclohexyl-3-methyl-N-(3-pyridinyl)-IH-thieno[2,3-c]pyrazole-5-
carboxamide/
l-Cyclohexyl-3-methyl-N-(4-nitrophenyl)-IH-thieno[2,3-c]pyrazole-
5-carbcxamide;
N-(4-Aminophenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-
5-carboxamide;
N-[4-(Acetylamino)pheny]-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
[0048]
l-Cyclohexyl-N-{4-[(methoxyacetyl)amino]phenyl}-3-methyl-IH-
thieno [2,3-c]pyrazole-5-carboxamide;
Methyl 5-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-2-pyridinecarboxylate;
5-{[(l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)carbonyl]-
amino)-2-pyridinecarboxylic acid;
l-Cyclohexyl-3-methyl-N-{6-[(methylamino)carbonyl]-3-pyridinyl}-
IH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclchexyl-N-{6-[(dimethylamino)carbonyl]-3-pyridinyl}-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-IH-
thieno [2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-IH-
thieno [2,3-c]pyrazole-5-carboxamide methanesulfonate;
N-(4-Cyanophenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-
5-carboxamide;
l-Cyclohexyl-3-methyl-N-[6-(4-methyl-l-piperazinyl)-3-pyridinyl]-
IH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{3-[(4-methyl-l-piperazinyl)sulfonyl]-
phenyl}-IH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexy-3-methyl-N-{3-[(methylamino)sulfonyl]phenyl}-IH-
thieno [2,3-c]pyrazole-5-carboxamide;
[0049]
l-Cycloheptyl-3-methyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-1H-

thieno [2, 3-c]pyrcizole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[3-(4-methyl-l-piperazinyl)phenyl]-1H-
thieno [2, 3-c] pyreizole-5-carboxamide;
1-Cyclohexyl-N-[4-(4-hydroxy-l-piperidinyl)phenyl]-3-methyl-lH-
thieno[2, 3-c]pyrazole-5-carboxamide;
N-[4- (Acetylamino)-3-methoxyphenyl]-l-cycloheptyl-3-methyl-lH
-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-(3,5-dichloro-4-pyridinyl)-3-methyl-lH-thieno-
[2, 3-c]pyrazole-;3-carboxamide;
5-(4-Bromophenylj-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole;
l-Cyclohexyl-3-methyl-5-[4-(4-methyl-l-piperazinyl)phenyl]-1H-
thieno[2,3-c]pyrazole;
l-Cyclohexyl-3-methyl-5-[4-(4-methyl-l,4-diazepam-l-yl)phenyl]-
1H-thieno[2,3-c]pyrazole;
1-Cyclohexyl-N-{3-fluoro-4-[(2-hydroxyethyl) (methyl) ennino]phenyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-{3-fluoro-4-[(2-hydroxyethyl) (methyl)amino]phenyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt;
[0050]
Ethyl cis-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}cyclohexanecarboxylate;
cis-4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclohexanecarboxylic acid;
1-Cyclohexyl-N-[cis-4-(hydroxymethyl)cyclohexyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
Methyl trans-4-({[{l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino)methyl}cyclohexanecarboxylate;
1-Cyclohexyl-N-{[trans-4-(hydroxymethyl)cyclohexyl]methyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
tert-Butyl trans-4-({[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl) cairbonyl] amino} cyclohexyl carbamate;
N-(trans-4-&ainocyclohexyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c-
pyrazcle-5-carboxamide;

l-Cyclohexyl-3-methyl-N-[trans-4-(4-morpholinyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-(4-piperidinyl)-lH-thieno[2,3-c]pyrazole-
5-carboxaimde;
l-Cyclohexyl-3-methyl-N-(l-tetrahydoro-2H-pyran-4-yl-4-
piperidinyl)-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-[l-(1,4-diazaspiro[4.5]decan-8-yl)-4-piperidinyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0051]
l-Cyclohexyl-3-methyl-N-[1-(4-oxocyclohexyl)-4-piperidinyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[1-(trans-4-hydroxycyclohexyl)-4-piperidinyl]-3-
methyl-lH-thienc[2,3-c]pyrazole-5-carboxamide;
tert-Butyl 4-(4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}phenyl)-1-piperidinecarboxylate;
l-Cyclohexyl-3-methyl-N-[4-(4-piperidinyl)phenyl]-lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-niethyl-N-[4-(l-methyl-4-piperidinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-(4-ethyl-l-piperazinyl)-3-fluorophenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-1, 4-diazepam-l-yl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl] amino}--2-methoxybenzoate;
4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)carbonyl]-
amino]-2-methoxybenzoic acid;
1-Cyclohexyl-N-;3-methoxy-4-[(4-methyl-l-piperazinyl)carbonyl]-
phenyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0052]
1-Cyclohexyl-N-[3-methoxy-4-(4-morpholinylcarbonyl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-[(4-hydroxy-l-piperidinyl)carbonyl]-3-methoxy-

phenyl}-3-methyl--lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-(4-{[(2-hydroxyethyl) .amino]carbonyl}-3-methoxy-
phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-(3-methoxy-4-{[(2-methoxyethyl) amino]carbonyl}-
phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-{3-methoxy-4-[(methylamino)carbonyl]phenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-{4-[(dimethylamino)carbonyl]-3-methoxyphenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[3-Chloro-4-(4-methyl-1-piperazinyl)phenyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-(1, 4-dioxa-8-azaspiro[4.5]deca-8-yl)-3-fluoro-
phenyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0053]
1-Cyclohexyl-N-[3-fluoro-4-(4-oxo-l-piperidinyl)phenyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[3-fluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3
-methyl-lH-thiero[2,3-c]pyrazole-5-carboxamide;
N-[3-Chloro-4-(1,4-dioxa-8-azaspiro[4.5]deca-8-yl)phenyl]-1-
cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[3-Chloro-4-(4-oxo-l-piperidinyl)phenyl]-l-cyclohexyl-3-methyl-
lH-thieno [2,3-c] pyrazole-5-carboxam:Lde;
N-[3-Chloro-4-K-hydroxy-1-piperidinyl)phenyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N--3-fluoro-4-[4-(methylamino)-1-piperidinyl]phenyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
tert-Butyl 1-(2-chloro-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl)ca::bonyl] amino}phenyl)-4-piperidinyl(methyl)carbamate;
N-{3-Chloro-4-[4-(methylamino)-l-piperidinyl]phenyl}-l-cyclohexyl-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[trans-A-(4-methyl-l-piperazinyl)-

cyclohexyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0054]
l-Cyclohexyl-3-methyl-N-{trans-4-(4-methyl-l, 4-diazapam-l-yl)-
cyclohexyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[trans-4-(4-methoxy-l-piperidinyl)cyclohexyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Benzyl 4-{trans-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}cyclohexyl)-1, 4-diazepam-l-carboxylate;
1-Cyclohexyl-N-[trans-4-(1,4-diazepam-l-yl)cyclohexyl]-3-methyl-
lH-thieno[2, 3-cjpyrazole-5-carboxamide;
N-[trans-4-(4-Acetyl-l,4-diazepam-l-yl)cyclohexyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N--; trans-4- [ (2-methoxyethyl) (methyl) amino] cyclohexyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N--^ cis-4- [ (2-methoxyethyl) (methyl) amino] cyclohexyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-\trans-4-(1,4-dioxa-3-azaspiro[4.5]deca-8-yl)-
cyclohexyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-nethyl-N-[trans-4-(4-oxo-l-piperidinyl)cyclohexyl]-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[trans-4-(4-hydroxy-l-piperidinyl)cyclohexyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0055]
1-Cyclohexyl-N-{trans-4-[(2R,6S)-2,6-dimethylmorpholinyl]cyclo-
hexyl} -3-methyl--lH-thieno [2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[cis-4-[(2R,6S)-2, 6-dimethylmorpholinyl]cyclohexyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{trans-4-[4-(methylamino)-1-piperidinyl]-
cyclohexyl}-lH-i:hieno [2, 3-c]pyrazole-5-carboxamide;
N-(trans-4-{4-[Acetyl (methyl)amino]-1-piperidinyl}cyclohexyl)-1-
cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[trans-4~[4-(dimethylamino)-1-piperidinyl]cyclo-
hexyl} -3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;

tert-Butyl 1-{trans-A-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidinylcarbamate;
tert-Butyl l-(cis~4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidinylcarbamate;
N-[trans-4-(4-Am:.no-l-piperidinyl)cyclohexyl]-l-cyclohexyl-3-
methyl-lH-thieno ^2,3-c]pyrazole-5-carboxamide;
N- [cis-4- (4-Amino-l-piperidinyl)cyclohexyl]-l-cyclohexyl-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0056]
tert-Butyl 4-(tr pyrazol-5-yl)carbonyl]amino}cyclohexyl)-1-piperazinecarboxylate;
tert-Butyl 4-(ci,s-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}cyclohexyl)-l-piperazinecarboxyl£ite;
l-Cyclohexyl-3-methyl-N-[trans-4-(1-piperazinyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[cis-4-(1-piperazinyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
N-[trans-4-(4-Acetyl-l-piperazinyl)cyclohexyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-l,4-diazapam-l-yl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazole-5-carbcxamide;
3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxylic acid;
3-Methyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N- [3-Fluoro-4- (^:-methyl-l-piperazinyl) phenyl] -3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0057]
l-Cyclohexyl-3-nethyl-N-[4-(4-morpholinylmethyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[2-(dimethylamino)ethyl]phenyl}-3-methyl-lH-

thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{4-[2-(4-morpholinyl)ethyl]phenyl}-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{4-[(3-methy-2,5-dioxo-l-iraidazolidinyl)-
methyl]phenyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(3-methyl-2, 5-dioxo-l-imidazolidinyl)-
phenyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide;
Methyl trans-A-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}cyclohexanecarboxylate;
4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-yl)carbonyl]-
amino}cyclohexanecarboxylic acid;
1-Cyclohexyl-N-[4-(hydroxymethyl)cyclohexyl]-3-methyl-lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{4-[(4-methyl-l-piperazinyl)carbonyl]-
cyclohexyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4~[(dimethylamino)carbonyl]cyclohexyl}-3-methyl-
1H-thieno[2,3-c]pyrazole-5-carboxamide;
N-(4-Cyanocyclohexyl)-l-cyclohexyl-3-methyl-lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
[0058]
tert-Butyl 2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}ethyl(methyl)carbamate;
l-Cyclohexyl-3-methyl-N-[2- (methylaraino)ethyl]-lH-thieno-
[2,3-c]pyrazole-5-carboxamide;
N-{2-[Acetyl(methyl)amino]ethyl}-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-n\ethyl-N-{2-[methyl (methylsulfonyl) amino]ethyl}-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl (4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl] amino}--l-piperidinyl) acetate;
(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}-1-piperidinyl)acetic acid;
Ethyl 2-(4-{ [ (l--cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-

carbonyl]amino}-l-piperidinyl)-2-methylpropanoate;
2-(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-l-piperidinyl)-2-methylpropanoic acid;
1-Cyclohexyl-N-[2-(5,5-dimethyl-2,4-dioxo-l,3-oxazolidin-3-yl)-
ethyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{2-[methyl(4-morpholinylcarbonyl)amino]-
ethyl}-lH-thienC'[2, 3-c]pyrazole-5-carboxamide;
[0059]
l-Cyclohexyl-N-{2-[[(dimethylamino)carbonyl](methyl)amino]ethyl}-
3-methyl-lH-thi€no[2,3-c]pyrazole-5-carboxamide;
Methyl 2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}ethyl(methyl)carbamate;
1-Cyclohexyl-N-{2-[(methoxyacetyl)(methyl)amino]ethyl}-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carbcxamide;
l-Cyclohexyl-N-{2-[glycoloyl(methyl)amino]ethyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-I 4-{[(2-hydroxyethyl)(methyl)amino]carbonyl}cyclo-
hexyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Methyl (lS,3S)-3-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}cyclopentanecarboxylate;
(lS,3S)-3-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclopentanecarboxylic acid;
l-Cyclohexyl-3-methyl-N-[2-(4-methyl-2,3-dioxo-l-piperazinyl)-
ethyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-<. carbonyl cyclopentyl> methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Methyl (lR,3R)-3-{[(l-cyclohexyl~3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl) carbonyl] ar.iino}cyclopentanecarboxylate;
[0060]
(1R,3R)-3-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclopentanecarboxylic acid;
1-Cyclohexyl-N-[(1R,3R)-3-[(dimethylamino)carbonyl]cyclopentyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;

l-Cyclohexyl-N-{1-[(dimethyl amino)carbonyl]-4-piperidinyl}-3-
methyl-lH-thienc[2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(4-morpholinylcarbonyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{4-[(methylamino)carbonyl]cyclohexyl}-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[(cyclopropylamino)carbonyl]cyclohexyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[(4-hydroxy-l-piperidinyl)carbonyl]cyclohexyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{1-[(dimethylamino)sulfonyl]-4-piperidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
tert-Buryl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}-1-piperidinecarboxylate;
l-Cyclohexyl-3-methyl-N-(4-piperidinyl)-lH-thieno[2,3-c]pyrazole-
5-carboxamide;
N- [ (3S)-1-Benzylpyrrolidinyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[(3S)-pyrrolidinyl]-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
[0061]
1-Cyclohexyl-N-j (3S)-1-[(dimethylamino)carbonyl]pyrrolidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N--| 4- [ (2, 5-dioxo-l-imidazolidinyl)methyl] cyclohexyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 1- [ (l-cyclohexyl-3-methyl-lH-'chieno [2, 3-c] pyrazol-5-yl) -
carbonyl]-4-piperidinecarboxylate;
1-[(l-Cyclohexyl.-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
4-piperidinecarboxylic acid;
I 1-[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-N-
methyl-4-piperidinecarboxamide;
Ethyl (3S)-l-[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]-3-piperidinecarboxylate;

N- [ (6S, 7aS) -1, 30ioxohexahydro-lH-pyrrolo [1, 2-c] imidazol-6-yl] -1-
cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
N-[(6S,7aS)-2-Meuhyl-l,3-dioxohexahydro-lH-pyrrolo[1,2-c] imidazol-
6-yl]-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
{1-[(l-CyclohexyL-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)carbonyl]-
3-piperidinyl}methanol;
N-{4-[ (Dimethylamino)carbonyl]phenyl}-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0062]
l-Cyclohexyl-3-methyl-N-[6-(2-oxo-l-imidazolidinyl)-3-pyridinyl]-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(IS,3S)-3-(hydroxymethyl)cyclopentyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{(IS,3S)-3-[(2,5-dioxo-l-imidazolidinyl)methyl]-
cyclopentyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-[4-(2,5-dioxo-l-imidazolidinyl)phenyl]-3-methyl-
IH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[4-(3-methyl-2,5-dioxo-l-imidazolidinyl)phenyl]-1-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[6-(2-oxo-l-imidazolidinyl)-3-pyridinyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{4-[(3R)-3-hydroxypyrrolidinyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-{3-fluoro-4-[(3R)-3-hydroxypyrrolidinyl]phenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-{3-[(4-hydroxy-l-piperidinyl)sulfonyl]phenyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
N-{4-[4-{[tert-Butyl(dimethyl)silyl]oxy}-l-piperidinyl]sulfonyl}-
phenyl}-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
[0063]
1-Cyclohexyl-N-• 4~[(4-hydroxy-l-piperidinyl)sulfonyl]phenyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;

1-Cyclohexyl-N-[4-(2-hydroxyethyl)phenyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
N-[3-Fluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(4-methyl-l-piperazinyl)-3-(trifluoro-
methyl)phenyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[4-(2-oxo-lr 3-oxazolidin-3-yl)cyclohexyl]-
IH-thieno[2,3-c]pyrazole-5-carbcxamide;
l-Cyclohexyl-3-methyl-N-[4-(2-oxo-l-imidazolidinyl)cyclohexyl]-IH-
thieno [2, 3-c] pyrazole-5-carboxamide;
4-[(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclohexyl)amino]-4-oxobutanoic acid;
1-Cyclohexyl-N-14-(2,5-dioxo-l-pyrrolidinyl)cyclohexyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carbcxamide;
1-Cyclohexyl-N-[4-(1,l-dioxide-2-isothiazolidinyl)cyclohexyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0064]
Benzyl [{[(4-{[il-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclohexyl) amino]carbonyl}(methyl)amino]acetate;
l-Cyclohexyl-3-methyl-N-[4-(3-methyl-2, 5-dioxo-l-imidazolidinyl)-
cyclohexyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(3-methyl-2,5-dioxo-l-imidazolidinyl)-
ethyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[3-(3-methyl-2, 5-dioxo-l-imidazolidinyl)-
propyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N- A~{{[(2-hydroxyethyl) (methyl)amino]carbonyl}amino)-
cyclohexyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-i^ethyl-N- [4- (3-mef:hyl-2-oxo-l-imidazolidinyl) -
cyclohexyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 3-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}propanoate;
N-[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
(3-alanine;

tert-Butyl {[(l--cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}acetate;
[0065]
{[(l~Cyclohexyl--3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}acetic ac:.d;
l-Cyclohexyl-3-methyl-N-[3-(4-morpholinyl)-3-oxopropyl]-1H-
thieno [2, 3-c]pyrazole-5-carboxamide;
tert-Butyl 2-{[;i-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}ethylcarbamate;
N-(2-Aminoethyl!-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
1-Cyclohexyl-N-~3-(dimethylamino)-3-oxopropyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-nethyl-N-{3- [methyl(l-methyl-4-piperidinyl)amino]-3-
oxopropyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N- ~_3- (4-hydroxy-l-piperidinyl) -3-oxopropyl] -3-methyl-
lH-thieno [2, 3-c.'ipyrazole-5-carboxamide;
l-Cyclohexyl-3-raethyl-N-[2-(4-morpholinyl)-2-oxoethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[2-(dimethylamino)-2-oxoethyl]-3-methyl-lH-
thieno[2, 3-c]py::azole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(4-methyl-l-piperazinyl)-2-oxoethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[2-(4-hydroxy-l-piperidinyl)-2-oxoethyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[3-(4-methyl-l-piperazinyl)-3-oxopropyl]-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0066]
l-Cyclohexyl-3-methyl-N-{2-[methyl(l-methyl-4-piperidinyl)amino]-2-
oxoethyl}-IH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(2-oxo-l,3-oxazolidin-3-yl)ethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[2-(1,l-dioxide-2-isothiazolidinyl)ethyl]-3-methyl-

lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-N-[2-({[(2-hydroxyethyl) (methyl) amino]carbonyl}amino)-
ethyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(3-methyl-2-oxo-l-imidazolidinyl)ethyl]-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}butanoate;
4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}butanoic acid;
1-Cyclohexyl-N-[2-(2,5-dioxo-l-imidazolidinyl)ethyl]-3-methyl-lH-
thieno [2, 3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-(dimethylamino)-4-oxobutyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(3,4,4-trimethyl-2,5-dioxo-l-
imidazolidinyl) ethyl] -lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[2-(2,4-dioxo-l,3-thiazolidin-3-yl)ethyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0067]
1-Cyclohexyl-N-[1-(hydroxymethyl)cyclopropyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclonexyl-3-methyl-N-{l-[(3-methyl-2,5-dioxo-l-imidazolidinyl)-
methyl]cyclopropyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Methyl [(2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}ethyl) amino]acetate;
Methyl [(aminocarbonyl)(2-{[(l-cyclohexyl-3-methyl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}ethyl) amino]acetate;
1-Cyclohexyl-N-[2-(2,4-dioxo-l-imidazolidinyl)ethyl]-3-methyl-lH-
thieno [2, 3-c]pyi:azole-5-carboxamide;
1-Cyclohexyl-N-[2-(4,4-dimethyl-2,5-dioxo-l-imidazolidinyl)ethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(5-methyl-l,1-dioxide-l,2,5-thia-
diazolidin-2-yl)ethyl]-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N- 2-(3-ethyl-2,4-dioxo-l-imidazolidinyl)ethyl]-3-

methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(3-methyl-2, 4-dioxo-l-imidazolidinyl)-
ethyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(IS)-2-hydroxy-l-methylethyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
[0068]
1-Cyclohexyl-N-[(IS)-2-(2,5-dioxo-l-imidazolidinyl)-1-methylethyl]-
3-methyl-lH-thie:no[2, 3-c]pyrazole-5-carboxamide;
N-[(3R)-1-Benzylpyrrolidinyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[(3R)-pyrrolidinyl]-IH-thieno[2,3-c]-
pyrazoIe-5-carboxamide;
1-Cyclohexyl-N-{(3R)-1-[(dimethylamino)carbonyl]pyrrolidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(1R)-2-hydroxy-l-methylethyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(1R)-2-(2,5-dioxo-l-imidazolidinyl)-1-methylethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(2S)-2-hydroxypropyl]-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carbcxamide;
1-Cyclohexyl-N-[(2R)-2-(2,5-dioxo-l-imidazolidinyl)propyl]-3-
methyl-lH-thienc' [2, 3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(2R)-2-hydroxypropyl]-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(2S)-2-(2,5-dioxo-l-imidazolidinyl)propyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(1R)-1-(hydroxymethyl)propyl]-3-methyl-lH-
thieno [2, 3-c]py2:azole-5-carboxamide;
[0069]
1-Cyclohexyl-N--^ (1R) -1- [ (2, 5-dioxo-l-imidazolidinyl)methyl]propyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-methyl-lH-
thieno[2, 3-c]py::azole-5-carboxamide;

1-Cyclohexyl-N-{(lR)-l-[(2,5-dioxo-l-imidazolidinyl)methyl]-2-
methylpropyl}-3-methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
tert-Butyl 2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-2-methylpropylcarbamate;
N-(2-Amino-1,1-dimethylethyl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[2-(2,5-dioxo-l-imidazolidinyl)-1,1-dimethylethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-(3-Amino-2,2-dimethylpropyl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[3-(2,5-dioxo-l-imidazolidinyl)-2,2-dimethylpropyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
(±)-1-Cyclohexyl-N-[trans-2-(hydroxymethyl)cyclopropyl]-3-methy1-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[4-(4-Hydroxy-l-piperidinyl)phenyl]-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0070]
l-Cyclohexyl-3-methyl-N-[4-(3-oxo-l-piperazinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[4-(3-oxo-l-piperazinyl)phenyl]-l-tetrahydro-2H-pyran-
4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Methyl 3-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}benzoate;
3-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}benzoic acid;
1-Cyclohexyl-N-;3-[(dimethylamino)carbonyl]phenyl}-3-methyl-1H-
thieno [2, 3-c]py]:azole-5-carboxamide;
l-Cyclohexyl-3-nethyl-N-[3-(4-morpholinylcarbonyl)phenyl]-1H-
thieno[2, 3-c]pyi:azole-5-carboxamide;
Methyl trans-4--'. [ (3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2, 3-c]pyrazol-!3-yl) carbonyl] amino}cyclohexanecarboxylate;
trans-4-{[(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexanecarboxylic acid;

N-{trans-A-[(Dimethylamino)carbonyl]cyclohexyl}-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[trans-A-(4-morpholinylcarbonyl)cyclohexyl]-1-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{trans-4-[(4-Hydroxy-l-piperidinyl)carbonyl]cyclohexyl}-3-methyl-
l-tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
[0071]
3-Methyl-N-{trans-4-[(4-methyl-l-piperazinyl)carbonyl]cyclohexyl}-
l-tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[3-(4-morpholinyl)propyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-[2-(4-morpholinyl)ethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-mothyl-N-[2-(1-piperidinyl)ethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;
N-[trans-A-(Hydroxymethyl)cyclohexyl]-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
(trans-4-{[(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)methyl p-toluenesulfonate;
3-Methyl-N-[trans-A-(4-morpholinylmethyl)cyclohexyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{trans-A-[(Dimethylamino)methyl]cyclohexyl}-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{trans-A-[(4-Acetyl-l-piperazinyl) methyl]cyclohexyl}-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{3-[(Dimethylamino)sulfonyl]phenyl}-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0072]
3-Methyl-N-[3-(methylsulfonyl)phenyl]-l-tetrahydro-2H-pyran-4-yl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{3-[(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)sulfonyl]phenyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;

N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
3-Methyl-N-[trans-4-(4-morpholinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[6-(4-hydroxy-l-piperidinyl)-3-pyridinyl]-3-methyl-
IH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[2,3-difluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[4-(4-hydroxy-l-piperidinyl)-3-methylphenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[3-cyano-4-(4-hydroxy-l-piperidinyl)phenyl]-l-cyclohexyl-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
Methyl 5-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl] amino}--2- (4-hydroxy-l-piperidinyl) benzoate;
5-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}-2-(4-hydroxy-l-piperidinyl)benzoic acid;
[0073]
N-[6-(4-Hydroxy-l-piperidinyl)-3-pyridinyl]-3-methyl-l-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-l-tetrahydro-2H-pyran-4-yl-N-(l-tetrahydro-2H-pyran-4-yl-
4-piperidinyl)-!H-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-|6-[(4-hydroxy-l-piperidinyl)carbonyl]-3-pyridinyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-(6-{[(2-hydroxyethyl)amino]carbonyl}-3-pyridinyl)-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{6-[(4-methyl-l-piperazinyl)carbonyl]-3-
pyridinyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-1.6- ({ [2- (dimethylamino) ethyl] amino}carbonyl) -3-
pyridinyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-I6-{[(trans-4-hydroxycyclohexyl)amino]carbonyl}-3-
pyridinyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-methyl-N-{6-[(4-methyl-l,4-diazepam-1-yl)carbonyl]-
3-pyridinyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide;

tert-Butyl 4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino]-1-piperidinecarboxylate;
3-Methyl-N-(4-piperidinyl)-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2, 3-c]pyrazole-5-carboxamide;
[0074]
N-{ 1- [ (Dimethylamino) carbonyl] -4~piperidinyl}-3-methyl-1-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
tert-Butyl 4-{4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2, 3-c]pyrazol-5-yl)carbonyl]amino}piperidin-l-yl}-1-piperidine-
carboxylate;
3-Methyl-N-(piperidin-4-yl-4-piperidinyl)-l-tetrahydro-2H-pyran-
4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-(l-acetylpiperidin-4-yl-4-piperidinyl)-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-(l-methanesulfonylpiperidin-4-yl-4-piperidinyl)-1-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
tert-Bu^yl A-(trans-A-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-1-piperazine-
carboxylate;
tert-Butyl 4-(CJ.S-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-1-piperazine-
carboxylate;
3-Methyl-N-[tra.ns-4-(1-piperazinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[cis-4-(1-piperazinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[trans-A-(4-Acetyl-l-piperazinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-{trans-4-[4-(methylsulfonyl)-1-piperazinyl]cyclohexyl}-
l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0075]
N-[cis-4-(4-Acetyl-l-piperazinyl)cyclohexyl]-3-methyl-l-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;

3-Methyl-N-[1-(4-morpholinylcarbonyl; -4-piperidinyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-{1- [ (^:-methyl-l-piperazinyl) carbonyl] -4-piperidinyl}-1-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-(trar/s-4-Hydroxycyclohexyl)-3-methyl-l-tetrahydro-2H-pyran-4-yl-
lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-(4-oxocyclohexyl)-l-te~rahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazole-5-carboxamide;
N- [ trans-4- (cis-'Z, 6-Dimethylmorpholinyl) cyclohexyl] -3-methyl-l-
tetrahydro-2H-py::an-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
N-[cis-4-(cis-2,6-Dimethylmorpholinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
1-Cyclohexyl-N-[6-(hydroxymethyl)-3-pyridinyl]-3-methyl-lH-
thieno[2, 3-c]pyr,azole-5-carboxamide;
Methyl 5-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}-2-pyridinecarboxylate;
5-{[(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-pyrazol-
5-yl)carbonyl]amino}-2-pyridinecarboxylic acid;
[0076]
N-(6-{[Itrans-4-Hydroxycyclohexyl)amino]carbonyl}-3-pyridinyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lE-thieno[2,3-c]pyrazole-5-
carboxamide;
N-[6-({[2-(Dimethylamino)ethyl]amino}carbonyl)-3-pyridinyl]-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
3-Methyl-N-(6-{[(l-methyl-4-piperidinyl)amino]carbonyl}-3-
pyridinyl)-l-tetrahydro-2H-pyran~4-yl-lH-thieno[2,3-c]pyrazole-
5-carboxamide;
N-(6-{[(l-Acetyl-4-piperidinyl)amino]carbonyl}-3-pyridinyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
l-Cyclohexyl-3-methyl-N-[6-(4-morpholinylmethyl)-3-pyridinyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide;

l-Cyclohexyl-N-{6-[(4-hydroxy-l-piperidinyl)methyl]-3-pyridinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{6- [ (4-Acetyl-l-piperazinyl)methyl]-3-pyridinyl}-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[trans-4-(4-metyl-2-oxo-l-piperazinyl)cyclohexyl]-1-
tetrahydro-2H-pyran-4-yl-lH-thier.o[2,3-c]pyrazole-5-carboxamide;
l-Cyclohexyl-3-niethyl-N- [ trans-4- (4-rnethyl-2-oxo-l-piperazinyl) -
cyclohexyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[trans-4-(3-oxo-l-piperazinyl)cyclohexyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0077]
3-Methyl-N-[cis-4-(3-oxo-l-piperazinyl)cyclohexyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
3-Methyl-N-[trans-4-(4-methyl-3-oxo-l-piperazinyl)cyclohexyl]-1-
tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
3-Methyi-N-[cis-4-(4-methyl-3-oxo-l-piperazinyl)cyclohexyl]-1-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
Ethyl 1-(trans-4-{[(3-methyl-l-tetrahydro~2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidine-
carboxylate;
Ethyl 1-(cis-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidine-
carboxylate;
N-{trans-4-[4-(Kydroxymethyl)-1-piperidinyl]cyclohexyl}-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{cis-4-[4-(Hyclroxymethyl)-1-piperidinyl]cyclohexyl}-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide;
N-[trans-4-(4-Hydroxy-l-piperidinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-^-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-(cis-4-{4-[(Dimethylamino)carbonyl]-l-piperidinyl}cyclohexyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-
carboxamide;
1-(trans-4-{[(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-

pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidinecarboxylic acid;
[0078}
N- (trans-4-{4- [ (Dimethylamino) carbonyl] -1-piperidinyl}cyclohexyl) -
3-methyl-l-tetrcihydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
Ethyl 3-methyl-l-tetrahydro-2H-pyran-3-yl-lH-thieno[2,3-c]pyrazole-
5-carboxylate;
3-Methyl-l-tetreihydro-2H-pyran-3-yl-lH-thieno[2, 3-c]pyrazole-5-
carboxylic acid;
3-Methyl-N-[trans-4-(4-morpholinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-3-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[trans-4-(4-Ethyl-3-oxo-l-piperazinyl)cyclohexyl]-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-[cis-4-(4-Ethyl-3-oxo-l-piperazinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
N-{trans-A-[(4-Ethyl-3-oxo-l-piperazinyl)methyl]cyclohexyl}-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide;
3-Methyl-N-{ trans-A- [ (4-methyl-3--oxo-l-piperazinyl)methyl] -
cyclohexyl}-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-
5-carboxamide;
3-Methyl-N-[4-(4-methyl-2-oxo-l-piperazinyl)phenyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide;
[0079]
The compounds represented by the formula (I) of the present invention
may be prepared by the following methods.
[0080]
[Formula 8]


[0081]
(wherein, R1, R2, R3 and R4 have same meanings mentioned above; L is Ci-C3
lower eilkyl group)
[0082]
First, the compound (VI) obtained from the compound (VIII) by reacting
with R1NHNH2 (VII) in accordance with the known method (e.g., International
Patent Publication WO 03/053, 975) . Namely, the compound (VIII) is reacted
with 1 to 2 equivalents, preferably about 1 equivalent of the compound
(VII) in the solvent or absent of the solvent at room temperature to 120°C.
The solvent to be used in the reaction is inorganic acid aqueous solution
such as hydrochloric acid or sulfuric acid; aromatic carbon hydrate such
as benzene or toluene; organic acid such as acetic acid; ethers such as
1,4-dioxane or tetrahydrofuran; halogenated hydrocarbons such as
dichloromethane; alcohols such as methanol or ethanol; or the mixture
solvent there of.
[0083]
After the reaction is completed, the reaction mixture is neutralized
and the mixture is extracted with an organic solvent, which is nonmiscible
solvent with water, and the organic layer is washed sequentially with
waterandsaturatedsalinesolution. Then, thecompound (VI) canbeobtained
by removal of the solvent. This compound (VI) can be purified by

recrystallization, if necessary.
[0084]
The starting compounds (VII) and (VIII) to be used in this reaction
can be commercially available or can be known compounds (e.g., J. Org.
Chem., 1981, 46, 5414-5415). Further, the compounds (VII) can be used
as salt with acidic compounds, such as hydrochloric acid salt or acetic
acid salt.
[0085]
Then, the resulting compound (VI) is converted to the compound (V)
in accordance with the common method. Namely, the reaction can be conducted
by reacting the compound (VI) with 1 to 6 equivalents of halogenating
reagent such as phosphorous oxychloride or thionyl chloride in aromatic
hydrocarbon solvent such as benzene or toluene, or the absence of the
solvent, at room temperature to refluxing temperature of the solvent for
1 to 12 hours. After the reaction is completed, the compound (V) can be
obtained by removal of the solvent.
[0086]
The obtained compound (V) is converted, without further purification,
to the compound (IV) by an electrophilic substitution reaction. For example,
the compound, (V) in which R3 is a hydrogen atom, can be obtained by Vilsmeier
reaction with the reaction reagent prepared from 1 to 5 equivalents of
phosphorus oxychloride, in the amide solvent such as N, N-dimethylf ormamide .
The reaction is carried out at room temperature to 120°C for 1 to 12 hours.
After the reaction is completed, inorganic base aqueous solution
such as sodium hydroxide aqueous solution is added to the the reaction
mixture and the mixture is extracted with an organic solvent, which is
nonmiscible solvent with water, and the organic layer is washed sequentially
with warer and saturated saline solution. Then, the compound (IV) can
be obtained by removal of the solvent. This compound (IV) can be purified
by column chromatography or recrystallization, if necessary.
[0087]
Further, the compound (IV) can be converted directly from the compound
(IV) by Vilsmeier reaction in single process, or one-pot synthesis reaction

without separation of the intermediate compound (V) . Namely, the compound
(VI) is treated with 2 to 5 equivalents of phosphorous oxychloride without
using the reaction solvent at room temperature to 120°C to obtain the
compound (V) in the reaction mixture. Then, to this reaction mixture
containing the resulting compound (V) is added formamide solvents such
as N,N-dimethyl::ormamide at 0°C to 120°C, and the Vilsmeier reaction is
carried out at room temperature to 120°C for 1 to 24 hours.
After the reaction is completed, inorganic base aqueous solution
such as sodium hydroxide aqueous solution is added to the the reaction
mixture and the mixture is extracted with an organic solvent, which is
nonmiscible solvent with water, and the organic layer is washed sequentially
with water and saturated saline solution. Then, the compound (IV) can
be obtained by removal of the solvent. This compound (IV) can be purified
by column chromatography or recrystallization, if necessary.
[0088]
Then, the obtained compound (IV) is converted to the compound (II) .
The reaction is carried out by treating the compound (IV) with 1 to 1.5
equivalents of the compound (III), in the solvent at room temperature
to 80°C for 0.5 to 8 hours. The solvent to be used in this reaction is
polar solvent such as acetonitrile or N,N-dimethylformamide; ethers such
as 1,4-dioxane or tetrahydrofuran; halogenated hydrocarbons such as
dichloromethane; alcohols such as methanol or ethanol; or the mixture
solvent thereof. In this reaction, the compound (III) is previously treated
with base such as potassium carbonate, sodium hydride, potassium
tert-butoxide, sodium methylate or sodium hydroxide.
After the reaction is completed, water is added to the the reaction
mixture and the mixture is extracted with an organic solvent, which is
nonmiscible solvent with water, and the organic layer is washed sequentially
with water and saturated saline solution. Then, the compound (II) can
be obtained by removal of the solvent. This compound (II) can be purified
by column chromatography or recrystallization, if necessary.
[0089]
Then, the obtained compound (II) is converted to the compound (I)

of the present invention by ring formation reaction.
The reaction condition of this ring formation may vary depending
on the variety of the group R4. When the group R4 is the group: -CO2R7,
the compound (I) can be obtained from the compound (II) by treating with
1 to 1.5 equivalents of the base such as potassium carbonate, sodium hydride,
sodium methylate or sodium hydroxide in the solvent at 0°C to 80°C for
0.5 to 24 hours. The solvent to be used in this reaction is polar solvent
such as acetonitrile or N,N-dimethylformamide; ethers such as 1, 4-dioxane
or tetrahydrofuran; halogenated hydrocarbons such as dichloromethane;
alcohols such as methanol or ethanol; or the mixture solvent there of.
After the reaction is completed, water is added to the the reaction
mixture and the mixture is extracted with an organic solvent, which is
nonmiscible solvent with water, and the organic layer is washed sequentially
with water and Sciturated saline solution. Then, the compound (I) can be
obtained by removal of the solvent. This compound (I) can be purified
by column chromatography, if necessary.
[0090]
Further, when the group R4 is the group: -C02R7, the compound (I)
can be obtained from the compound (IV), without the separatiuon of the
compound (II) in the corresponding stepwise reaction.
[0091]
When the group R4 is an aryl group which may be substituted or a
heteroaryl group which may be substituted, the compound (I) can be obtained
from the compound (II) by treating with 1 to 3 equivalents of the strong
base such as lithium diisopropylamide or lithium bis (trimethylsilyl) amide
in the ethers such as diethylether or tetrahydrofuran.
After the reaction is completed, water is added to the the reaction
mixture and the mixture is extracted with an organic solvent, which is
nonmiscible solvent with water, and the organic layer is washed sequentially
with water and saturated saline solution, then, the organic solvent is
removed off. The resulting residue is dissolved in alcohols such as methanol
or ethanol, and the acid such as hydrochloric acid is added to the mixture,
and then, the mixture is stirred at room temperature to 60°C to obtain

the compound (I).
After the reaction is completed, water is added to the the reaction
mixture and the mixture is extracted with an organic solvent, which is
nonmiscible solvent with water, and the organic layer is washed sequentially
with water and saturated saline solution. Then, the compound (I) can be
obtained by removal of the solvent. This compound (I) can be purified
by column chromatography or recrystallization, if necessary.
[0092]
In the case of the group R4 is the group: -CONR5R6, first, the compound
(I) in which the group R4 is -C02R7 obtained by the method described above,
is converted to -;he compound (I) in which the group R4 is -CO2H. This
convertion reaction is the hydrolysis reaction of ester compound, and
can be carried out in the several manners. For example, the hydrolysis
reaction can be carried out in the presence of the base such as sodium
hydroxide, in the solvent at room temperature to refluxing temperature
of the solvent. The solvent to be used in the reaction may be alcohols
such as methanol or ethanol; water; or ~he mixture solvent thereof. After
the reaction is completed, the reaction mixture is condensed, and the
mixture is neutralized by adding hydrochloric acid to obtain the compound
(I) in which the group R4 is -C0?H.
Then, the resulting compound (I) in which the group R4 is -CO2H is
converted to the compound in which the group R4 is -CONR5R6 by amidation
reaction in accordance with the several known methods. For example, the
compound (I) in which the group R4 is -CO2H is converted to the corresponding
acid chloride by treating with the halogenating reagent such as phosphorous
oxychloride or thionyl chloride. Then, the obtained acid chloride is
treated with the amine compound HNR5R6 in the presence of base catalyst
such as triethylcimine in solvent at 0°C to room temperature. The solvent
to be used in the reaction may be halogenated hydrocarbons such as
dichloromethane; aromoatic hydrocarbons such as toluene or benzene;
ethers such as di.ethylether or tetrahydrofurane; or the mixture solvent
thereof.
After the reaction is completed, the reaction mixture is diluted

with the organic: solvent, which is nonmiscible solvent with water, and
the organic layer is washed sequentially with water and saturated saline
solution. Then, the compound (I) in which the group R4 is -CONR5Rb can
be obtained by removal of the solvent. This compound can be purified by
column chromatography or recrystallization, if necessary.
[0093]
All reaction mentioned above are well known, and the reagents to
be used or the reaction conditions to be applied can be easily established
in accordance with the standard text book and the examples mentioned later.
Further, the other methods or modified methods for obtaining the compound
(I) of the present invention can be easily selected by the person skilled
in this field.
Examples
[0094]
The present invention is illustrated in more detail by way of the
following Biological Test, Examples, and Manufacturing Examples.
[0095]
The synthesis of the compounds of the present invention and
intermediate compounds to be used in the synthesis are illustrated in
the Examples and Manufacturing Examples mentioned later. Further, the
physicochemical data and chemical structure of the compounds and
intermediate compounds obtained by the Examples and Manufacturing Examples
are summarized in the Tables mentions later.
[0096]
The compoiond numbers in the Examples are identical to those in the
Tables.
[0097]
It is to be noted that the present invention is not limited by those
Examples in any way.
[0098]
Biological Test 1:
Methods for evaluating the PDE 7 inhibiting effect

The PDE 7 (phosphodiesterase VII) inhibiting effect of the compounds
of the present invention was performed by the following method, which
was modified assay method described in Biochemical. Pharmacol. 48(6),
1219-1223 (1994).
(1) The active fraction of PDE 7 (phosphodiesterase VII) was obtained.
That is, MOLT-4 (obtainable from ATCC as ATCC No. CRL-1582), which was
cell line of human acute lymphoblastic lymphoma T cells, was incubated
in RPMI1640 culture medium containing 10% fetal bovine serum to obtain
5 X 108 MOLT-4 cells. The cells were collected by centrifugation and
suspended with lOmL of buffer solution A [25mM of tris-HCl, 5mM of
2-mercaptoethnol, 2mM of benzamidine, 2mM of EDTA, 0. ImM of
4- (2-aminoethyl)benzensulfonyl hydrochloride; pH 7.5], then homogenized
by Polytron® homogenizer. The homogenate were centrifuged under 25,000
X G for 10 minutes at 4°C. The supernatant was separated and thus obtained
supernatant was further centrifuged under 100,000 X G for 60 minutes at
4°C, and then filtrated with 0.2um filter to obtain the soluble fraction.
[0100]
(2) The obtained soluble fraction was filled in equilibrium HiTrap Q
column (5mL X 2) with buffer solution A, and phosphodiesterase fractions
were eluted by 300mL of buffer solution A with linear gradient from 0
to 0.8 M NaCl concentration. 5mL each of 60 eluents were collected, and
each eluents were examined for cyclic AMP metabolic activities of
phosphodiesterase. The fraction eluting with about 350mM NaCl
concentration parts, where metabolic activities were not inactivated by
lOuM of rolipram (selective inhibitor for phosphodiesterase IV) and lOuM
of milrinone (selective inhibitor for phosphodiesterase III), were
collected as storage solution for using to test PDE 7 inhibiting effect.
[0101]
(3) The tested compound having desired concentration was reacted in
the solution of 2 OmM tris-HCl (pH7.5), lmMofMgCl2, lOOuM of EDTA, 330ug/mL
of bovine serum albumin, 4ug/mL of 5'-nucleotidase, O.luCi of 3H~cAMP
(0.064uM of cAMP), lOuM of rolipram in storage solution of PDE 7 for 2
hours at 25°C. After the reaction, suspension of Sephadex®-QAE in lOmM

of HEPES-Na (pH 7.0) was added to the reaction mixture, and the mixture
was left at rest for 5 minutes. Further, Sephadex®-QAE was added to the
obtained superneitant and the mixture was left at rest for 5 minutes, then,
the radioactivity of the solution was measured.
[0102]
(4) IC50 was calculated as 50% inhibiting concentration of the metabolic
activities of phosphodiesterase VII of the tested compound.
[0103]
The compounds of the present invention selectively inhibit PDE 7
and their selectivities are more than 10 times compared to other
phosphodiesterase. Therefore, it is expected that the side effect of the
compounds of the present invention caused by other isozyme to be less.
[0104]
For exampLe, the selectivity against PDE 4 (phosphodiesterase IV)
of the compounds of the present invention was affirmed by means of the
following Biological Test.
[0105]
Biological Test 2:
Methods for evaluating the PDE 4 inhibiting effect
The PDE 4 (phosphodiesterase IV) inhibiting effect of the compounds
of the present invention was performed by the following method, which
was modified assay method described in Biochemical. Pharmacol. 48(6),
1219-1223 (1994).
[0106]
(1) The active fraction of PDE 4 (phosphodiesterase IV) was obtained.
That is, the livers obtained from three Balb/c mice (male, 12 weeks:
obtainable from CXEA Japan, Inc.) were suspended with 3 OmL of buffer solution
B [20mM of bis--;ris, 5mM of 2-mercaptoethnol, 2mM of benzamidine, 2mM
of EDTA, O.lmM of 4-(2-aminoethyl)benzensulfonyl hydrochloride, 50mM of
sodium acetate; pH6.5], then homogenized by Polytron® homogenizer. The
homogenate were centrifuged under 25,000 X G for 10 minutes at 4°C. The
supernatant was separated and thus obtained supernatant was further
centrifuged under 100,000 X G for 6C minutes at 4°C, and then filtrated

with 0.2um filter to obtain the soluble fraction.
[0107]
(2) The obtained soluble fraction was filled in equilibrium DEAE
sepharose column (1 X 10cm) with buffer solution B, and phosphodiesterase
fractions were eluted by 120mL of buffer solution B with linear gradient
from 0.05 to 1M sodium acetate concentration. 5 mL each of 24 eluents
were collected, and each eluents were examined for cyclic AMP metabolic
activities of phosphodiesterase. The fraction eluting with about 620mM
of sodium acetate concentration parts, where metabolic activities were
inactivated by 30uMof rolipram (selective inhibitor for phosphodiesterase
IV) , were collected as storage solution to test PDE 4 inhibiting effect.
[0107]
(3) The tested compound having desired concentration was reacted in
the solution of 2 OmMtris-HCl (pH7.5), lmMofMgCl2, lOOuMof EDTA, 330ug/mL
of bovine serum albumin, 4ug/mL of 5'-nucleotidase, O.luCi of 3H-cAMP
(0.064pM of cAMP), and storage solution of PDE 4 for 2 hours at 25°C.
After rhe reaction, suspension of [email protected] in lOmM of HEPES-Na (pH
7.0) was added to the reaction mixture, and the mixture was left at rest
for 5 minutes. Further, Sephadex®-QAE was added to the obtained supernatant
and the mixture was left at rest for 5 minutes, then, the radioactivity
of the solution was measured.
[0109]
(4) IC50 was calculated as 50% inhibiting concentration of the metabolic
activities of phosphodiesterase IV of the tested compound.
[0110]
As the results of the mentioned above Biological Test 2, the IC50
of the compounds of PDE 4 inhibiting effect of the present invention was
more than 10 times weaker than that of PDE 7 inhibiting effect.
In the following Tables 1 to 4, the IC50 values of PDE 7 inhibiting
activities and PDE 4 inhibiting activities were summarized.
[0111]
[Table 1]








[0115]
5 The compounds of the present invention inhibit PDE 7 selectively,
and therefore, enhance cellular cAMP level. Consequently, the compounds
of the present invention are useful for treating various kinds of diseases
such as allergic diseases, inflammatory diseases or immunological diseases .
For example, the compounds of the present invention are useful for treating
10 or preventing the diseases such as bronchial asthma, chronic bronchitis,
chronic obstructive pulmonary disease, allergic rhinitis, psoriasis,
atopic dermatitis, conjunctivitis, osteoarthritis, rheumatoid arthritis,
multiple sclerosis, systemic lupus erythematosus, inflammatory bowel
disease, hepatitis, pancreatitis, encephalomyelitis, sepsis, Crohn's
15 disease, rejection for organ transplantation, GVH disease, and restenosis
after angioplasty.

[0116]
The compounds of the present invention can be used for preparation
of the pharmaceutical composition or PDE 7 inhibitor. As an active
ingredient, one or more compounds may be administered in the appropriated
formulation. The formulation for oral administration may include for
example, capsules, granules, fine granules, syrups, dry syrups or the
like; the formulation for parenteral administration may include, for
example injectable solution, suppository formulation such as rectal
suppository or vaginal suppository, nasal administration such as sprays,
or percutaneous absorption formulation such as ointment and tapes, and
the like.
[0117]
The administration dose may vary depending on the various kinds
of factors . These factors may be the condition of the patients, the severity
of the diseases, ages, existence of a complication, as well as formulation.
A usual recommended daily dose for oral administration is within the range
of 0.1 - 1, OOOmg/day/adult, preferably 0.1 - 500mg/day/adult, and more
preferably 1 - lOOmg/day/adult. In the case of parenteral administration,
a usual recommended daily dose is within the range of 1/10 tol/2 based
on dose of oral administration. These doses can be adjusted depending
on age, as well as the patient's condition.
[0118]
The toxicological properties of the compounds of the present
invention is low, therefore, the compounds of the present invention is
expected to have high safety margin.
[0119]
[Examples and Manufacturing Exmples]
The compounds of the present invention and intermediate compounds
used for the synthesis of the compounds of the present invention are
illustrated in the following Manufacturing Examples and Examples.
[0120]
The physicochemical data and chemical structure of the compounds
are summarized in the Tables mentions later. The compound numbers in the

Examples and Manufacturing Examples are identical to those in the Tables.
[0121] Manufacturing Example 1:
tert-Butyl 5-nitro-l-indolinecarboxylate
To a solution of 500mg (3.05mrnol) of 5-nitroindoline in lOmL of
anhydrous dichlcromethane was added 7 98mg (3.65mmol) of di-tert-butyl
dicarbonate under ice cooling, and the mixture was stirred for 1.5 hours.
Then, to this mixture was added catalytic amount of 4-dimethylamiopyridine
and the mixture was stirred for 1 hour at room temperature. Water was
added to the reaction mixture and the mixture was extracted with
dichloromethane. The organic layer was washed with saturated saline
solution and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure and the resulting residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 6/1)
to give 800mg (99%) of the title compound.
[0122]
Manufacturing Example 2:
tert-Butyl 5-amino-l-indolinecarboxylate
80mg of 10% palladium-carbon was added to a solution of 760mg
(2.88mmol) of the compound obtained in the Manufacturing Example 1 in
60mL of methanol, and the reaction atmosphere was exchanged to hydrogen
gas atmosphere. Then, the mixture was stirred for 30 minutes at room
temperature and filtrated by Celite®. The filtrate was removed under
reduced pressure to give 670mg (99%) of the title compound.
[0123]
Manufacturing Example 3:
tert-Butyl 5-(acetylamino)-1-indolinecarboxylate
To a solution of 300mg (1.28mmol) of the compound obtained in the
Manufacturing Example 2 in lOmL of anhydrous dichloromethane were added
191uL (2.69mmol) of acetyl chloride and 37 5uL (2.69mmol) of triethylamine,
and the mixture was stirred for 1 hour at room temperature. Then, water
was added to the reaction mixture and the mixture was extracted with
dichloromethane . The organic layer was dried over with anhydrous sodium

sulfate and removed under reduced pressure. The resulting residue was
purified by silica gel column chromatography (eluent: hexane/ethyl acetate
= 1/1 to 1/2) to give 370mg (quantitative) of the title compound.
[0124]
Manufacturing Excample 4:
N-(2,3-Dihydro-lH-indol-5-yl)acetamide HC1 salt
A mixture solution of 330mg (1.19mmol) of the compound obtained
in the Manufacturing Example 3 in 15mL of 4M-HCl/dioxane was stirred for
1. 5 hours at room temperature. Then, diethyl ether was added to the reaction
mixture and the resulting precipitates were collected to give 173mg (68%)
of the title compound.
[0125]
Manufacturing Example 5:
6-Amino-N-isoprooylnicotinamide
To a solution of 300mg (2.17mmol) of 6-aminonicotinic acid in 50mL
of chloroform were added 370uL (4.24mmol) of isopropylamine, 4mL of
anhydrous propanephosphonic acid (25 wt% solution in ethyl acetate) and
1.4mL (lOmmol) of triethylamin, and the mixture was stirred for 6 hours
at room temperature. Then, saturated sodium bicarbonate aqueous solution
was added to the reaction mixture, and the mixture was extracted with
dichloromethane. The organic layer was washed with saturated saline
solution and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: dichloromethane/methanol = 10/1 to
5/1) to give 30irg (8%) of the title compound.
[0126]
Manufacturing Example 6:
1-(Methylsulfonyl)-5-nitroindoline
To a solution of 300mg (1.83mmol) of 5-nitroindoline in 20mL of
dichloromethane were added 141uL (2.74mmol) of methanesulfonyl chloride
and 382uL (2.74mmol) of triethylamine, and the mixture was stirred for
2 hours at room temperature . 141uL (2.74mmol) of methanesulfonyl chloride
and 255µL (1.83mmol) of triethylamine were further added to the reaction

mixture, and the mixture was stirred for 2 hours at room temperature.
Then, water was added to the reaction mixture and the mixture was extracted
with dichloromethane. The organic layer was washed with saturated saline
solution and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure and the residue was treated with diethyl
ether, then, the orecipitates were collected by filtration to give 410mg
(92%) of the title compound.
[0127]
Manufacturing Example 7:
1-(Methylsulfonyl)-5-indolineamine
The title compound 150mg (58%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 6, instead of the compound obtained in the
Manufacturing Example 1.
[0128]
Manufacturing Example 8:
2-{4-[(4-Nitrophenyl)sulfonyl]-l-piperazinyl}ethanol
To a solution of 415uL (3.33mmol) of 1-piperazineethanol in 20mL
of dichloromethane were added 500mg (2.26mmol) of 4-nitrobenzenesulfonyl
chloride and 472uL (3.38mmol) of triethylamine under ice cooling, and
the mixture was stirred for 30 minutes at the same temperature. The reaction
mixture was diluted with dichloromethane and the organic layer was washed
with water, saturated sodium bicarbonate aqueous solution and saturated
saline solution and then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel cclumn chromatography (eluent: dichloromethane/methanol
= 30/1) to give 670mg (94%) of the title compound.
[0129]
Manufacturing Example 9:
2-{4-[(4-Nitrophenyl)sulfonyl]-1-piperazinyl}ethyl acetate
The title compound 175mg (77%) was obtained in a manner similar
to the Manufacturing Example 3 by use of the compound obtained in the
Manufacturing Example 8, instead of the compound obtained in the

Manufacturing Example 2.
[0130]
Manufacturing Example 10:
2-{4-(4-Aminophenyl)sulfonyl}-l-piperazinyl}ethyl acetate
The title compound 130mg (95%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 9, instead of the compound obtained in the
Manufacturing Example 1.
[0131]
Manufacturing Example 11:
tert-Butyl tran;;-4- (acetylamino) cyclohexylcarbamate
The title compound 130mg (68%) was obtained in a manner similar
to the Manufacturing Example 3 by use of tert-butyl fcrans-4-amino-
cyclohexylcarbanate, instead of the compound obtained in the Manufacturing
Example 2.
[0132]
Manufacturing Example 12:
N-(trans-4-Aminocyclohexyl)acetamide trifluoroacetic acid salt
To a solution of 220mg (0.86mmol) of the compound obtained in the
Manufacturing Example 11 in 8mL Of dichloromethane was added 8mL of
trifluoroacetic acid at room temperature, and the mixture was stirred
for 30 minutes at the same temperature. The reaction mixture was condensed
and the residue was treated with diethyl ether. The resulting precipitates
were collected by filtration to give 194mg (84%) of the title compound.
[0133]
Manufacturing Example 13:
2-Methoxy-N-(4-nitrophenyl)acetamide
To a mixture solution of 384uL (5.0mmol) of methoxyacetic acid and
691mg (5.0mmol) of p-nitroaniline in lOmL of dichloromethane were added
1.53mg (5.5mmol) of2-chloro-l,3-dimethylimidazoliumhexafluorophosphate
and 1.53mL (ll.Onmol) of triethylamine, and the mixture was refluxed for
7 hours. Then, the reaction mixture was extracted with ethyl acetate,
the extract was washed with water and saturated saline solution, then,

dried over with anhydrous sodium sulfate. The solvent was removed under
reduced pressure and the residue was purified by silica gel column
chromatography (eluent: hexane/ethyl acetate = 2/1) to give 750mg (71%)
of the title compound.
[0134]
Manufacturing Example 14:
N-(4-Aminophenyl)-2-methoxyacetamide
The title compound 604mg (86%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 13, instead of the compound obtained in the
Manufacturing Example 1.
[0135]
Manufacturing Example 15:
6- (4-Methyl-l-piperazinyl) -3-pyridirtylamine
The title compound 536mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of l-methyl-4-
(5-nitro-2-pyridinyl)piperazine, instead of the compound obtained in the
Manufacturing Example 1.
[0136]
Manufacturing Example 16:
l-Methyl-4-[(3-ritrophenyl)sulfonyl]piperazine
Toasolutionof 500mg (2.26mmol) of 3-nitrobenzenesulfonyl chloride
in 30mL of dichloromethane were added 275uL (2.48mmol) of N-methyl-
piperazine and 7 86uL (5.64mmol) of triethylamine, and the mixture was
stirred for 1 hour at room temperature . The reaction mixture was extracted
with dichloromethane and the organic layer was washed with water and
saturated saline solution, and then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was treated with diethyl ether to give 510mg (79%) of the title compound.
[0137]
Manufacturing Example 17:
3-[(4-Methyl-l-piperazinyl)sulfonyl]aniline
The title compound 350mg (98%) was obtained in a manner similar

to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 16, instead of the compound obtained in the
Manufacturing Example 1.
[0138]
Manufacturing Example 18:
2-[2-Fluoro (methyl)-4-nitroanilino]ethanol
To a solution of 554uL (5.0mmol) of 3,4-difluoronitrobenzene in
lOmL of dimethyl sulfoxide were added 1.38mg (lO.Ommol) of potassium
carbonate and 803uL (lO.Ommol) of 2-methylaminoetanol, and the mixture
was stirred for L.5 hours at 100°C. The reaction mixture was cooled to
room temperature and extracted with ethyl acetate, then, the extract was
washed with water and saturated saline solution. After dried over with
anhydrous sodium sulfate, the solvent was removed under reduced pressure
ant the residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 1/1) to give 1.06g (99%) of the title compound.
[0139]
Manufacturing Example 19:
2-(4-Amino-2-fluoromethylanilino)ethanol
The title compound 900mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Manufacturing Examplel8, instead of the compound obtained in the
Manufacturing Example 1.
[0140]
Manufacturing Example 20:
tert-Butyl 4-(4-nitrophenyl)-1-piperidinecarboxylate
To a solution of 4.84g (30rrmol) of 4-phenylpiperidine in 30mL of
cone, sulfuric acid was added gradually a solution of 1.26mL of fuming
nitric acid in 5mL of cone, sulfuric acid under ice cooling, and after
addition, the reaction mixture was warmed up to room temperature. Then,
the reaction mixture was poured into 200g of ice and sodium hydroxide
aqueous solution was added slowly until the mixture to be alkalified.
The mixture was extracted with chloroform and the organic layer was dried
over with anhydrous sodium sulfate. The solvent removed under reduced

pressure. Then,. 2.18g (lOramol) of di-tert-butyl dicarbonate was added
to a solution of the resulting residue in 20mL of dichloromethane, and
the mixture was stirred for 1 hour at room temperature. The mixture was
concentrated and the residue was purified by silica gel column
chromatography (eluent: dichloromethane/methanol = 40/1) to give 0.78g
(8%) of the title compound.
[0141]
Manufacturing Example 21:
tert-Butyl 4-(4-aminophenyl)-1-piperidinecarboxylate
The title compound 392mg (57%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 20, instead of the compound obtained in the
Manufacturing Example 1.
[0142]
Manufacturing Example 22:
l-Ethyl-4-(2-fluoro-4-nitrophenyl)piperazine
The title compound 2.33g (92%) was obtained in a manner similar
to the Manufacturing Example 18 by use of N-ethylpiperazine instead of
2-methylaminoethanol.
[0143]
Manufacturing Example 23:
1-(2-riuoro-4-nitrophenyl)-4-methyl-l,4-diazepam
The title compound 2.21g (87%) was obtained in a manner similar
to the Manufacturing Example 18 by use of N-methylhomopiperazine, instead
of 2-methylaminoethanol.
[0144]
Manufacturing Example 24:
4-(4-Ethyl-l-piperazinyl)-3-fluoroaniline
The title compound 1.85g (94%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 22, instead of the compound obtained in the
Manufacturing Example 1.
[0145]

Manufacturing Example 25:
1-(2-Fluoro-4-nitrophenyl)-4-methylpiperazine
To a solution of 3 . 9mL (35mmol) of 3, 4-dif luoronitrobenzene in 60mL
of dimethyl sulfoxide were added 9.7mL (87.5mmol) of N-methylpiperazine
and 12 . lg (87 .5mmol) of potassium carbonate, and the mixture was refluxed
for 5 hours at 100°C. The reaction mixture was cooled to room temperature
and poured into 500mL of ice water, and the resulting precipitates were
collected. The collected precipitates were dissolved in 2M-HC1 aqueous
solution and washed with ether. The aqueous layer was neutralized with
4M-NaOH aqueous solution to give the precipitates. The precipitates were
collected to give 5.71g (68%) of the title compound.
[0146]
Manufacturing Example 26:
3-Fluoro-4-(4-methyl-l-piperazinyl)aniline
The title compound 2.76g (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Manufacturing Example 25, instead of the compound obtained in the
Manufacturing Example 1.
[0147]
Manufacturing Example 27:
8-(2-Fluoro-4-nitrophenyl)-1, 4-dioxa-8-azaspiro[4.5]decane
The title compound 2.82g (quantitative) was obtained in a manner
similar to the Manufacturing Example 25 by use of l,4-dioxa-8-
azaspiro[4.5]decane, instead of N-methylpiperazine.
[0148]
Manufacturing Example 28:
4-(1,4-Dioxa-8-azaspiro[4.5]deca-8-yl)-3-fluoroaniline
To a solution of 2.0g (7.09mmol) of the compound obtained in the
Manufacturing Example 27 in 30mL of methanol was added 200mg of platinum
on sulfide carbcn, and the reaction atmosphere was changed to hydrogen
gas atmosphere. Then, the mixture was stirred for 5 hours at normal
pressures and temperature. The reaction mixture was filtrated by Celite®,
and the filtrate was removed under reduced pressure. The residue was

purified by silica, gel column chromatography (eluent: hexane/ethyl acetate
= 3/1 to 1/1) to give 1.71g (96%) of the title compound.
[0149]
Manufacturing Example 29:
8-(2-Chloro-4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane
The title compound 3.05g (quantitative) was obtained in a manner
similar to the Manufacturing Example 25 by use of 3, 4-dichloronitrobenzene
and 1,4-dioxa-8-azaspiro[4.5]decane, instead of 3,4-difluoronitoro-
benzene and N-me"hylpiperazine, respectively.
[0150]
Manufacturing Example 30:
3-Chloro-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)aniline
The title compound 1.84g (85%) was obtained in a manner similar
to the Manufacturing Example 28 by use of the compound obtained in the
Manufacturing Example 29, instead of the compound obtained in the
Manufacturing Example 27.
[0151]
Manufacturing Example 31:
3-Fluoro-4-(4-methyl-l,4-diazapam-l-yl)aniline
The title compound 1.85g (94%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 23, instead of the compound obtained in the
Manufacturing Example 1.
[0152]
Manufacturing Example 32:
4-[2-(4-Morpholinyl)ethyl]aniline
The title compound 2.17g (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of 4-[2-(4-morpholinyl)-
ethyl] nitrobenzene, instead of the compound obtained in the Manufacturing
Example 1.
[0153]
Manufacturing Example 33:
l-Methyl-3-(4-nitrobenzyl)-2,4-imidazodinedione

To a mixture solution of 685mg (6.0mmol) of 1-methylhydantoin in
lOmL of N,N-dimethylformamide and lOmL of tetrahydrofuran was added 240mg
(6.9mmol) of sodiumhydride (60% oily) at room temperature, and the mixture
was stirred for 3D minutes at the same remperature. Then, 1.08g (5.0mmol)
of p-nitrobenzyl bromide was added to the reaction mixture, and the mixture
was stirred for over night at room temperature. Water was added to the
reaction mixture and the mixture was extracted with ethyl acetate. The
organic layer was dried over with anhydrous sodium sulfate and the solvent
was removed under reduced pressure to give 1.38g (quantitative) of the
title compound.
[0154]
Manufacturing Example 34:
3-(4-Aminobenzyl)-l-methyl-2,4-imidazolidinedione
To a mixture solution of 1.33g (5.34mmol) of the compound obtained
in the Manufacturing Example 33 in 12mL of ethanol and 6mL of conc,
hydrochloric acid was added 5. 4 lg (24.01mmol) of tin chloride (II) dehydrate
at room temperature, and the mixture was stirred for 2 hours at 75°C.
The reaction mixture was cooled to room temperature, alkalized by adding
of 4N-sodium hydroxide aqueous solution and treated with chloroform. The
mixture was filtered with Celite©, and chloroform layer was separated
and dried over with anhydrous sodium sulfate. The solvent was removed
under reduced pressure to give 1.148g (98%) of the title compound.
[0155]
Manufacturing Example 35:
tert-Buryl trani.'-4-cyanocyclohexylcarbamate
To a solution of 765mg (4.99mmol) of trans-4-cyanocyclohexane
carboxylic acid in lOmL of tert-butanol was added 766uL (5.49mmol) of
triethylamine and 1.13mL (5.24mmol) of diphenylphosphorylazide at room
temperature, and the mixture was refluxed for 6 hours. After the reaction
mixture was cooled to room temperature, ethyl acetate was added to this
mixture and the organic layer was washed with saturated sodium bicarbonate
aqueous solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified

by silica gel column chromatography (eluent: hexane/ethyl acetate=2/l)
to give 608mg (54%) of the title compound.
[0156]
Manufacturing Example 36:
trans-4-Aminocyclohexane carbonitrile HC1 salt
The title compound 361mg (50%) was obtained in a manner similar
to the Manufacturing Example 4 by use of the compound obtained in the
Manufacturing Example 35, instead of the compound obtained in the
Manufacturing Example 3.
[0157]
Manufacturing Example 37:
1-(2-Aminoethyl)-4-methyl-2,3-piperazinedione HC1 salt
To a solution of 3.60g (11.95mmol) of 2-[2-(4-methyl-2,3-dioxo-
1-piperazinyl)ethyl]phthalimide in 30mL of ethanol was added 695uL
(14.34mmol) of hydrazine monohydrate and the mixture was stirred at 40°C
for over night. The reaction mixture was cooled to room temperature, then,
25mL of water and 6mL of 6N-HC1 were added to this mixture and the mixture
was stirred for 5 hours at room temperature. After removed off the insoluble
substances by filtration, the filtrate was concentrated and the residue
was re-crystallized by 2% water-ethanol solution to give 2.12g (85%) of
the title compound.
[0158]
Manufacturing Example 38:
tert-Butyl 1-[(dimethylamino)carbonyl]-4-piperidinylcarbamate
To a solution of 500mg (2.50mmol) of tert-butyl 4-piperidinyl-
carbamate in 20mL of dichloromethane was added 522uL (3.74mmol) of
triethylamine and 276uL (3.00mmol) of dimethylaminocarbonyl chloride and
the mixture was stirred for 2 hours at room temperature. Then, the mixture
was treated with ethyl acetate and the organic layer was washed with water
and saturated saline solution, and then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure to give 636mg
(94%) of the title compound.
[0159]

Manufacturing Example 39:
4-Amino-N,N-dimethyl-l-piperidinecarboxamide HC1 salt
The title compound 571mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 4 by use of the compound obtained
in the Manufacturing Example 38, instead of the compound obtained in the
Manufacturing Example 3.
[0160]
Manufacturing Example 40:
tert-Butyl 1-[(dimethylamino)sulfonyl]-4-piperidinecarbamate
To a solution of 412mg (2.06mmol) of tert-butyl 4-piperidinyl-
carbamate in 20:.µL of dichloromethane were added 430uL (3.09mmol) of
triethylamine and 265µL (2.47mmol) of dimethylsulfamoyl chloride and the
mixture was stirred for 2 hours at room temperature. Then, the mixture
was treated with ethyl acetate and the organic layer was washed with water
and saturated saline solution, and then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 40/1) togive536mg (85%) of the title compound.
[0161]
Manufacturing Example 41:
4-7Amino-N,N-dimethyl-l-piperidinesulfonamide HC1 salt
The title compound 0.42g (quantitative) was obtained in a manner
similar to the Manufacturing Example 4 by use of the compound obtained
in the Manufacturing Example 40, instead of the compound obtained in the
Manufacturing Example 3.
[0162]
Manufacturing Example 42:
Methyl (2S, 4S) -<:- amino> The title compound 4.70g (96%) was obtained in a manner similar
to the Manufacturing Example 2 by using methyl (2S, 4S)-1-benzyloxy-
carbonyl-4-tert-butoxycarbonylaminopyrrolidine-2-carboxylate, instead
of the compound obtained in the Manufacturing Example 1.
[0163]

Manufacturing Example 43:
Methyl (2S,4S)-1-(aminocarbonyl)-4-[(tert-butoxycarbonyl)amino]-2-
pyrroliclinecarboxylate
To a solution of 4.60g (18.83mmol) of the compound obtained in the
Manufacturing Example 42 in 80mL of dioxane and 80mL of water were added
2.29g (28 . 55mmol) of potassium isocyanate and 3 .23mL (56.49mmol) of acetic
acid, amd the mixture was stirred for 17 hour at room temperature. Then,
the mixture was treated with ethyl acetate and the organic layer was washed
with water and saturated saline solution, and then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 20/1) togive2.32g (43%) of the title compound.
[0164]
Manufacturing Example 44:
tert-Butyl (6S,7aS)-1,3-dioxohexahydro-lH-pyrrolo[1,2-c]imidazol-6-
ylcarbamate
To a solution of 2.21g (7.69mmol) of the compound obtained in the
Manufacturing Example 43 in 150ml of methanol was added gradually 615mg
(15.38mmol) of sodium hydride (60% oily) and the mixture was stirred for
30 minutes at room temperature. After condensed the reaction mixture,
ethyl acetate and diluted hydrochloric acid were added to this mixture.
The organic layer was separated and dried over with anhydrous sodium sulfate,
and the solvent removed under reduced pressure to give 1.8g (92%) of the
title compound.
[0165]
Manufacturing Example 45:
(6S,7aS)-6-Aminotetrahydro-lH-pyrrolo[1,2-c]imidazole-1,3(2H)-dione
HC1 salt
The title compound 1.18g (91%) was obtained in a manner similar
to the Manufacturing Example 4 by use of the compound obtained in the
Manufacturing Example 44, instead of the compound obtained in the
Manufacturing Example 3.
[0166]

Manufacturing Exeimple 46:
1- (5-Amino-2-pyr:iciinyl) -2-imidazolidinone
The title compound 730mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of 1- (5-nitro-2-pyridinyl) -
2-imidazolidinone, instead of the compound obtained in the Manufacturing
Example 1.
[0167]
Manufacturing Example 47:
3-(4-Aminophenyl)-2,4-imidazolidinedione
The title compound 179mg (69%) was obtained in a manner similar
to the Manufacturing Example 2 by use of 3- (4-nitrophenyl) -2, 4-imidazoli-
dinedione, instead of the compound obtained in the Manufacturing Example
1.
[0168]
Manufacturing Example 48:
3-(4-Aminophenyl)-l-methyl-2,4-imidazolidinedione
The title compound 413mg (95%) was obtained in a manner similar
to the Manufacturing Example 2 by use of 3-(4-nitrophenyl)-l-methyl-2,4-
imidazoiidinedicne, instead of the compound obtained in the Manufacturing
Example 1.
[0169]
Manufacturing Example 49:
(3R)-1-(4-Aminophenyl)-3-pyrrolidinol
The title compound 1.98g (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of (3R) -1- (4-nitrophenyl) -3-
pyrrolidinol, instead of the compound obtained in the Manufacturing Example
1.
[0170]
Manufacturing Example 50:
(3R)-1-(2-Fluoro-4-nitrophenyl)-3-pyrrolidinol
The title compound 2.19g (65%) was obtained in a manner similar
to the Manufacturing Example 18 by use of (R)-3-pyrrolidinol, instead
of 2-methylarainoethanol.

[0171]
Manufacturing Example 51:
(3R)-1-(4-Amino-2-fluorophenyl)-3-pyrrolidinol
The title compound 1.81g (99%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Elxample 50, instead of the compound obtained in the
Manufalcturing Example 1.
[0172]
Manufacturing Example 52:
1- [ (3--Nitrophen/l) sulfonyl] -4-piperidinol
The title compound 1.91g (49%) was obtained in a manner similar
to the Manufacturing Example 16 by use of 4-hydroxypiperidine, instead
of N-methylpiperazine.
[0173]
Manufacturing Example 53:
1-[(3-Aminophenyl)sulfonyl]-4-piperidinol
The title compound 1.56g (52%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 52, instead of the compound obtained in the
Manufacturing Example 1.
[0174]
Manufacturing Example 54:
1-[(4-Nitrophenyl)sulfonyl]-4-piperidinol
The title compound 1.91g (49%) was obtained in a manner similar
to the Manufacturing Example 8 by use of 4-hydroxypiperidine, instead
of 1-piperazineethanol.
[0175]
Manufacturing Example 55:
4-{[tert-Butyl(dimethyl)silyl]oxy}-l-[(4-nitrophenyl)sulfonyl]-
piperidine
To a solution of 1.5g (5.24mmol) of the compound obtained in the
Manufacturing Example 54 in 60mL of dichloromethane was added 1.32mL
(5.76:nimol) of tert-butyldimethylsilyl trifluorate at 0°C, and the mixture

was stirred over night at room temperature. After the reaction, the reaction
mixture was washed with water and the organic layer was dried over with
anhydrous sodium sulfate. The solvent was removed under reduced pressure
and the residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 5/1) to give 2.04g (97%) of the title compound.
[0176]
ManufPicturing Example 56:
4-[(4-{[terfc-Bu"yl(dimethyl)silyl]oxy}-l-piperidinyl)sulfonyl]-
aniline
The title compound 1.67g (98%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 55, instead of the compound obtained in the
Manufacturing Example 1.
[0177]
Manufacturing Example 57:
l-Methyl-4-[4-nitro-2-(trifluoromethyl)phenyl]piperazine
The title compound 2.28g (82%) was obtained in a manner similar
to the Manufacturing Example 2 5 by use of 2-fluoro-5-nitrobenzotrifluoride,
instead of 3,4-difluoronitrobenzene.
[0178]
Manufacturing Example 58:
4-(4-Methyl-l-piperidinyl)-3-(trifluoromethyl)phenylamine
The title compound 1.96g (99%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 57, instead of the compound obtained in the
Manufacturing Example 1.
[0179]
Manufacturing Example 59:
2-[2-(5-Methyl-l,1-dioxide-l,2, 5-thiadiazolidin-2yl)ethyl]-1H-
isoinclole-1, 3 (2H) -dione
To a solution of 68 6mg (5.04mmol) of 2-methyl-l, 2, 5-thiadiazolidine
1,1-dioxide in lOmL of N,N-dimethylformamide was added 212mg (5.30mmol)
of sodium hydride (60% oily) at room temperature, and the mixture was

stirred for 1 hour at the same temperature. Then, 1.41g (5.54mmol) of
N-(2-bromoethyl)phthalimide was added to the reaction mixture, and the
mixture was stirred for 1.5 hours at 75°C. After the reaction, water was
added tc the react ionmixture and solvent was removed under reduced pressure.
The resulting residue was treated with water and extracted with
dichloromethane and the organic layer was washed with water and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 1/5) ,
and solidified by treating with ethyl acetate/ether to give 526mg (34%)
of the title compound.
[0180]
Manufacturing Example 60:
2-(5-Methyl-l-l-dioxide-l, 2, 5-thiadiazolidin-2-yl)ethanamine HC1 salt
To a suspension of 500mg (1.62mmol) of the compound obtained in
the Manufacturing Example 59 in 5mL cf ethanol was added 94uL (1.94mmol)
of hydrazine monohydrate, and the mixture was stirred for 6 hours at 70°C.
Then, insoluble substances were removed off by filtration and the filtrate
was removed under reduced pressure, and 5mL of water and 1. 5mL of 6M-HC1
aqueous solution were added to the residue. Then, the mixture was stirred
for 6 hours at room temperature and insoluble substances were removed
off by filtration and the filtrate was removed under reduced pressure.
The resulting reaidue was recrystallized from ethanol to give 287mg (82%)
of the title compound.
[0181]
Manufacturing Example 61:
1- (2-Fluoro-4-nitrophenyl) -4-piperidinol
To a solution of 4.77g(30.Ommol) of 3, 4-difluoronitrobenzene in
lOOmL of N,N-dimethylformamide were added 5.33g (40. Ommol) of potassium
carbonate and 3.03g (30.Ommol) of 4-hydroxypiperidine and the mixture
was stirred for 1 hour at 120°C. After the reaction mixture was cooled
to room temperature, the reaction mixture was diluted with chloroform
and insoluble substances were removed off by filtration. The filtrate

was condensed and the residue was purified by silica gel column
chromatography (eluent: hexane/ethyl acetate = 1.5/1) to give 3. lg (43%)
of the title compound.
[0182]
Manufacturing Example 62:
1- (4-ftmino-2-fluorophenyl)-4-piperidinol
To a solution of 2.95g (12.28mmol) of the compound obtained in the
Manufacturing Example 61 in lOOmL of ethanol was added 600mg of 5%-palladium
carbon, and the atmosphere was exchanged to hydrogen atmosphere. The
mixture was stirred for 2 hours at room temperature and filtered. The
filtrate was removed under reduced pressure to give 2.48g (96%) of the
title compound.
[0183]
Manufacturing Example 63:
tert-Butyl tran;;-4- (4-morpholinyl) cyclohexylcarbamate
To a solution of 21.43g (O.lmol) of tert-butyl N-(trans-4-amino-
cyclohexyl) carbamate in 250mL of N, N-dimethylformamide were added 16. 7 6mL
(0.12mol) of bis (2-bromoethyl) ether and 34 . 85mL (0.25mol) of triethylamine,
and the mixture v/as stirred for 6 hours at 7 0°C. Then solvent was removed
under reduced pressure and the residue was treated with ethyl acetate.
The organic layer was washed with sodium carbonate aqueous solution and
saturated saline solution, then, dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: chloroform alone to
chloroform/methanol = 30/1) to give 19.92g (70%) of the title compound.
[0184]
Manufacturing Example 64:
trans-A- (4-Morpholinyl) cyclohexylamine di-HCl salt
To a solution of 18.53g (65.16mmol) of the compound obtained in
the Manufacturing Example 63 in 65mL of chloroform was added 130mL of
4N-HCl/ethyl acetate solution, and the mixture was stirred for 3 hours
at room temperature. The reaction mixture was treatedwith200mL of diethyl
ether and separated precipitates were collected to give 16.22g (97%) of

the title compound.
[0185]
Manufacturing Example 65:
4-(4-Nitrophenyl)-2-piperazinone
To a solution of 1.275g (9.04mmol) of 4-fluoronitrobenzene in 30mL
of N,N-clime thy If ormamide were added 1.87g (13.56mmol) of potassium
carbonate and 905mg (9.04mmol) of piperazine-2-one, and the mixture was
stirred for 1 hour at 130°C and for 1 hour at 140°C. The reaction mixture
was cooled to room temperature and diluted with chloroform, then, insoluble
substances were iremoved off by filtration. The filtrate was condensed
under reduced pressure and the resulting solid was washed with ethanol
to give 859mg (43%) of the title compound.
[0186]
Manufacturing Ex.ample 66:
4-(4-Aminophenyl)-2-piperadinone
The title compound 640mg (89%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 65, instead of the compound obtained in the
Manufacturing Example 1.
[0187]
Manufacturing Example 67:
3-Amino-N,N-dimethylbenzenesulfonamide
The title compound 2.55g (99%) was obtained in a manner similar
to the Manufacturing Example 2 by use of N,N-dimethyl-3-nitrobenzene-
sulfonamide, instead of the compound obtained in the Manufacturing Example
1.
[0188]
Manufacturing Example 68:
3-[(2-{[tert-Butyl(dimethyl)siliyl]oxy}ethyl)sulfonyl]nitrobenzene
To a solution of 955mg (4.13mmol) of 3-[(2-hydroxyethyl)sulfonyl]-
nitrobenzene in 30mL of dichloromethane were added 747mg (4.96mmol) of
tert-butyldimethylsilyl chloride and lOmg of 4-dimethylaminopyridine,
and the mixture was stirred for over night at room temperature. Then,

the reaction mixture was diluted with dichloromethane and the organic
layer was washed with water and dried over anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 4/1
to 2/1) to give 1.27g (89%) of the title compound.
[0189]
Manufacturing Example 69:
3-[(2-tert-Butyl(dimethyl)silyl)oxy]ethyl)sulfonyl}aniline
The title compound 856mg (94%) was obtained in a manner similar
to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 68, instead of the compound obtained in the
Manufacturing Example 1.
[0190]
Manufacturing Example 7 0:
2-[(2-Hydroxyethyl)(methyl)amino]-N-(4-nitrophenyl)acetamide
To a suspension of 2.946g (13.73mmol) of 2-chloro-N-(4-nitro-
phenyl) acetamide in 30mL of ethanol was added 3.31mL (41.18mmol) of
2- (methyamino)ethanol and the mixture was refluxed for 4 hours. After
the reaiction mixture was cooled to room temperature and condensed, then,
the residue was treated with ethyl acetate. The organic layer was washed
with water and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: dichloromethane/methanol = 40/1) to
give 2.05g (59%) of the title compound.
[0191]
Manufacturing Example 71:
4-Methyl-l-(4-nitrophenyl)-2-piperazinone
To a solution of 1.48g (5.84mmol) of the compound obtained in the
Manufacturing Example 70 in 50mL of tetrahydrofuran were added 1.75mL
(7.01mmol) of tri-n-butylphosphine and 1.21g (7.01mmol) of l,l'-azobis-
(N,N-dimethylfoimamide) , and the mixture was stirred for 4 hours at room
temperature. Water was added to the reaction mixture and the mixture was
extracted with ethyl acetate. The organic layer was washed with saturated

saline solution and dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was purified by silica
gel column chromatography to give 738mg (54%) of the title compound.
[0192]
Manufacturing Example 72:
1-(4-Aminophenyl)-4-methyl-2-piperazinone
The title compound 545mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Manufacturing Example 71, instead of the compound obtained in the
Manufacturing Example 1.
[0193]
Manufacturing Example 73:
1-(5-Nitro-2-pyridinyl)-4-piperidinol
To a suspension of 1.Og (6.3mmol) of 2-chloro-5-nitropyridine in
20mL of n-propanol was added 1.9g (18.9mmol) of 4-hydroxypiperidine, and
the mixture was stirred for 1.5 hours at 100°C. After cooling the reaction
mixture, the solvent was removed under reduced pressure, and the residue
was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 50/1) to give 1.37g (97%) of the title compound.
[0194]
Manufacturing Example 74:
1- (5-Amino-2-py:ridinyl) -4-piperidinol
To a suspension of 1.35g (6.04mmol) of the compound obtained in
the Manufacturing Example 73 in 18mL of ethanol and 3mL of water were
added 1.3g of reduced iron and 0.25mL of cone, hydrochloric acid, and
the mixture was stirred for 2 hours at 90°C. After cooling the reaction
mixture, the mixture was filtrated by Celite© and filtrate was condensed
under reduced pressure. The resulting residue was purified by silica gel
column chromatography (eluent: dichloromethane/methanol = 10/1) to give
601mg (51%) of the title compound.
[0195]
Manufacturing Example 75:
1-(2,3-Difluoro-4-nitrophenyl)-4-piperidinol

To a solution of 1.72mL (15inmol) of 2,3,4-trifluorobenzene in
N,N-dimethylfor:riamide were added l.Olg (lOmmol) of 4-hydroxypiperidine
and 2.3mL (20mmol) of 2, 6-lutidine, and the mixture was stirred for 24
hours at room temperature. The solvent was removed under reduced pressure,
and saturated sodium bicarbonate aqueous solution was added to the residue
and the mixture was extracted with ethyl acetate. The organic layer was
washed with water and saturated saline solution, and dried over with
anhydrous sodium sulfate. The solvent was removed under reduced pressure
and the residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 2/1 to ethyl acetate alone) to give 1.82g (70%)
of the title compound.
[0196]
Manufacturing Example 76:
1-(4-Amino-2,3-difluorophenyl)-4-piperidinol
The title compound 1.23g (78%) was obtained in a manner similar
to the Manufacturing Example 74 by use of the compound obtained in the
Manufacturing E.xample 75, instead of the compound obtained in the
Manufacturing Example 73.
[0197]
Manufacturing Example 77:
1-(2-Methyl-4-nitrophenyl)-4-piperidinol
To a solution of 1.55g (lOmmol) of 2-fluoro-5-nitrotoluene in 35mL
of N,N-dimethylf ormamide were added 1. Olg (lOmmol) of 4-hydroxypiperidine
and 1.8g (13mmol) of potassium carbonate, and the mixture was stirred
for 2 hours at 120°C. The reaction mixture was poured into ice and the
mixture was extracted with ethyl acetate. The organic layer was washed
with water and saturated saline solution, and dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 1/1) to give 1.5g (63%) of the title compound.
[0198]
Manufacturing Example 78:
1- (4-Aird.no-2-me"hylphenyl) -4-piperidinol

The title compound 1.2g (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Manufacturing Example 77, instead of the compound obtained in the
Manufacturing Example 1.
[0199]
Manufacturing Example 79:
2-(4-Hydroxy-l-piperidinyl)-5-nitrobenzonitrile
The title compound 2. Og (81%) was obtained in a manner similar to
the Manufacturing Example 77 by use of 2-fluoro-5-nitrobenzonitrile,
instead of 2-fluoro-5-nitrotoluene.
[0200]
Manufacturing Example 80:
5-Amino-2-(4-hydroxy-l-piperidinyl)benzonitrile
To a suspension of l.Og (4.04mmol) of the compound obtained in the
Manufacturing Example 79 in lOmL of water were added 790mg (14.14mmol)
of iron and 130mg (2.42mmol) of ammonium chloride, and the mixture was
refluxed for 3 hours. After the reaction mixture was cooled to room
temperature, water was added to ~he reaction mixture, and the mixture
was extracted with chloroform. The organic layer was washed with water
and saturated saline solution, and dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate := 1/1
to 1/4) to give 327mg (37%) of the title compound.
[0201]
Manufacturing Example 81:
Methyl 2-(4-hydroxy-l-piperidinyl)-5-nitrobenzoate
The title compound 2.30g (98%) was obtained in a manner similar
to the Manufacturing Example 77 by use of methyl 2-f luoro-5-nitrobenzoate,
instead of 2-fluoro~5-nitrotoluene.
[0202]
Manufacturing Example 82:
Methyl 5-amino-2-(4-hydroxy-l-piperidinyl)benzoate
The title compound 1.83g (91%) was obtained in a manner similar

to the Manufacturing Example 2 by use of the compound obtained in the
Manufacturing Example 81, instead of the compound obtained in the
Manufacturing Example 1.
[0203]
Manufacturing Example 83:
tert-Butyl l-tetrahydro-2H-pyran-4-yl-4-piperidinylcarbamate
To a suspension of 9.5g (184mmol) of tert-butyl piperidin-4-yl
carbamate in 200mL of 1,2-dichloroethane were added 4.4mL (47.4mmol) of
tetrahydro-4H-pyran-4-one and l.OmL of acetic acid, and the mixture was
stirred for 30 minute. The reaction mixture was cooled to 0°C, and to
this mixture was added 15g (71.1mmol) of sodium triacetoxyborohydride
and the mixture was stirred for 4 hours at room temperature, then, 5. Og
(23. 6mmol) of sodium triacetoxyborohydride was further added to the mixture
and the mixture was stirred for 64 hours at room temperature. Saturated
sodium bicarbonate aqueous solution was added to the reaction mixture,
and the mixture was extracted with dichloromethane. The organic layer
was washed with water and saturated saline solution, and dried over with
anhydrous sodium sulfate. The solvent was removed under reduced pressure
and the residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 2/1) to give 11.54g (86%) of the title compound.
[0204]
Manufocturinq Example 84:
l-Tetrahydro-2H-pyran-4-yl-4-piperidineamine di-HCl salt
The title compound 10.8g (quantitative) was obtained in a manner
similar to the Manufacturing Example 4 by use of the compound obtained
in the Manufacturing Example 83, instead of the compound obtained in the
Manufacturing Example 3.
[0205]
Manufacturing Example 85:
tert-Butyl 4-(4--{[(benzyloxy)carbonyl]amino}cyclohexyl)-1-piperazine-
carboxylate
The title compound 4.0g (96%) was obtained in a manner similar to
the Manufacturing Example 83 by use of benzyl 4-oxocyclohexylcarbamate

and cert-butyl 1-piperazinecarbamate, instead of tetrahydro-4H-
pyran-4-one and tert-butyl piperidin-4-ylcarbamate, respectively.
[0206]
Manufacturing Example 86:
tert-Butyl 4- (4--aminocyclohexy) -1-piperazinecarboxylate
The title compound 2.6g (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Manufacturing Example 85, instead of the compound obtained in the
Manufacturing Example 1.
[0207]
Manufacturing Example 87:
(5-Amino-2-pyridinyl) methanol di-HCl salt
The title compound 68 6mg (78%) was obtained in a manner similar
to the Manufacturing Example 4 by use of tert-butyl 6-(hydroxyl-
methyl)pyridin-3-ylcarbamate, instead of the compound obtained in the
Manufacturing Example 3.
[0208]
Manufacturing Example 88:
tert-Butyl trans-A-[(chloroacetyl)amino]cyclohexylcarbamate
The title compound 604mg (89%) was obtained in a manner similar
to the Manufacturing Example 3 by use of tert-butyl trans-4-aminocyclo-
hexylcarbamate and chloroacetyl chloride, instead of the compound obtained
in the Manufacturing Example 2 and acetyl chloride, respectively.
[0209]
Manufacturing Example 89:
tert-Butyl trans-A-({[(2-hydroxyethyl) (methyl) amino]acetyl}amino)-
cyclohexylcarbamate
To a suspension of 560mg (1.93mml) of the compound obtained in the
Manufacturing Example 88 in 5mL of ethanol was added 464uL (5.78mmol)
of 2- (methylamirio) ethanol and the mixture was refluxed for 1 hour. After
cooling, the solvent was removed under reduced pressure and water was
added to the residue, and the mixture was extracted with dichloromethane.
The organic layer was washed with water and saturated saline solution,

and dried over vrith anhydrous sodiun sulfate. The solvent was removed
under reduced pressure and the residue was purified by recrystallization
(isopropanol) to give 391mg (61%) of the title compound.
[0210]
Manufacturing Example 90:
tert-Eutyl trans-A-(4-methyl-2-oxo-l-piperazinyl)cyclohexylcarbamate
589 mg (5.25mmol) of potassium t-butoxide was added to a suspension
solution of 560mg (1.7mmol) of the compound obtained in the Manufacturing
Example 89 in lOriL of tetrahydrofuran, and a solution of 499mg (2. 62mmol)
of p-toluenesulf onyl chloride in 5mL of tetrahydrofuran was added to this
mixture, then, the mixture was stirred for 2 hours at 0CC. 499mg (2.62mmol)
of p-toluenesulf onyl chloride and 589mg (5.25mmol) of potassium t-butoxide
were further adced to the reaction mixture, and the mixture was stirred
for 30minutes at room temperature. Water was added to the reaction mixture
and the mixture was extracted with chloroform. The organic layer was washed
with water and saturated saline solution, and dried over with anhydrous
sodium sulfate. The solvent was removed and the residue was purified by
silica gel column chromatography (eluent: dichloromethane/methanol = 10/1)
to give 398mg (75%) of the title compound.
[0211]
Manufacturing Example 91:
1- (traris-4-7Aminocyclohexyl)-4-methyl-2-piperazinone di-HCl salt
The title compound 349mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 4 by use of the compound obtained
in the Manufacturing Example 90, instead of the compound obtained in the
Manufacturing Example 3.
[0212]
Manufacturing Example 92:
Ethyl l-(4-{[(benzyloxy)carbonyl]amino}cyclohexyl)-4-piperidine-
carboxylate
The title compound 2. 6g (67%) was obtained in a manner similar to
the Manufacturing Example 83 by use of benzyl 4-oxocyclohexylcarbamate
and ethyl isonipecocotinate, instead of tetrahydro-4H-pyran-4-one and

fcert-butyl piperidin-4-ylcarbamate, respectively.
[0213]
Manufacturing Example 93:
Ethyl 1-(4-aminocyclohexyl)-4-pirepidinecarboxylate
The title compound 1.58g (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Manufacturing Example 92, instead the compound obtained in the
Manufacturing Example 1.
[0214]
Manufacturing Example 94:
Ethyl 1-(4-nitrophenyl)-4-pirepidinol
To a solution of 14.lg (O.lOmol) of 4-fluoronitrobenzene in 200mL
of N,N- dimethyl formamide were added 20.73 (0.15mol) of potassium carbonate
and 10.lg (O.lOnol) of 4-hydroxypiperidine and the mixture was stirred
for 1 hour at 140°C. The reaction mixture was cooled to room temperature
and the mixture was treated with chloroform, then insoluble substances
were removed off by filtration. The filtrate was condensed and the residue
was recirystallized fromethanol to give 17 .27g (78%) of the title compound.
[0215]
Manufacturing Example 95:
1-(Aminophenyl)-4-pipreridinol
To a solution of 17.09g (76.95mmol) of the compound obtained in
the Manufacturing Example 94 in 300mL of methanol was added 2.0g of
5%-palladium-carbon, and the atmosphere was exchanged to hydrogen
atmosphere. The mixture was stirred for over night at room temperature
and the mixture was filtrated. The filtrate was removed under reduced
pressure to give 13.04g (88%) of the title compound.
[0216]
Example 1:
2-Cyclohexyl-5-methyl-2,4-dihydro-3H-pyrazol-3-one
h mixture solution of 39.88g (0.265mol) of cyclohexylhydazine HC1
salt in 28.57mL (0.265mol) of methyl acetoacetate was heated for 1 hour
at 120°C. After the reaction mixture was cooled to room temperature,

dichloromethane was added to this mixture and the mixture was neutralized
by 2N-NaOH aqueous solution. The organic layer was dried over with anhydrous
sodium sulfate and the solvent was removed under reduced pressure. The
resulting residue was treated with hexane to give crystalline and the
crystalline was collected by filtration to give 33.84g (71%) of the title
compound.
[0217]
Example 2:
5-Chloro-l-cyclohexyl-3-methyl-lH-pyrazole
A mixture of 13. 5g (74 . 9mmol) of the compound obtained in the Example
1 and 13.5mL of phosphorus oxychloride was heated for 2 hours at 110°C.
Then, the reaction mixture was cooled to room temperature and condensed
under reduced pressure. The residue was extracted with ethyl acetate,
and the extract was washed with saturated sodium bicarbonate aqueous
solution and saturated saline solution, then, dried over with anhydrous
sodium sulfate. The solvent removed under reduced pressure to give 9.84g
(66%) of the title compound.
[0218]
Example 3-1:
5-Chloro-l-cyclohexyl-3-methyl-lH-pyrazole-4-carboaldehyde
To a solution of 9.84g (49.52mmol) of the compound obtained in the
Example 2 in 50mL of N,N-dimethylformamide was added 11.5mL (123. 8mmol)
of phosphorous oxychloride under ice cooling, and the mixture was stirred
for 30 minutes at room temperature and for 1 hour at 80 °C. Then, the reaction
mixture was cooled to room temperature and condensed under reduced pressure.
The residue was extracted with ethyl acetate and the extract was washed
with saturated sodium bicarbonate aqueous solution and saturates saline
solution, then, dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: hexane/ethyl acetate = 10/1) to give
8.73g (76%) of the title compound.
[0219]
Example 3-2 r

5-Chloro-l-cycl3hexyl-3-methyl-lH-pyrazole-4-carboaldehyde
A mixture of llOg (0.61mol) of the compound obtained in the Example
1 and 216mL (2.32mol) of phosphorus oxychloride was heated and stirred
for 2 hours at 110°C. Then, the reaction mixture was cooled to room
temperature and added gradually to 630mL of cooled N, N-dimethylf ormamide.
After adding, the mixture was stirred for 30 minutes at room temperature
and for 5 hours at 8 0 °C. The reactionmixture was cooled to room temperature,
and the mixture was poured slowly into ice. Chloroform was added to this
mixture and pH cf the mixture was adjusted to about 4 by 4N-NaOH aqueous
solution (about 2.3L). The organic layer was separated and water layer
was extracted with chloroform. The combined organic layer was washed with
water and saturated saline solution, then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent: ethyl
acetate/hexane == 1/10 to 1/7) to give 100. 8g (73%) of the title compound.
[0220]
Example 4:
Ethyl [(l-cyclohexyl-4-formyl-3-:methyl-lH-pyrazol-5-yl)sulfanil]-
acetate
To a solution of 8. Og (35. 3mmol) of the compound obtained in the
Example 3 in lOOmL of acetonitrile were added 4.84mL (44.1 lmmol) of ethyl
thioglycolateand7 .32g (52.93mmol) of potassium carbonate, and themixture
was refluxed for 4 hours. Then, 1. 93mL (17 . 64mmol) of ethyl thioglycolate
and 2.43g (17.64mmol) of potassium carbonate were further added to the
reaction mixture and the mixture was refluxed for 2 hours. After the
reaction mixture was cooled to room temperature and condensed under reduced
pressure. The residue was extracted with ethyl acetate and the extract
was washed with water and saturated saline solution, then, dried over
with anhydrous sodium sulfate. The solvent was removed under reduced
pressure and the residue was purified by silica gel column chromatography
(eluent: hexane/ethyl acetate = 4/1) to give 8.09g (74%) of the title
compound.
[0221]

Example; 5-1:
Ethyl l-cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazole-5-carboxylate
To a solution of 7.95g (25. 61mmol) of the compound obtained in the
Example 4 in lOOmL of N,N-dimethylformamide were added 5.31g (38.42mmol)
of potassium carbonate and 677mg (2.56mmol) of 18-crown-6, and the mixture
was heated for 2 hours at 120°C to 130°C. After cooling the reaction mixture
to room temperature, the mixture was extracted with ethyl acetate, and
the extract was washed with water and saturated saline solution, then,
dried over with anhydrous sodium sulfate. The solvent was removed under
reduced pressure and the residue was purified by silica gel column
chromatography (eluent: hexane/acetone =15/1) to give 2.2g (29%) of the
title compound.
[0222]
Example 5-2:
Ethyl l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylate
To a solution of 63.4mL (0.578mmol) of ethyl thioglycolate in 1L
of tetrahydrofuran was added gradually 23g (0.578mol) of sodium hydride
(60% oily) under ice cooling, and the mixture was stirred for 1 hour at
room temperature. The reaction mixture was cooled with ice water, and
a solution of 100.8g (0.444mol) of the compound obtained in the Example
3 in 400mL of tetrahydrofuran was added gradually to this reaction mixture
during 4 5 minutes, and the mixture was stirred for 2 hours at room temperature.
Then, the reaction mixture was cooled with ice water, and 23g (0.578mol)
of sodium hydride (60% oily) was added gradually to this reaction mixture,
and the mixture was stirred for 30 minutes at 0°C. After the reaction,
the reaction mixture was poured slowly into ice/ethyl acetate solution,
and the organic layer was separated. The water layer was extracted with
ethyl acetate, and the combined organic layer was washed with water and
saturated saline solution, then dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: ethyl acetate/hexane = 1/8
to 1/5) to give 104.7g (81%) of the title compound.
[0223]

Example 6:
l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylic acid
To a solution of 11.89g (40.66mmol) of the compound obtained in
the Example 5 in lOOmL of ethanol was added 44.7mL (44.7mmol) of IN sodium
hydroxide solution, and the mixture was heated for 1 hour at 60°C. Then,
the reaction mixture was cooled to room temperature and condensed under
reduced pressure. Water and diethyl ether were added to the residue and
the water layer was separated. 23mL of 2N-HC1 aqueous solution was added
to the water layer, and the resulting precipitates were; collected to give
10.38g (97%) of the title compound.
[0224]
Example 7:
N-Benzyl-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
To a suspension of 60mg (0.23mmol) of the compound obtained in the
Example 6 in 2mL of dichloromethane was added 33uL (0.45mmol) of thionyl
chloride, and the mixture was stirred for 8 hours at 80°C. Then, the solvent
was removed under reduced pressure to give the corresponding acid chloride
intermediate compound.
Next, 27]xli (0.25mmol) of benzylamine and 79uL of triethylamine were
added to the solution of the above acid chloride intermediate compound
in 2mL of anhydrous dichloromethane under ice-cooling, and the mixture
was stirred for 1.5 hours at room temperature. Then, water was added to
the reaction mixture and the mixture was extracted with dichloromethane.
The organic layer was dried over with anhydrous sodium sulfate and removed
under reduced pressure. The residue was purified by silica gel column
chromatography (eluent: hexane/ethyl acetate = 4/1 to 3/1) to give 75mg
(94%) of the title compound.
•[0225]
Example 8:
l-Cyclohexyl-3-methyl-N-phenyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 65mg (84%) was obtained in a manner similar to

the Example 7 by use of aniline, instead of benzylamine.
[0226]
Example 9:
N-{4-[Acetyl(methyl) amino]phenyl}-l-cyclohexyl-3-methyl-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 8 9mg (82%) was obtained in a manner similar to
the Example 7 by use of N- (4-aminophenyl) -N-methylacetamide, instead of
benzylamine.
[0227]
Example 10:
N-[4-(Acetylamino)-3-methoxyphenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 73mg (65%) was obtained in a manner similar to
the Example 7 by use of N-(4-amino-3-methoxyphenyl)acetamide, instead
of benzylamine.
[0228]
Example 11:
N-(l-Acetyl-2,3--dihydor-lH-indol-5-yl)-l-cyclohexyl-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 30mg (27%) was obtained in a manner similar to
the Example 7 by use of l-acetyl-2, 3-clihydro-lH-indol-5-ylamine, instead
of benzylamine.
[0229]
Example 12:
Ethyl 4-{ [ (l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl] amino}phenylcarbamate
The title compound lOlmg (89%) was obtained in a manner similar
to the Example 7 by use of ethyl 4-aminophenylcarbamate, instead of
benzylamine.
[0230]
Example 13:
tert-Butyl 5-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl] amino}-1-indolinecarboxylate

The title: compound 133mg (92%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 2, instead of benzylamine.
[0231]
Example 14:
1-Cyclohexyl-N-(2,3-dihydro-lH-indcl-5-yl)-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 68mg (99%) was obtained in a manner similar to
the Manufacturing Example 4 by use of the compound obtained in the Example
13, instead of the compound obtained in the Manufacturing Example 3.
[0232]
Example 15:
1-Cyclohexyl-N-(lH-indol-5-yl)-3-methyl-lH-thieno[2,3-c]pyrazole-
5-carboxamide
The title compound 95mg (95%) was obtained in a manner similar to
the Example 7 by use of 5-aminoindole, instead of benzylamine.
[0233]
Example 16:
l-Cyclohexyl-3-methyl-N-[4-(4-morpholinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 85mg (89%) was obtained in a manner similar to
the Example 7 by use of 4- (4-morpholinyl) aniline, instead of benzylamine.
[0234]
Example 17:
l-Cyclohexyl-3-methyl-N-(3-nitrophenyl)-lH-thieno[2, 3-c]pyrazole-
5-carboxartiide
The title compound 175mg (60%) was obtained in a manner similar
to the Example 7 by use of 3-nitroaniline, instead of benzylamine.
[0235]
Example 18:
N-(3-Aminophenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrozole- •
5-carboxaimde
The title compound 142mg (quantitative) was obtained in a manner

similar to the Manufacturing Example 2 by use of the compound obtained
in the Example 17, instead of the compound obtained in the Manufacturing
Example 1.
[0236]
Example 19:
N- [3- (Acetylami.no)phenyl] -l-cyoclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 60mg (0.17mmol) of the compound obtained in the
Example 18 in 4mL of anhydrous tetrahydrofuran were added 25uL (0.35mmol)
of acetyl chloride and 50uL (0.35mmol) of triethylamine under ice cooling,
and the mixture was stirred for 2 hour at room temperature. Then, water
was added to the reaction mixture and the mixture was extracted with ethyl
acetate. The organic layer was dried over with anhydrous sodium sulfate
and removed under reduced pressure. The residue was purified by silica
gel column chromatography (eluent: hexane/ethyl acetate = 2/1 to 1/2)
to give 15mg (22%) of the title compound.
[0237]
Example 20:
l-Cyclohexyl-3-methyl-N-{4-(methylamino)carbonyl}phenyl}-lH-
thieno [2, 3-c] py::azole-5-carboxamide
The title compound 37mg (41%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N-methylbenzamide, instead of benzylamine.
[0238]
Example 21:
l-Cyclohexyl-3-iaethyl-N-(l-propionyl-2,3-dihydro-lH-indol-5-yl)-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 47mg (75%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 14 andpropionyl
chloride, insteiid of using the compound obtained in the Example 18 and
acetyl chloride, respectively.
[0239]
Example 22:
Ethyl 5-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-

carbonyl]amino}-l-indolinecarboxylate
The title compound 62mg (82%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 14 and ethyl
chlorocarbonate, instead of the compound obtained in the Example 18 and
acetyl chloride, respectively.
[0240]
Example 23:
1-Cyclohexyl-N-(l-isobutyl-2,3-dihydro-lH-indol-5-yl)-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 68mg (89%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 14 and isobutyryl
chloride, instead of the compound obtained in the Example 18 and acetyl
chloride, respectively.
[0241]
Example 24:
N-(l-Butyryl-2,3-dihydro-lH-indol-5-yl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The tirle compound 66mg (87%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 14 andn-butyryl
chloride, instead of the compound obtained in the Example 18 and acetyl
chloride, respectively.
[0242]
Example 25:
l-Cyclohexyl-N-:;i- (2, 2-dimethylpropanoyl) -2, 3-dihydro-lH-indol-5-
yl] -3-methyl-lH--thieno [2, 3-c] pyrazole-5-carboxamide
The title compound 59mg (76%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 14 and propanoyl
chloride, instead of the compound obtained in the Example 18 and acetyl
chloride, respectively.
[0243]
Example 26:
l-Cyclohexyl-3-nethyl-N-(2-oxo-2,3-dihydro-lH-indol-5-yl)-1H-
thienc[2, 3-c]pyrazole-5-carboxamide

The title compound 60mg (58%) was obtained in a manner similar to
the Example 7 by use of 5-amino-l,3-dihydro-2H-indol-2-one, instead of
benzylamine.
[0244]
Example 27:
N-[4-(Acetylamino)-3-chlorophenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 28mg (43%) was obtained in a manner similar to
the Example 7 b^ use of N-(4-amino-2-chloropheny)acetamide, instead of
benzylamine.
[0245]
Example 28:
1-Cyclohexyl-N--4-[(ethylamino)carbonyl]phenyl}-3-methyl-lH-
thienc[2,3-c]pyrazole-5-carboxamide
The title compound 30mg (32%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N-ethylbenzamide, instead of benzylamine.
[0246]
Example 29:
1-Cyclohexyl-N-[4-(methoxymethyl)phenyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 62mg (70%) was obtained in a manner similar to
the Example 7 by use of 4- (methoxymethyl) aniline, instead of benzylamine.
[0247]
Example 30:
1-Cyclohexyl-N-[4-(hydroxymethyl)phenyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 65mg (76%) was obtained in a manner similar to
the Example 7 by use of (4-aminophenyl)methanol, instead of benzylamine.
[0248]
Example 31:
l-Cyclohexyl-3-ruethyl-N-[4-(morpholinylcarbonyl)phenyl]-1H-
thienc [ 2, 3-c] py3:azole-5-carboxamide
The title compound 88mg (90%) was obtained in a manner similar to

the Exeimple 7 by use of 4-(4-morpholinylcarbonyl) aniline, instead of
benzylamine.
[0249]
Example 32:
l-Cyclohexyl-3-methyl-N-{4-[(4-methyl-l-piperazinyl)carbonyl]-
phenyl}-lH-thie:no [2, 3-c]pyrazole-5-carboxamide
The title compound 57mg (53%) was obtained in a manner similar to
the Example 7 by use of 4-[(4-methyl-l-piperazinyl)carbonyl]aniline,
instead of benzylamine.
[0250]
Example 33:
l-Cyclohexyl-3-methyl-N-{4-[(methylsulfonyl)amino]phenyl}-1H-
thieno[2,3-c]py.razole-5-carboxamide
The title compound 33mg (33%) was obtained in a manner similar to
the Example 7 by use of N-(4-aminophenyl)methanesulfonamide, instead of
benzylamine.
[0251]
Example 34:
l-Cyclchexyl-3-methyl-N-{4-[(methylamino)sulfonyl]phenyl}-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 22mg (22%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N-methylbenzenesulfonamide, instead of
benzylamine.
[0252]
Example 35:
N-{1-[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
2,3-dihydro-lH-indol-5-yl}acetamide
The title compound 76mg (80%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
4, instead of benzylamine.
[0253]
Example 36:
l-Cyclohexyl-3-methyl-N-{4-[(4-methyl-l-piperazinyl)sulfonyl]-

phenyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 36mg (32%) was obtained in a manner similar to
the Example 7 by use of 4-[(4-methyl-l-piperazinyl)sulfonyl]aniline,
instead of benzylamine.
[0254]
Example 37:
1-Cyclohexyl-N-(4-{[(2-methoxyethyl) amino]carbonyl}phenyl)-3-
methyl-lH-thieno[2,3-c]pyrazple-5-carboxamide
The title compound 50mg (50%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N-(2-methoxyethyl)benzamide, instead of
benzylamine.
[0255]
Example 38:
N-(4-Acetylphenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-
5-carboxamide
The title compound 54mg (62%) was obtained in a manner similar to
the Example 7 by use of p-aminoacetophenone, instead of benzylamine.
[0256]
Example 3 9:
1-Cyclohexyl-N-(4-[(dimethylamino)carbonyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 8 6mg (92%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N,N-dimethylbenzamide, instead of
benzylamine.
[0257]
Example 40:
Ethyl 4-([(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}benzoate
The title compound 80mg (51%) was obtained in a manner similar to
the Example 7 by use of ethyl 4-aminobenzoate, instead of benzylamine.
[0258]
Example 41:
4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-

amino)benzoic acid
To a solution of 55mg (0.13mmol) of the compound obtained in the
Example 40 in 8mL of ethanol was added 134uL of 1M sodium hydroxide solution,
and the mixture was stirred for 1 hour at room temperature. Then, 20mL
of water was added to the reaction mixture and the water layer was washed
with ethyl acetate. The water layer was neutralized by adding of 1M-HC1
solution, and the resulting precipitates were collected to give 33mg (65%)
of the title compound.
[0259]
Example 42:
1-Cyclohexyl-N-(2-methoxy-4-nitrophenyl)-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 73mg (31%) was obtained in a manner similar to
the Example 7 by use of 2-methoxy-4-nitroaniline, instead of benzylamine.
[0260]
Example 43:
N-(4-Amino-2-met.hoxyphenyl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 22mg (37%) was obtained in a manner similar to
the Manufacturing Example 2 by use of rhe compound obtained in the Example
42, instead of the compound obtained in the Manufacturing Example 1.
[0261]
Example 44:
N-[4-(Acetylamino)-2-methoxyphenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 27mg (49%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example
43, instead of the compound obtained in the Manufacturing Example 2.
[0262]
Example 45:
1-Cyclohexyl-N-[4-[(isopropylamino)carbonyl]phenyl}-3-methyl-lH-
thieno [2, 3-c] py:razole-5-carboxamide
The title compound 47mg (49%) was obtained in a manner similar to

the Example 7 by use of 4-amino-N-isopropylbenzamide, instead of
benzylamine.
[0263]
Example 4 6:
1-Cyclohexyl-N-(4-{[(2-hydroxyethyl) amino]carbonyl}phenyl)-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxaimde
The title compound 93mg (72%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N- (2-hydroxyethyl)benzamide, instead of
benzylamine.
[0264]
Example 4 7:
N- [6- (Acetylamino)-3-pyridinyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 33mg (37%) was obtained in a manner similar to
the Example 7 by use of N- (5-amino-2-pyridinyl) acetamide, instead of
benzylamine.
[0265]
Example 48:
1-Cyclohexyl-N-(4-methoxyphenyl)-3-methyl-lH-thieno[2, 3-c]pyrazole-
5-carboxamide
The title compound 81mg (96%) was obtained in a manner similar to
the Example 7 by use of p-anisidine, instead of benzylamine.
[0266]
Example 49:
l-Cyclohexyl-N-cyclopentyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 65mg (85%) was obtained in a manner similar to
the Example 7 by use of cyclopentylamine, instead of benzylamine.
[0267]
Example 50:
N,l-Dicyclohexy].-3-methyl-lH-thieno[2/3-c]pyrazole-5-carboxamide
The title compound 82mg (quantitative) was obtained in a manner
similar to the Example 7 by use of cyclohexylamine, instead of benzylamine .

[0268]
Example 51:
N-{4-[(ter t-Butylamino)carbonyl]phenyl}-l-cyclohexyl-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 89mg (89%) was obtained in a manner similar to
the Example 7 by use of 4-amino-N~ (tert-butyl)benzamide, instead of
benzylamine.
[0269]
Example 52:
1-Cyclohexyl-N-{5-[(isopropylamino)carbonyl]-2-pyridinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 13mg (20%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
5, instead of benzylamine.
[0270]
Example 53:
1-Cyclohexyl-N-[4-(fromylamino)phenyl]-3-methyl-lH-
thieno [2, 3-c]py:razole-5-carboxaraide
The title compound llmg (19%) v/as obtained in a manner similar to
the Example 7 by use of 4-aminophenylformamide, instead of benzylamine.
[0271]
Example 54:
tert-Butyl 4-[(4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}phenyl)sulfonyl]-1-piperazinecarboxylate
The title compound 71mg (32%) was obtained in a manner similar to
the Example 7 by use of tert-butyl 4-[(4-aminopehnyl)sulfonyl]-1-pipera-
zinecarboxylate., instead of benzylamine.
[0272]
Example 55:
l-Cyclohexyl-3-methyl-N-[4-(1-piperazinylsulfonyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 30mg (61%) was obtained in a manner similar to
the Manufacturing Example 4 by use of the compound obtained in the Example

54, instead of the compound obtained in the Manufacturing Example 3.
[0273]
Example 56:
l-Cyclohexyl-3-methyl-N-[4-(4-morpholinylsulfonyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 14mg (12%) was obtained in a manner similar to
the Example 7 by use of 4-(4-morpholinylsulfonyl)aniline, instead of
benzylamine.
[0274]
Example 57:
l-Cyclohexyl-3-methyl-N-[4-(methylsulfonyl)phenyl]-1H-
thieno [2, 3-c]pyrazole-5-carboxarnide
The title compound 41mg (43%) was obtained in a manner similar to
the Example 7 by use of 4- (methylsulfonyl) aniline, instead of benzylamine.
[0275]
Example 58:
1-Cyclchexyl-N-[1-(cyclopropylcarbonyl)-2,3-dihydro-lH-indol-
5-yl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 42mg (49%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 14 and
cyclopropanecarbonyl chloride, instead of the compound obtained in the
Example 18 and acetyl chloride, respectively.
[0276]
Example 59:
l-Cyclohexyl-3-methyl-N-[1-(methysulfonyl)-2,3-dihydro-lH-indol-
5-yl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 106mg (quantitative) was obtained in a manner
similar to the Example 7 by use of the compound obtained in the Manufacturing
Example 7, instead of benzylamine.
[0277]
Example 60:
N-(l-Acetyl-lH-indol-5-yl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide

The title compound 94mg (97%) was obtained in a manner similar to
the Example 7 by use of l-acetyl-lH-indole-5-amine, instead of benzylamine.
[0278]
Example 61:
l-Cyclohexyl-N-cylopropyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 67mg (96%) was obtained in a manner similar to
the Example 7 by use of cyclopropylamine, instead of benzylamine.
[0279]
Example 62:
N-(l-Benzyl-4-piperidinyl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 200mg (81%) was obtained in a manner similar
to the Example 7 by use of l-benzyl-4-piperidinylamine, instead of
benzylamine.
[0280]
Example 63:
l-Cyclohexyl-3-methyl-N-(4-piperidinyl)-lH-thieno[2,3-c]pyrazole-
5-carboxamide HC1 salt
To a solution of 180mg (0.42mol) of the compound obtained in the
Example 62 in 4mL of 1,2-dichloroethane was added 50 uL of 1-chloroethyl
chloroformate, and the mixture was re fluxed for 2 hours . Then, the reaction
mixture was coole^d to room temperature and condensed under reduced pressure.
The residue was dissolved in 6mL of methanol and the mixture was ref luxed
for 3 hours. After the reaction mixture was cooled to room temperature,
the solvent was removed under reduced pressure. , The residue was washed
with ethyl acetate and the resulting precipitates were collected to give
109mg (69%) of ;he title compound.
[0281]
Example 64:
N-(l-Acetyl-4-piperidinyl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 40mg (78%) was obtained in a manner similar to

the Manufacturing Example 3 by use of the compound obtained in the Example
63, instead of the compound obtained in the Manufacturing Example 2.
[0282]
Example 65:
Ethyl (4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amio}phenoxy)acetate
The title compound 320mg (96%) was obtained in a manner similar
to the Example 7 by use of ethyl (4-aminophenoxy)acetate, instead of
benzyiamine.
[0283]
Example 66:
(4-{[(l-Cyclohexyl-3-methyl-lH-theino[2,3-c]pyrazol-5-yl)carbonyl]-
amino}phenoxy)acetic acid
The title compound 268mg (95%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 65, instead
of the compound obtained in the Example 40.
[0284]
Example 67:
l-Cyclohexyl-3-methyl-N-{[(4-[2-(methylamino)-2-oxoethoxy]phenyl)-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 24mg (39%) was obtained in a manner similar to
the Manufacturing Example 5 by use of the compound obtained in the Example
66 and methylamlne (30%-methanol solution), instead of 6-aminonicotic
acid and isopropylamine, respectively.
[0285]
Example 68:
Ethyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}phenyl)acetate
The title compound 223mg (93%) was obtained in a manner similar
to the Example 7 by use of ethyl (4-aminopehnyl) acetate, instead of
benzyiamine.
[0286]
Example 69:

(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}phenyl)acetic acid
The title compound 157mg (84%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 68, instead
of the compound obtained in the example 40.
[0287]
Example 70:
l-Cyclohexyl-3-nethyl-N-{4-[2-(methylamino)-2-oxoethyl]phenyl}-
lH-thieno[2,3-c" pyrazole-5-carboxamide
The title compound 31mg (50%) was obtained in a manner similar to
the Manufacturing Example 5 by use of the compound obtained in the Example .
69 and methylam:_ne (30%-methanol solution), instead of 6-aminonicotic
acid and isopropylamine, respectively.
[0288]
Example 71:
tert-Butyl 4-(4--{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}phenyl)-1-piperazinecarboxylate
The title compound 158mg (quantitative) was obtained in a manner
similar to the Example 7 by use of tert-buty 4-(4-aminophenyl)-1-
piperazine-carboxylate, instead of benzylamine.
[0289]
Example 72:
l-Cyclohexyl-3-nethyl-N-[4-(1-piperazinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 108mg (88%) was obtained in a manner similar
to the Manufacturing Example 4 by use of the compound obtained in the
Example 71, instead of the compound obtained in the Manufacturing Example
3.
[0290]
Example 73:
N-[4-(4-Acetyl-l-piperazinyl)phenyl]-l-cyclohexyl-3-methyl-lH-
thieno [2, 3-c] py::azole-5-carboxamide
The title compound 32mg (63%) was obtained in a manner similar to

the Manufacturing Example 3 by use of the compound obtained in the Example
72, instead of the compound obtained in the Manufacturing Example 2.
[0291]
Example 7 4:
1-Cyclchexyl-N-(trans-4-hydroxycyclohexyl)-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 82mg (quantitative) was obtained in a manner
similar to the Example 7 by use of trans-4-aminocyclohexanol, instead
of benzylamine.
[0292]
Example 7 5:
l-Cyclchexyl-3-methyl-N-(4-oxocyclohexyl)-lH-thieno[2, 3-c]pyrazole-
5-carbcxamide
To a solution of 4.0g (ll.lmmol) of the compound obtained in the
Example 74 in 2 00mL of dichloromethane was added 5.0g (13.3mmol) of
pyridinium dich::omate, and the mixture was stirred for 6 hours at room
temperature. Then, 5.0g (13.3mmol) of pyridinium dichromate was further
added to the reaction mixture and the mixture was stirred for 18 hours.
The reaction mixture was filtrated with Celite® and the filtrate was removed
under reduced pressure. The residue was purified by silica gel column
chromatography (eluent: dichloromethane/methanol = 40/1) to give the 2.6g
(65%) of the ti'ile compound.
[0293]
Example 7 6:
l-Cyclchexyl-3-methyl-N-{4-[2-(4-methyl-l-piperazinyl)-2-oxoethoxy]-
phenyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 65mg (90%) was obtained in a manner similar to
the Manufacturing Example 5 by use of the compound obtained in the Example
66 and N-methylpiperazine, instead of 6-aminonicotic acid and
isopropylamine, respectively.
[0294]
Example 77:
1-Cyclchexyl-N-(4-[2-(dimethylamino)-2-oxoethoxy]phenyl}-3-methyl-

lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 43mg (67%) was obtained in a manner similar to
the Manufacturing Example 5 by use of the compound obtained in the Example
66 and dimethylamine HC1 salt, instead of 6-aminonicotic acid and
isopropylamine, respectively.
[0295]
Example 7 8:
2-{4- [ (4-{ [ (l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)-
carbonyl]amino}phenyl)sulfonyl]-1-piperazinyl}ethyl acetate
The title compound 60mg (28%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
10, instead of benzylamine.
[0296]
Example 79:
1-Cyclohexyl-N-(4-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}-
phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 45mg (O.CSmmol) of the compound obtained in the
Example 78 in 4mL of ethanol was added 86pL of 1M sodium hydroxide aqueous
solution, and the mixture was stirred for 1 hour at room temperature.
Then, weiter was added to the reaction mixture and the mixture was extracted
with ethyl acetate. The organic layer was washed with saturated saline
solution and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: dichloromethane/methanol = 20/1) to
give 31mg (74%) of the title compound.
[0297]
Example 8 0:
N- [ trains-4- (Ace'iylamino) cyclohexyl] -l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 28mg (30%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
12, instead of benzylamine.
[0298]

Example 81:
1-Cyclohexyl-N,3-dimethyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 58mg (92%) was obtained in a manner similar to
the Example 7 by use of methylamine HC1 salt, instead of benzylamine.
[0299]
Example 82:
2-Cyclcpentyl-5-methyl-2,4-dihydro-3H-pyrazole-3-one
The title compound 9.70g (80%) was obtained in a manner similar
to the Example 1 by use of cyclopentylhydrazine HC1 salt, instead of
cyclohexylhydrazine HC1 salt.
[0300]
Example 83:
5-Chloro-l-cyclopentyl-3-methyl-lH-pyrazole
The title compound 4.5g (81%) was obtained in a manner similar to
the Example 2 by use of the compound obtained in the Example 82, instead
of the compound obtained in the Example 1.
[0301]
Example 84:
5-Chloro-l-cyclopentyl-3-methyl-lH-pyrazole-4-carboaldehyde
The title compound 4. Og (79%) was obtained in a manner similar to
the Example 3-1 by use of the compound obtained in the Example 83, instead
of the compound obtained in the Example 2.
[0302]
Example 8 5:
Ethyl [(l-cyclopentyl-4-formyl-3-methyl-lH-pyrazol-5-yl)sulfanil]-
acetate
The title compound 1.9g (36%) was obtained in a manner similar to
the Example 4 by use of the compound obtained in the Example 84, instead
of the compound obtained in the Example 3.
[0303]
Example 8 6:
Ethyl l-cyclopentyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylate
The title compound 1.47g (87%) was obtained in a manner similar

to the Example 5-1 by use of the compound obtained in the Example 85,
instead of the compound obtained in the Example 4.
[0304]
Example 87:
l-Cyclopentyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylic acid
The title compound 0.49g (68%) was obtained in a manner similar
to the Example 6 by use of the compound obtained in the Example 86, instead
of the compound obtained in the Example 5.
[0305]
Example 88:
N-[4-(Acetylamino)phenyl]-l-cyclopentyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 88mg (72%) was obtained in a manner similar to
the Example 7 by use of N- (4-aminophenyl) acetamide and the compound obtained
in the Example 87, instead of benzylaminen and the compound obtained in
the Example 6 respectively.
[0306]
Example 89:
2-Cycloheptyl-5--methyl-2,4-dihydro-3H-pyrazole-3-one
The title compound 16.27g (52%) was obtained in a manner similar
to the Example 1 by use of cycloheptylhydrazine HC1 salt, instead of using
cyclohexylhydrazine HC1 salt.
[0307]
Example 90:
5-Chloro-l-cycloheptyl-3-methyl-lH-pyrazole
The title compound 6.92g (79%) was obtained in a manner similar
to the Example 2 by use of the compound obtained in the Example 89, instead
of the compound obtained in the Example 1.
[0308]
Example 91:
5-Chloro-l-cycloheptyl-3-methyl-lH-pyrazole-4-carboaldehyde
The title compound 6.47g (84%) was obtained in a manner similar
to the Example 3-1 by use of the compound obtained in the Example 90,

instead of the compound obtained in the Example 2.
[0309]
Example 92:
Ethyl l-cycloheptyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylate
To a solution of 6.4g (2 6.6mmol) of the compound obtained in the
Example 91 in lOOraL of acetonitrile were added 3.06mL (27.9mmol) of ethyl
thioglycolate and 7.72g (55.8mmol) of potassium carbonate, and the mixture
was refluxed for 23 hours . Then, 3.06mL (27.9mmol) of ethyl thioglycolate
was further added ant the mixture weis refluxed for 3 hours. After cooling
the reaction mixture to room temperature, the mixture was condensed and
the residue was extracted with dichloromethane. The organic layer was
washed with water: and saturated saline solution, then, dried over with
anhydrous sodium sulfate. The solvent was removed under reduced pressure,
and the residue was purified by silica gel column chromatography (eluent:
hexane/acetone =20/1) to give 2.46g (30%) of the title compound.
[0310]
Example 93:
l-Cycloheptyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxylic acid
The title compound 1.40g (67%) was obtained in a manner similar
to the Example 6 by use of the compound obtained in the Example 92, instead
of the compound obtained in the Example 5.
[0311]
Example 94:
N- [4- (Acetylamir.o) phenyl] -l-cycloheptyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 71mg (60%) was obtained in a manner similar to
the Example 7 by use of N- (4-aminophenyl) acetamide and the compound obtained
in the Example 93, instead of benzylaminen and the compound obtained in
the Example 6, respectively.
[0312]
Example 95:
l-Cyclohexyl-N,3-dimethyl-N-phenyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide

The title compound 103mg (96%) was obtained in a manner similar
to the Example 7 by use of N-methylaniline, instead of benzylamine.
[0313]
Example 96:
l-Cyclohexyl-3-methyl-N-(4-pyridinyl)-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 80mg (96%) was obtained in a manner similar to
the Example 7 by use of 4-aminopyricIine, instead of benzylamine.
[0314]
Example 97:
l-Cyclohexyl-3-roethyl-N-(3-pyridinyl)-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 48mg (57%) was obtained in a manner similar to
the Example 7 by use of 3-aminopyricline, instead of benzylamine.
[0315]
Example 98:
l-Cyclohexyl-3-ir.ethyl-N- (4-nitrophenyl) lH-thieno [2, 3-c]pyrazole-5-
carboxamide
To a suspension of 170mg (0.643mmol) of the compound obtained in
the Example 6 in 3mL of 1,2-dichloroethane was added 94uL (1.29mmol) of
thionyl chloride, and the mixture was stirred for 1.5 hours at 90 °C. After
cooling the reaction mixture to room temperature, and the solvent was
removed under the? reduced pressure to give the corresponding acid chloride
intermediate compound.
Then, to a. solution of 170mg (0.643mmol) of 4-nitroaniline in 4mL
of tetrahydrofuranwasadded77mg (50%oily; 1.93mmol) of sodiumborohydride,
and the mixture was stirred for lOminutes at room temperature. Next, a
solution of the above acid chloride in 3mL of tetrahydrofuran was added
to this mixture, and the mixture was stirred for 30 minutes at room
temperature. We.ter was added to the reaction mixture and the mixture was
extracted with ethyl acetate. The organic layer was washed with saturated
saline solution and dried over with anhydrous sodium sulfate . The solvent
was removed under reduced pressure and the resulting solid was washed

with methanol to give 150mg (61%) of the title compound.
[0316]
Example 99:
N-(4-Aminophenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 142mg (quantitative) was obtained in a manner
similar to the Manufacturing Example 2 by use of the compound obtained
in the Example 98, instead of the compound obtained in the Manufacturing
Example 1.
[0317]
Example 100:
N-[4-(Acetylamino)phenyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound lOmg (24%) was obtained in a manner similar to
the Example 19 by use of the compound obtained in the Example 99, instead
of the compound obtained in the Example 18.
[0318]
Example 101:
l-Cyclohexyl-N--,'4- [ (methoxyacetyl) amino] phenyl }-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 92mg (88%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
14, instead of benzylamine.
[0319]
Example 102:
Methyl 5-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-2-pyridinecarboxylate
The title compound 98mg (43%) was obtained in a manner similar to
the Example 7 by use of methyl 5-amino-2-pyridinecarboxylate, instead
of benzylamine.
[0320]
Example 103:
5-{[(l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)carbonyl]-

amino}-2-pyridinecarboxylic acid
The title compound 160mg (87%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 102,
instead of the compound obtained in the Example 40.
[0321]
Example 104:
l-Cyclohexyl-3-ir.ethyl-N-{ 6- [ (methylamino) carbonyl] -3-pyridinyl}-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 44mg (77%) was obtained in a manner similar to
the Manufacturing Example 5 by use of the compound obtained in the Example
103 and methylamine (30%-methanol solution), instead of 6-aminonicotic
acid and isopropylamine, respectively.
[0322]
Example 105:
l-Cyclohexyl-N-{6-[(dimethylamino)carbonyl]-3-pyridinyl}-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 50mg (85%) was obtained in a manner similar to
the Manufacturing Example 5 by use of rhe compound obtained in the Example
103 and dimethylamine HC1 salt, instead of 6-aminonicotic acid and
isopropylamine, respectively.
[0323]
Example 106:
l-Cyclohexyl-3-methyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-1H-
thienc[2,3-c]pyrazole-5-carboxamide
The title compound 76mg (77%) was obtained in a manner similar to
the Example 7 by use of 4-(4-methyl-l-piperazinyl)aniline, instead of
benzylamine.
[0324]
Example 107:
l-Cyclohexyl-3-iaethyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-1H-
thieno[2,3-c]py:cazole-5-carboxamide methanesulfonate
To a suspension of 563mg (1.237mmol) of the compound obtained in
the Example 106 in 5.6mL of methanol was added 85.6uL (1.319mmol) of

methanesulfonic acid at 50°C, and the mixture was refluxed. Then, the
reaction mixture was gradually cooled to 0 ° C and the resulting precipitates
were collected to give 452mg (66%) of the title compound.
[0325]
Example 108:
N-(4-Cyanophenyli-l-cyclohexyl-3-methyl-lH-thieno[2,3-cj pyrazole-
5-carboxamide
The title compound 300mg (quantitative) was obtained in a manner
similar to the Example 7 by use of 4-cyanoaniline, instead of benzylamine.
[0326]
Example 109:
l-Cyclohexyl-3-methyl-N-[6-(4-methyl-l-piperazinyl)-3-pyridinyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide di-HCl salt
l-Cyclohexyl-3-methyl-N-[6-(4-methyl-l-piperazinyl)-3-pyridin-
yl] -lH-thieno[2,3-c]pyrazole-5-carboxamide 235mg (79%) was obtained in
a manne^r similar to the Example 7 by use of 4-cyanoaniline, instead of
benzylamine. Next, to a solution of 132mg (0.301mmol) of the above free
base compound in 2mL of methanol was added 166uL of 4N-HCl/dioxane, and
the mixture was diluted with diethyl ether. The resulting precipitates
were collected to give 140mg (91%) of the title compound.
[0327]
Example 110:
l-Cyclohexyl-3-rrethyl-N-{3- [ (4-methyl-l-piperazinyl) sulfonyl] -
phenyl}-lH-thier.o [2, 3-c] pyrazole-5-carboxamide HC1 salt
l-Cyclohexyl-3-methyl-N-{3-[(4-methyl-l-piperazinyl)sulfonyl]-
phenyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide 133mg (87%) was obtained
in a manner similar to the Example 7 by use of the compound obtained in
the Manufacturing Example 17, instead of benzylamine. Next, to a solution
of 133mg (0.265itimol) of the above free base compound in 3mL of methanol
was added 80uL of 4N-HCl/dioxane, and the mixture was diluted with diethyl
ether. The resulting precipitates were collected to give 138mg (97%) of
the title compound.
[0328]

Example 111:
l-Cyclohexyl-3-methyl-N-{3-[(methylamino)sulfonyl]phenyl}-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 45mg (34%) was obtained in a manner similar to
the Example 7 by use of 3-amino-N-methylbenzenesulfonamide, instead of
benzylamine.
[0329]
Example 112:
l-Cycloheptyl-3-methyl-N-[(4-(4-methyl-l-piperazinyl)phenyl)-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 89mg (78%) was obtained in a manner similar to
the Example 106 by use of the compound obtained in the Example 93, instead
of the compound obtained in the Example 6.
[0330]
Example 113:
l-Cyclohexyl-3-methyl-N-[(3-(4-methyl-l-piperazinyl)phenyl)-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 106mg (80%} was obtained in a manner similar
to the Example 7 by use of 3-(4-methyl-l-piperazinyl)aniline, instead
of benzylamine.
[0331]
Example 114:
1-Cyclohexyl-N-[(4-(4-hydroxy-l-piperidinyl)phenyl)-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 4.lg (15.51mmol) of the compound obtained in
the Example 6 in 50mL of 1, 2-dichloroethane was added 2.26mL (31.02mmol)
of thionyl chloride, and the mixture was refluxed for 1.5 hours. After
cooling of the reaction and the solvent was removed under reduced pressure
to give the corresponding acid chloride intermediate compound.
Then, 3.04g (15.82mmol) of the compound obtained in the Manufacturing
Example 95 and 4 .32mL (31. 02mmol) of triethylamine were added to a solution
of the above acid chloride intermediate compound in 150mL of anhydrous
dichloromethane under ice cooling, and the mixture was stirred for 20

hours at room temperature. Water was added to the reaction mixture, and
the mixture was extracted with dichloromethane. The organic layer was
dried over with anhydrous sodium sulfate and the solvent was removed under
reduced pressure. The residue was purified by silica gel column
chromatography (eluent: dichloromethane/methanol = 40/1 to 30/1) to give
7.5g (83%) of the title compound.
[0332]
Example 115:
N-[4-(Acetylamino)-3-methoxyphenyl]-l-cycloheptyl-3-methyl-lH-
thieno [ 2,3-c] py.razole-5-carboxamide
The title compound 160mg (59%) was obtained in a manner similar
to the Example 1C by use of the compound obtained in the Example 93, instead
of the compound obtained in the Example 6.
[0333]
Example 116:
1-Cyclohexyl-N-(3,5-dichloro-4-pyridinyl)-3-methyl-lH-
thieno[2,3-c]py:razole-5-carboxamide
The title compound 342mg (88%) was obtained in a manner similar
to the Example 98 by use of 4-amino-3,5-dichloropyridine, instead of
4-nitoraniline.
[0334]
Example 117:
5-[(4-Bromobenzyl)sulfanil]-l-cyclohexyl-3-methyl-lH-pyrazole-4-
ca rboa1dehyde
To a solution of 1.2g (5.29mmol) of the compound obtained in the
Example 3 in 21mL of ethanol were added 2.07g (6.35mmol) of
S- (4-bromobenzyl) isothioureahydrobromic acid salt and 10 . 6mLof 2N-sodium
hydroxide solution , and the mixture was refluxed for 2 hours. After the
reaction mixture was cooled to room temperature, the mixture was condensed
and the residue was diluted with ethyl acetate. The organic layer was
washed wirh saturated saline solution and dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent: hexane/ethyl

acetate =7/1) to give 1.723g (82%) of the title compound.
[0335]
Example 118:
5-(4-Bromophenyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole
To a solution of 1.623g (4.13mmol) of the compound obtained in the
Example 117 in 30mL of tetrahydrofuran was added gradually a solution
of 10.3mL (10.3mmol) of 1M lithium bis(trimethylsilyl)amide in
tetrahydrofuran at -78°C, and the mixture was stirred for 30 minutes at
the seme temperature. Then, the reaction mixture was warmed slowly to
0°C during lhour, and water was added to the reaction mixture. The mixture
was extracted with dichloromethane and the organic layer was dried over
with anhydrous sodium sulfate. The solvent was removed under reduced
pressure and 15mL of ethanol and lOmL of 4N-HCl/dioxnae were added to
the residue and the mixture was stirred for 30 minutes at room temperature
and for 30 minutes at 60°C. Then, the reaction mixture was cooled to room
temperature and condensed under reduced pressure. The residue was diluted
with ethyl acetate and the organic layer was washed with saturated sodium
bicarbonate aqueous solution, then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent: hexane/ethyl
acetate = 8/1) zo give 717mg (46%) of the title compound.
[0336]
Example 119:
l-Cyclchexyl-3-methyl-5-[4-(4-methyl-l-piperazinyl)phenyl]-1H-
thieno[2,3-cjpyrazole
To a solution of 175mg (0.4S6mmol) of the compound obtained in the
Example 118 in 30mL of toluene were added 115uL (1.40mmol) of
N-methylpiperazine, 89.6mg (0.933mmol) of sodium tex-t-butoxide, 5.2mg
(0.023mmol) of palladium acetate (II) and 9.4mg (0.0466mmol) of tri-
tert-butyl-phosphine, and the mixture was refluxed for 5 hours. After
the mixture was cooled to room temperature, ethyl acetate was added to
the mixture and the organic layer was washed with waiter and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The

solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: dichloromethane/methanol
= 40/1) to give 158mg (86%) of the title compound.
[0337]
Example 120:
l-Cyclchexyl-3-methyl-5~[4-(4-methyl-l-piperazinyl)phenyl]-1H-
thieno[2,3-c]pyrazole methanesulfanate
The title compound 143mg (94%) was obtained in a manner similar
to the Examplel07 by use of the compound obtained in the Example 119,
instead of the compound obtained in the Example 106.
[0338]
Example 121:
l-Cyclohexyl-3-methyl-5-[4-(4-methyl-l,4-diazepam-l-yl)phenyl]-1H-
thieno [2, 3-c] py::azole
The title compound 124mg (65%) was obtained in a manner similar
to the Example 119 by use of N-methylhomopirerazine, instead of
N-methylpiperazine.
[0339]
Example 122:
1-Cyclohexyl-N-(2-hydroxypropyl)-3-metyl-lH-thoieno[2,3-c]pyrazole-
5-carboxamide
The title compound 82mg (78%) was obtained in a manner similar to
the Example 7 by use of 2-aminoethanol, instead of benzylamine.
[0340]
Example 123:
1-Cyclohexyl-N-(3-hyrdroxypropyl)-3-methyl-lH-thieno[2,3-c]pyrazle-
5-carboxamde
The title compound 103mg (94%) was obtained in a manner similar
to the Example 7 by use of 3-amir_o-l-propanol, instead of benzylamine.
[0341]
Example 124:
1-Cyclohexyl-N-(3-fluoro-4-[(2-hydroxyethyl) (methyl) amino]phenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide

The title compound 99mg (68%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
19, instead of benzylamine.
[0342]
Example 125:
l-Cyclohexyl-N-{3-fluoro-4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
To a solution of 91mg (0.211mmol) of the compound obtained in the
Example 124 in 2mL of diethyl ether and ImL of ethyl acetate was added
63uL (0.25mmol) of 4N-HC1/1, 4-dioxane, and 3mL of diethyl ether was further
added to the mixture. The resulting precipitates were collected to give
86mg (87%) of the title compound.
[0343]
Example 126:
Ethyl cis-A-{[(l-cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)-
carbonyl]amino}cyclohexanecarboxylate
The title compound 365rng (92%) was obtained in a manner similar
to the Elxample 7 by use of ethyl cis- 4-aminocyclohexanecarboxylate, instead
of benzylamine.
[0344]
Example 127:
cis-4-{[(l-Cyclchexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclohenxanecarboxylic acid
The title compound 123mg (88%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 126,
instead of the compound obtained in the Example 40.
[0345]
Example 128:
1-Cyclohexyl-N- [ci.s-4- (hydroxymethyl) cyclohexyl] -3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 185mg (0.433mmol) of the compound obtained in the
Example 126 in 6mL of tetrahydrofuran were added 56mg (1.33mmol) of lithium
chloride and 50mg (1.33mmol) of sodium borohydride, and the mixture was

stirred for 14 hours at room temperature. Then, ethyl acetate was added
to the mixture and the organic layer was washed with water and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 1/3)
to give HOmg (66%) of the title compound.
[0346]
Example 129:
Methyl trans-A- ■[{ [ (l-cyclohexyl-3-methyl-lH-thoieno[2, 3-c]pyrazol-
5-yl)carbonyl]amino}methyl)cyclohexanecarboxylate
The title compound 605mg (96%) was obtained in a manner similar
to the Example 7 by use of ethyl trans-4-aminocyclohexanecarboxylate
hydrochloric acid salt, instead of benzylamine.
[0347]
Example 130:
l-Cyclohexyl-N-methyl{[trans-A-(hydroxymethyl)cyclohexyl]methyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 150mg (80%) was obtained in a manner similar
to the Example 128 by use of the compound obtained in the Example 129,
instead of the compound obtained in the Example 126.
[0348]
Example 131:
tert-Eutyl trans-A-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}cyclohexylcarbamate
The title compound 90mg (quantitative) was obtained in a manner
similar to the Elxample 7 by use of tert-butyl trans-4-aminocyclohexyl-
carbamate, instead of benzylamine.
[0349]
Example 132:
N-(trams-4-Aminocyclohexyl)-l-cyclohexyl-3-methyl-lH-
thieno[2, 3-c]py:razole-5-carboxamide
To a solution of 890mg (1.93mmol) of the compound obtained in the
Example 131 in 5mL of N,N-dimethylformamide was added 9.66mL of

4N-HCl/cioxane, and the mixture was stirred for 3 hours at room temperature.
Then, the mixture was diluted with dichloromethane and 50mL of lN-sodium
hydroxide solution was added to the mixture. The organic layer was dried
over with anhydrous sodium sulfate and the solvent was removed under reduced
pressure. The residue was purified by alkaline silica gel column
chromatography (eluent: chloroform/methanol = 60/1) to give 495mg (71%)
of the title compound.
[0350]
Example 133:
l-Cyclohexyl-3-methyl-N-[trans-4-(4-morpholinyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 120mg (0.333mmol) of the compound obtained in the
Example 132 in 8mL of N,N-dimethylformamide were added 46.8uL (0.333mmol)
of bis(2-chloroethyl)ether, 116uL (0.832mmol) of triethylamine, 50mg
(0.333mmol) of sodium iodide, and 6.5uL (0.333mmol) of 15-crown-5, and
the mixture was stirred for 24 hours at 100°C. After the reaction mixture
was cooled to room temperature, the mixture was extracted with ethyl acetate
and the organic layer was washed with saturated sodium bicarbonate aqueous
solution and saturated saline solution, then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
chloroform/methanol = 20/1) to give 22mg (15%) of the title compound.
[0351]
Example 134:
l-Cyclohexyl-3-methyl-N-(4-piperidinyl)-lH-thieno[2,3-c]pyrazole-
5-carboxamide
Saturated sodium bicarbonate solution and ethyl acetate were added
to the compound obtained in the Example 63, and the organic layer was
dried over with anhydrous sodium sulfate. The solvent was removed and
the residue was purified by alkaline silica gel column chromatography
(eluent: chloroform/methanol =60/1) to give 411mg (60%) of the title
compound.
[0352]

Example 135:
l-Cyclohexyl-3-methyl-N-(l-tetrahydro-2H-pyran-4-yl-4-piperidinyl)-
lH-thieno[2,3-c] ;oyrazole-5-carboxamide
To a solution of 150mg (0.433mmol) of the compound obtained in the
Example 134 in 8roL of dichloromethane were added 44uL (0.476mmol) of
tetrahydro-4-pyranone and 128mg (0.606mmol) of sodium triacetoxyboro-
hydride, and the mixture was stirred for 24 hours at room temperature.
Then, saturated sodium bicarbonate solution was added to the reaction
mixture and the mixture was extracted with dichloromethane. The organic
layer was washed with water and saturated saline solution, then, dried
over with anhydrous sodium sulfate . The solvent was removed under reduced
pressure and the residue was purified by silica gel column chromatography
(eluent: dichloromethane/methanol = 20/1) to give 70mg (38%) of the title
compound.
[0353]
Example 136:
l-Cyclohexyl-N-[l-(1,4-diazaspiro[4.5]decan-8-yl)-4-piperazdinyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 180mg (92%) was obtained in a manner similar
to the Example 135 by use of 1,4-cyclohexanedione monoethyleneketal,
instead of tetrahydro-4-pyranone.
[0354]
Example 137:
l-Cyclohexyl-3-iuethyl-N-[1-(4-oxocyclohexyl)-4-piperidinyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 153mg (0 .314mrnol) of the compound obtained in the
Example 136 in 3mL of acetone and lmL of water was added 71.8mg (0.377mmol)
of p-toluenesulfonic acid monohydrate, and the mixture was refluxed for
2 days. Then, saturated sodium bicarbonate aqueous solution was added
to the reaction mixture and the mixture was extracted with dichloromethane .
The organic layer was dried over with anhydrous sodium sulfate and removed
under reduced pressure to give 120mg (86%) of the title compound.
[0355]

Example 138:
1-Cyclohexyl-N-[1-(trans-4-hydroxycyclohexyl)-4-piperidinyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 109mg (0.246mmol) of the compound obtained in the
Example 137 in 8mL of ethanol was added 14.0mg (0.369mmol) of sodium
borohydride, and the mixture was stirred for 1 hour at 0°C. Then,
dichloromethane was added to the reaction mixture and the organic layer
was washed with water, then, dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: dichloromethane/methanol
= 20/1) to give 67mg (61%) of the title compound.
[0356]
Example 139:
tert-E>utyl 4- (4-{ [ (l-cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazpl-
5-yl)carbonyl]amino}phenyl)-1-piperidinecarboxylate
The title compound 649mg (quantitative) was obtained in a manner
similar to the Example 7 by use of the compound obtained in the Manufacturing
Example 21, instead of benzylamine.
[0357]
Example 140:
l-Cyclohexyl-3-methyl-N-[4-(4-piperidinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 584mg (1.12mmol) of the compound obtained in the
Example 139 in 3mL of dichloromethane was added 0.86mL (11.2mmol) of
trifluoroacetic acid at room temperature, and the mixture was stirred
for 1.5 hours at. the same temperature. Then, the mixture was extracted
with dichloromethane and the organic layer was washed with 2N sodium
hydroxide solution and then, dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: dichloromethane/methanol
= 100/1) to give 437mg (92%) of the title compound.
[0358]
Example 141:

l-Cyclohexyl-3-raethyl-N-[4-(4-piperidinyl)phenyl]-1H-
thieno[2, 3-c]py::azole-5-carboxamide HC1 salt
The title compound 94mg (86%) was obtained in a manner similar to
the Example 125 by use of the compound obtained in the Example 140, instead
of the compound obtained in the Example 124.
[0359]
Example 142:
l-Cyclohexyl-3-methyl-N-[4(1-methyl-4-piperidinyl)phenyl]-1H-
thieno [2, 3-c] py:razole-5-carboxaraide
To a solution of 174mg (0.412mmol) of the compound obtained in the
Example 140 in 5mL of chloroform were added 31uL (0.494mmol) of methyl
iodide and 86uL \0.618mmol) of triethylamine, and the mixture was stirred
for 2 hours at room temperature. Then, saturated sodiumbicarbonate aqueous
solution was added to the reaction mixture and the mixture was extracted
with dichloromethane. The organic layer was dried over with anhydrous
sodium sulfate ard removed under reducedpressure . The residue was purified
by alkaline silica gel column chromatography (eluent: dichloromethane/
methanol = 40/1) to give 4 6mg (26%) of the title compound.
[0360]
Example 143:
1-Cyclohexyl-N-[4-(4-ethyl-l-piperazinyl)-3-fluorophenyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 90mg (42%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
24, instead of :oenzylamine.
[0361]
Example 144:
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-l, 4-diazepam-l-yl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 161mg (76%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 31, instead of benzylamine.
[0362]

Example 145:
Ethyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino-2-methoxybenzoate
The title compound 401mg (80%) was obtained in a manner similar
to the Example 7 by use of ethyl 4-amino-2~methoxybenzoate, instead of
benzylamine.
[0363]
Example 146:
4-{[(l-Cyclohexyl-3-methyl-lH-ohieno[2, 3-c]pyrazol-5-yl)carbonyl]-
amino^-2-methoxybenzoic acid
The title: compound 242mg (59%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 145,
instead of the compound obtained in the Example 40.
[0364]
Example 147:
l-Cyclohexyl-N-{3-methoxy-4-[(4-methyl-l-piperazinyl)carbonyl]-
phenyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
To a solution of 200mg (0.48mmol) of the compound obtained in the
Example 146 in 3mL of anhydrous dichloromethane were added 64uL (0. 58mmol)
of N-methylpiperazine and lllmg (0.58mmol) of l-ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide HC1 salt, and the mixture was stirred for 3 hours
at room temperature. Then, saturated sodium bicarbonate aqueous solution
was added to the reaction mixture and the mixture was extracted with
dichloromethane. The organic layer was washed with water and saturated
saline solution and dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: dichloromethane/methanol = 20/1 to
10/1). The obtained crude crystalline was dissolved in 4M-HCl/dioxane
and the solvent was removed under reduced pressure. The obtained solid
was collected to give 124mg (49%) of the title compound.
[0365]
Example 148:
1-Cyclohexyl-N-[3-methoxy-4-(4-morpholinylcarbonyl)phenyl]-3-

methyl~lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 7 6mg (73%) was obtained in a manner similar to
the Examplel47 by use of morpholine, instead of N-methylpiperazine.
[0366]
Example 149:
l-Cyclohexyl-N-{4-[(4-hydroxy-l-piperidinyl)carbonyl]phenyl}-3-
methoxyphenyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 68mg (69%) was obtained in a manner similar to
the Examplel47 by use of 4-hydroxypiperidine, instead of
N-methylpiperazine.
[0367]
Example 150:
1-Cyclohexyl-N-(4-{[(2-hydroxyethyl) amino]carbonyl}-3-methoxy-
phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 53mg (58%) was obtained in a manner similar to
the Examplel47 by use of 2-aminoethanol, instead of N-methylpiperazine.
[03681
Example 151:
1-Cyclohexyl-N-(3-methoxy-4-{[(2-methoxyethyl)amino]carbonyl}-
phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 73mg (78%) was obtained in a manner similar to
the Examplel47 by use of 2-methoxyethylamine, instead of N-methyl-
piperazine.
[0369]
Example 152:
1-Cyclohexyl-N-{3-methoxy-4-[(methylamino)carbonyl]phenyl}-3-
methyl-lH-thieno[2y3-clpyrazole-5-carboxanu.de
The title compound 31mg (36%) was obtained in a manner similar to
the Examplel47 by use of methylamine HC1 salt, instead of N-methyl-
piperazine.
[0370]
Example 153:
1-Cyclohexyl-N-{4-[(dimethylamino)carbonyl]-3-methoxyphenyl}-3-

methyl-lH-thier.o[2,3-c]pyrazole-5-carboxamide
The title.' compound 70mg (80%) was obtained in a manner similar to
the Examplel47 by use of dimethylamine HC1 salt, instead of N-methyl-
piperazine.
[0371]
Example 154:
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-l-piperazinyl)phenyl]-3-
methyl--lH-thieno [2, 3-c] pyrazole-5-carboxamide
The title compound 136mg (79%) was obtained in a manner similar
to the Example7 by use of the compound obtained in the Manufacturing Example
26, instead of benzylamine.
[0372]
Example 155:
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-l-piperazinyl)phenyl]-3-methyl-
lH-th;i6;no [2, 3-c]pyrazole-5-carbcxamide methanesulfonic acid salt
A suspension of lOOmg (0.22mmol) of the compound obtained in the
Example 154 in 2mL of methanol was heated at 50°C, and to this suspension
was added 14mL (0.22mmol) of methanesulfonic acid, then, the mixture was
refluxed for 10 minutes. The reaction mixture was cooled gradually and
the appeared precipitates were collected to give 68mg (56%) of the title
compound.
[0373]
Example 156:
N-[3-Chloro-4-(4-methyl-l-piperzinyl)phenyl]-l-cyclohexyl-3-methyl-
lH-thieno[2/3-c]pyrazole-5-carboxamide
The title compound 169mg (95%) was obtained in a manner similar
to the Example7 by use of 3-chloro-4-(4-methyl-l-piperazinyl)aniline,
instead, of benzylamine.
[0374]
Example 157:
1-Cyclohexyl-N-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluoro-
phenyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 54 6mg (96%) was obtained in a manner similar

to the Example7 by use of the compound obtained in the Manufacturing Example
28, instead of benzylamine.
[0375]
Example 158:
1-Cyclohexyl-N-[3-fluoro-4-(4-oxo-l-piperidinyl)phenyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 500mg (l.OOmmol) of the compound obtained in the
Example 157 in a mixture solution of 20mL of toluene and 2mL of water
was added 229mg (1.20mmol) of p-toluenesulfonic acid monohydrate, and
the mixture was lefluxed for 8 hours. Then, the reaction mixture was cooled
to room temperature and condensed under reduced pressure . Saturated sodium
bicarbonate aqueous solution was added to the residue and the mixture
was extracted with ethyl acetate . The organic layer was washed with water
and saturated saline solution, and then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure to give 460mg
(quantitative) of the title compound.
[0376]
Example 159-1:
1-Cyclohexyl-N-[3-fluoro-4-(4-hydrcxy-l-piperidinyl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 150mg (0.33mmol) of the compound obtained in
the Example 158 in anhydrous methanol was added 15mg (0.39mmol) of sodium
borohydride under ice cooling, and the mixture was stirred for 3 hours
at the same temperature and for 2 hours at room temperature. Then, acetone
was added to the reaction mixture and the solvent was removed under reduced
pressure. The residue was diluted with ethyl acetate and the organic layer
was washed with water and saturated saline solution. The solvent was removed
under reduced pressure and the residue was purified by silica gel column
chromatography [eluent: hexane/ethyl acetate = 1/2 t 0/1) to give 114mg
(76%) cf the ti;le compound.
[0377]
Example 159-2:
To a suspension of 900mg (3.40mmol) of the compound obtained in

15mLcf 1,2-dichloroethane was added497uL (6.81mmol) of thionyl chloride,
and the mixture was refluxed for 1.5 hours. After cooling the reaction
mixture, the solvent removed under reduced pressure to give acid chloride
intermediate compound.
Then, 752mg (3.57mmol) of the compound obtained in the Manufacturing
Example 62 and 949uL (6.81mmol) of triethylamine were added to a solution
of acid chloride intermediate compound obtained above in 40mL of anhydrous
dichloromethane, and the mixture was stirred for 6 hours at room temperature.
Water was added to the reaction mixture and the mixture was extracted
with dichloromethane. The organic layer was dried over with anhydrous
sodium sulfate, and the solvent was removed under reduced pressure. The
resulting residue was recrystallized from ethanol to give 0.86g (55%)
of the title compound.
[0378]
Example 160:
N-[3-Chloro-4-(1,4-dioza-8-azaspiro[4.5]decan-8yl)phenyl]-1-
cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 565mg (96%) was obtained in a manner similar
to the Example7 by use of the compound obtained in the Manufacturing Example
30, instead of benzylamine.
[0379]
Example 161:
N-[3-Chloro-4-(4-oxo-l-piperidinyl)phenyl]-l-cyclohexyl-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 282mg (61%) was obtained in a manner similar
to the Examplel58 by use of the compound obtained in the Example 160,
instead of the compound obtained in the Example 157.
[0380]
Example 162:
N-[3-Chloro-4-(4-hydroxy-l-piperidinyl)phenyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 90mg (90%) was obtained in a manner similar to
the Example 159-1 by use of the compound obtained in the Example 161, instead

of the compound obtained in the Example 158.
[0381]
Example 163:
1-Cyclohexyl-N-{3-fluoro-4-[4-(methylamino)-1-piperidinyl]phenyl}-
3-methyl-lH-thi3no[2,3-c]pyrazole-5-carboxamide
To a suspension of 150mg (0.33mmol) of the compound obtained in
the Example 158 in 3mL of 1,2-dichloroethane were added 68uL (0.66mmol)
of trimethylamine (30%-ethanol solution), 20uL of acetic acid and 105mg
(0.50mmol) of sodium triacetoxyborohydride, and the mixture was stirred
for 18 hours at room temperature. Then, saturated sodium bicarbonate
solution was added to the reaction mixture and the mixture was extracted
withdichloromethane. The organic layer was washed with water and saturated
saline solution, and then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by alkaline s;.lica gel column chromatography (eluent: dichloro-
methane/methanol = 20/1) to give 148mg (97%) of the title compound.
[0382]
Example 164:
tert-Butyl 1-(2-chloro-4-{[(l-cyclohexyl-3-methy-3-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl] amino}phenyl)-4-piperidinyl(methyl)carbamate
To a suspension of 200mg (0.43mmol) of the compound obtained in
the Example 161 in 3mL of 1, 2-dichloroethane were added 88uL (0.85mmol)
of trimethylamine (30%-ethanol solution) , 15uL of acetic acid and 135mg
(0. 64mmol) of sodium triacetoxyborohydride, and the mixture was stirred
for 4 hours at room temperature. Then, saturated sodium bicarbonate
solution was added to the reaction mixture and the mixture was extracted
withdichloromethane. The organic layer was washed with water and saturated
saline solution, the dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was dissolved in 4mL
of dichloromethane. To this mixture were added 186mg (0.85mmol) of
tert-butyldicarbonate and 0.14mL (1.02mmol) of triethylamine, and the
mixture was stirred for 1 hour at room temperature. Water was added to
the reaction mixture and the mixture was extracted with dichloromethane.

The organic layer was washed with water and saturated saline solution
and dried over with anhydrous sodium sulfate. The solvent was removed
under reduced piessure and the residue was purified by silica gel column
chromatography Jeluent: hexane/ethyl acetate = 1/1) to give 236mg (95%)
of the title compound.
[0383]
Example 165:
N-{3-Chloro-4-[4-(methylamino)-1-piperidinyl]phenyl}-1-cyclohexyl-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 211mg (0.36mmol) of the compound obtained in the
Example 164 in 3mL of dichloromethane was added 1.5mL of trifluoroacetic
acid, and the mixture was stirred for 1. 5 hours at room temperature. After
removal of the solvent under reduced pressure, water was added to the
residue and the mixture was extracted with chloroform. The organic layer
was washed with water and saturated saline solution and dried over with
anhydrous sodium sulfate. The solvent was removed under reduced pressure
and the residue was purified by alkaline silica gel column chromatography
(eluent = dichloromethane/methanol = 40/1) to give 116mg (66%) of the
title compound.
[0384]
Example 166:
l-Cyclohexyl-3-nethyl-N-[trans-4-(4-methyl-l-piperazinyl)-
cyclohexyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.42mmol) of the compound obtained in the
Example 75 in 3mL of dichloromethane were added 93uL (0.84mmol) of
N-methylpiperaz:.ne, 15uL of acetic acid and 133mg (0.63mmol) of sodium
triacetoxyborohydride, and the mixture was stirred for 3 hours at room
temperature. Then, saturated sodium bicarbonate solution was added to
the reaction mixture and the mixture was extracted with dichloromethane.
The organic layer was washed with water and saturated saline solution,
then, dried over with anhydrous sodium sulfate. The solvent was removed
under reduced pressure and the residue was purified by alkaline silica
gel column chromatography (eluenc: ethyl acetate) to give 103mg (56%)

of the title compound.
[0385]
Example 167:
l-Cyclohexyl-3-methyl-N- [ trans- cyclohexyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound lOlmg (53%) was obtained in a manner similar
to the Example 166 by use of N-methylhomopirerazine, instead of
N-methylpiperazine.
[0386]
Example 168:
1-Cyclohexyl-N-[trans-4-(4-methoxyl-l-piperidinyl)cyclohexyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 30mg (20%) was obtained in a manner similar to
the Example 166 by use of 4-methoxypiperidine p-toluenesulfonic acid salt,
instead of N-me;hylpiperazine.
[0387]
Example 169:
Benzyl 4-(trans-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-pyrazol-
5-yl)carbonyl]amino}cyclohexyl)-1,4-diazepam-l-carboxylate
The title compound 252mg (78%) was obtained in a manner similar
to the Example 166 by use of benzyl 1-homopirerazinecarboxylate, instead
of N-methylpiperazine.
[0388]
Example 170:
1-Cyclohexyl-N-[trans-A-(1,4-diazepam-l-yl)cyclohexyl]-3-methyl-
lH-thieno[2,3-c|pyrazole-5-carboxamide
h mixture solution of 219mg (0.38mmol) of the compound obtained
in the Example 169 in 3mL of 30%-KBr/acetic acid was stirred for 3 hours
at room temperature. Then, the reaction mixture was neutralized by
4M-sodium hydroxide aqueous solution and the mixture was extracted with
dichloromethane. The organic layer was washed with water and saturated
saline solution and dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was purified by alkaline

silica gel column chromatography (eluent: dichloromethane/methanol = 30/l)
to give 126mg (75%) of the title compound.
[0389]
Example 171:
N-[trans-A-(4-Acetyl-l,4-diazepam-l-yl)cyclohexyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 96mg (99%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example
170 and acetic anhydride, instead of the compound obtained in the
Manufacturing Example 2 and acetyl chloride, respectively.
[0390]
Example 172:
l-Cyclchexyl-N-{trans-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 131mg (73%) was obtained in a manner similar
to the Example 166 by use of N-(2-methoxylethyl)methylamine, instead of
N-methylpiperazine.
[0391]
Example 173:
1-Cyclohexyl-N-[cis-4-[(2-methoxyethyl)(methyl)amino]cyclohexyl}-3-
methyl-lH-thieno[2/3-c]pyrazole-5-carboxamide
The title compound 34mg (19%) was obtained as by-product in the
Example 172.
[0392]
Example 174:
1-Cyclohexyl-N-[trans-4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-
cyclohexyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 664mg (98%) was obtained in a manner similar
to the Example 166 by use of 1,4-dioxa-8-azaspiro[4.5]decane, instead
of N-niethylpiperazine.
[0393]
Example 175:
l-Cyclohexyl-3-methyl-N-[trans-4-(4-oxo-l-piperidinyl)cyclohexyl]-

lH-thieno[2,3-c]pyrazole-5-carboxamide
Amixture of 384mg (0.79mmol) of the compound obtained in the Example
174 in 6mL of 6M-HC1 aqueous solution was stirred for 9 days at room
temperature. Then, the reaction mixture was neutralized by saturated
sodium bicarbonate aqueous solution and the mixture was extracted with
chloroform. The organic layer was washed with water and saturated saline
solution, and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure to give 317mg (91%) of the title compound.
[0394]
Example 17 6:
1-Cyclohexyl-N-[trans-A-(4-hydroxy-l-piperidinyl)cyclohexyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 102mg (quantitative) was obtained in a manner
similar to the Example 159 by use of the compound obtained in the Example
175, instead of the compound obtained in the Example 158.
[0395]
Example 177:
1-Cyclohexyl-N-{trans-A-[(2R,6S)-2,6-dimethylmorpholinyl]-
cyclohexyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 126mg (66%) was obtained in a manner similar
to the Example 166 by use of cis-2, 6-dimethylmorpholine, instead of
N-methylpiperaz.ine.
[0396]
Example 178:
1-Cyclohexyl-N-(cis-4-[(2R,6S)-2,6-dimethylmorpholinyl]cyclohexyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 50mg (26%) was obtained as by-product in the
Example 177.
[0397]
Example 179:
l-Cyclohexyl-3-methyl-N-{trans-4-[4- (methylamino)-1-piperidinyl]-
cyclohexyl}-lH-"hieno[2,3-c]pyrazole-5-carboxamide
The title compound 182mg (89%) was obtained in a manner similar

to the Example 166 by use of the compound obtained in the Example 175
and methylamine (30% ethanol solution), instead of the compound obtained
in the Example 75 and N-methylpiperazine, respectively.
[0398]
Example 180:
N- (trans-4-{4-[Acetyl(methyl)amino]-l-piperidinyl}cyclohexyl)-1-
cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 35mg (72%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example
179 and acetic anhydride, instead of the compound obtained in the
Manufacturing Example 2 and acetyl chloride, respectively.
[0399]
Example 181:
l-Cyclohexyl-N-{trans-A-[4-(dimethylamino)-1-piperidinyl]-
cyclohexyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a mixture solution of 7Cmg (0.15mmol) of the compound obtained
in the Example 179 in 2mL of ethanol and 2mL of water were added 30mg
of paraformaldehyde and lmL of formic acid, and the mixture was refluxed
for 6 hours. Further 30mg of paraformaldehyde and lmL of formic acid were
added to the reaction mixture, and the mixture was refluxed for 18 hours.
Then, the reaction mixture was cooled to room temperature and neutralized
with saturated sodium bicarbonate aqueous solution, and extracted with
dichloromethane. The organic layer was washed with water and saturated
saline solution, and dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was recrystallized
from ethyl acetate to give 32mg (44%) of the title compound.
[0400]
Example 182:
tert-Butyl 1-(trans-A-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidinylcarbamate
The title compound 176mg (58%) was obtained in a manner similar
to the Example 166 by use of tert-butyl 4-piperidinecarbamate, instead
of N-methylpiperazine.

[0401]
Example 183:
tert-Butyl 1-{cis-A-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidinylcarbamate
The title compound 94mg (31%) was obtained as by-product in the
Example 182.
[0402]
Example 184:
N- [ trans-A- (4-Artiino-l-piperidinyl) cyclohexyl]-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 82mg (60%) was obtained in a manner similar to
the Example 165 by use of the compound obtained in the Example 182, instead
of the compound obtained in the Example 164.
[0403]
Example 185:
N-[ci.s-4-(4-Amino-l-piperidinyl)cyclohexyl]-l-cyclohexyl-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 63mg (95%) was obtained in a manner similar to
the Example 165 by use of the compound obtained in the Example 183, instead
of the compound obtained in the Example 164.
[0404]
Example 186:
tert-Butyl 4- (t.cans-A-{ [ (l-cyclohexyl-3-methyl-lH-thieno [2, 3-c] -
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-1-piperazinecarboxylate
The title compound 218mg (74%) was obtained in a manner similar
to the Example 166 by use of tert-butyl 1-piperazinecarboxylate, instead
of N-methylpipe::azine.
[0405]
Example 187:
tert-Butyl 4-(cis-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-1-piperazinecarboxylate
The title compound 72mg (14%) was obtained as by-product in the
Example 186.

[0406]
Example 188:
l-Cyclohexyl-3-methyl-N-[trans-A-(1-piperazinyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 146mg (86%) was obtained in a manner similar
to the Example 165 by use of the compound obtained in the Example 186,
instead of the compound obtained in the Example 164.
[0407]
Example 189:
l-Cyclohexyl-3-methyl-N-[cis-4-(1-piperazinyl)cyclohexyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 51mg (97%) was obtained in a manner similar to
the Example 165 by use of the compound obtained in the Example 187, instead
of the compound obtained in the Example 164.
[0408]
Example 190:
N- [trans-A- (4-Acetyl-l-piperazinyl) cyclohexyl] -l-cyclohexyl-3-methyl
-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 81mg (95%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example
188, instead of the compound obtained in the Manufacturing Example 2.
[0409]
Example 191:
1-Cyclohexyl-N-[3-fluoro-4-(4-methyl-l, 4-diazepam-l-yl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide hemifumarate
To a solution of 143mg (0.305mmol) of the compound obtained in the
Example 144 in 2mL of ethanol was added 38.9mg (0.335mmol) of fumaric
acid, and the resulting precipitates were collected to give 139mg (86%)
of the title compound.
[0410]
Example 192:
5-Methyl-2-tetrahydro-2H-pyran-4-yl-2, 4-dihydro-3H-pyrazole-3-one
The title compound 6.93g (58%) was obtained in a manner similar

to the Example 1 by use of 4-tetrahydropyranylhydrazine, instead of
cyclohexylhydrazine HC1 salt.
[0411]
Example 193:
5-Chloro-3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-pyrazole-4-
carboaldehyde
h mixture solution of 6.87g (3.77mmol) of the compound obtained
in the Example 132 and 14.1mL (150.8mmol) of phosphorous oxychloride was
stirred for 1 hour at 110°C. After the reaction mixture was cooled to
room temperature, this mixture was added gradually to ice-cooled 40mL
of N,N-dimethylformamide, and the mixture was stirred for 1 hour at room
temperature and for 3 hours at 90 °C. Then, the reaction mixture was cooled
with ice and diluted with ethyl acetate, and pH of the reaction mixture
was adjusted to 4 by adding 2N-NaOH aqueous solution. The mixture was
extracted with ethyl acetate and the organic layer was washed with saturated
saline solution and then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 2/1)
to give 4.64g (54%) of the title compound.
[0412]
Example 194:
Ethyl 3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-
5-carboxylate
To a solution of 16.54mL (0.151mol) of ethyl thioglycolate in 300mL
of tetrahydrofuran was added 6. 03g (0.151mol) of sodium hydride (60% oily)
in small portions, and the mixture was stirred for 3 minutes . Then, 31. 36g
(0.137mol) of the compound obtained in the Example 193 was added to this
mixture at once, and the mixture was stirred for 1 hour. Further, 6.03g
(0.151mol) of sodium hydride (60% oily) was added to this mixture in small
portions at 0°C, and the mixture was stirred for 1 hour. The reaction
mixture was diluted with ethyl acetate and the organic layer was washed
with water and saturated saline solution, and dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the

residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 3/1 to 2/1) to give 30. lg (76%) of the title compound.
[0413]
Example 195:
3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-
carboxylic acid
The title compound 4.26g (99%) was obtained in a manner similar
to the Example 6 by use of the compound obtained in the Example 194, instead
of the compound obtained in the Example 5.
[0414]
Example 196:
3-Methyl-N-[4-(4-methyl-l-piperazinyl)phenyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 166mg (84%) was obtained in a manner similar
to the Example 7 by use of 4-(4-merhyl-l-piperazinyl)aniline and the
compound obtained in Example 194, instead of benzylamine and the compound
obtained in the Example 6, respectively.
[0415]
Example 197:
N-[3-Fluoro-4-(4-methyl-l-piperazinyl)phenyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 214mg (83%) was obtained in a manner similar
to the Example 7 by use of [3-fluoro-4-(4-methyl-l-piperazinyl)]aniline
and the compound, obtained in Example 195, instead of benzylamine and the
compound obtained in the Example 6, respectively.
[0416]
Example 198:
l-Cyclohexyl-3-itiethyl-N- [4- (4-morpholinylmethyl) phenyl] -1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 173mg (87%) was obtained in a manner similar
to the Example 7 by use of 4-(4-morpholinylmethyl)aniline, instead of
benzylamine.
[0417]

Example 199:
l-Cyclohexyl-3-methyl-N-[4-(4-morpholinylmethyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide fumarate
41.7mg (0.59mmol) of fumaric acid was added to a mixture of 150mg
(0.432mmol) of the compound obtained in the Example 198 in ImL of ethanol,
and 2mL of diethyl ether was further added to the mixture. Then, the mixture
was stirred for over night and appeared precipitates were collected by
filtration to give 112mg (59%) of the title compound.
[0418]
Example 200:
l-Cyclchexyl-N-{4-[2-(dimethylamino)ethyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 83mg (75%) was obtained in a manner similar to
the Example 7 by use of 4-[(2-dimethylamino)ethyl]aniline, instead of
benzylamine.
[0419]
Example 201:
l-Cyclohexyl-3-methyl-N-{4-[2-(4-morpholinyl)ethyl]phenyl}-1H-
thieno[2,3-c]pyrazole~5-carboxamide
The title compound 140mg (68%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Example 32, instead
of benzylamine.
[0420]
Example 202:
l-Cyclohexyl-3-methyl-N-{4-[(3-methyl-2, 5-diaxo-l-imidazolidinyl)-
methyl]phenyl}-IH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 185mg (88%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Example 34, instead
of benzylamine.
[0421]
Example 203:
l-Cyclohexyl-3-rnethyl-N-[4-(3-methyl-2,5-dioxo-l-imidazolidinyl)-
phenyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide

The title compound 116mg (57%) was obtained in a manner similar
to the Example 7 by use of 4- (3-methyl-2, 5-dioxo-l-imidazolidinyl) aniline,
instead of benzylamine.
[0422]
Example 204:
Methyl fcrans-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}cyclohexane carbcxylate
The title compound 2.18g (95%) was obtained in a manner similar
to the Example ' by use of methyl trans-4-aminocyclohexanecarboxylate,
instead of benzylamine.
[0423]
Example 205:
4-{[ (l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c3pyrazol-5-yl)carbonyl]-
amino}cyclohexane carboxylic acid
The title compound 1.48g (quantitative) was obtained in a manner
similar to the Example 41 by use of the compound obtained in the Example
204, instead of the compound obtained in the Example 40.
[0424]
Example 206:
1-Cyclohexyl-N-[4-(hydroxymethyl)cyclohexyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 200mg (0.496mmol) of the compound obtained in the
Example 204 in 5mL of tetrahydrofuran was added 43mg (1.98mmol) of lithium
borohydride, and the mixture was stirred for 1.5 hours under heating at
70°C. The reaction mixture was cooled to room temperature and water was
added to the mixture and mixture was extracted with dichloromethane. The
organic layer was dried over with anhydrous sodium sulfate and the solvent
was removed under reduced pressure. The resulting residue was
recrystallized from isopropanol/hexane (1/1) to give 76mg (41%) of the
title compound.
[0425]
Example 207:
l-Cyclchexyl-3-methyl-N-{4-[(4-methyl-l-piperazinyl)carbonyl]-

cyclohexyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 200mg (0.513mmol) of the compound obtained in the
Example 205 in 5mL of dichloromethane and lmL of N,N-dimethylformamide
were added 51.3uL (0.462mmol) of N-methylpiperazine and 750mg of PS
carbodiimide (Argonaut Co.) , and the mixture was stirred for over night
at room temperature. The reagent removed off by filtration and the filtrate
was condensed to give 36mg (15%) of the title compound.
[0426]
Example 208:
1-Cyclohexyl-N-{4-[(dimethylamino)carbonyl]cyclohexyl}-3-methyl-lH-
thieno[2,3-cjpyrazole-5-carboxamide
The title compound 18mg (8%) was obtained in a manner similar to
the Example 207 by use of 2M-dimethylamine in tetrahydrofuran, instead
of N-methylpiperazine.
[0427]
Example 209:
N-(4-Cyanocyclohexyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide
The title compound 18Stag (84%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Example 36, instead
of benzylamine.
[0428]
Example 210:
tert-Butyl 2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}ethyl(methyl)carbamate
The title compound 1.89g (99%) was obtained in a manner similar
to the Example 7 by use of [2- (N-Boc-N-methyl) amino] ethylamine, instead
of benzylamine.
[0429]
Example 211:
l-Cyclohexyl-3-methyl-N-[2-(methylamino)ethyl]-iH-thieno[2,3-c]-
pyrazole-5-carboxamide 2HC1 salt
The title compound 1.71g (quantitative) was obtained in a manner

similar to the Manufacturing Example 4 by use of the compound obtained
in the example 210, instead of the compound obtained in the Manufacturing
Example 3.
[0430J
Example 212:
N-{2-[Acetyl(methyl)amino]ethyl}-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.381mmol) of the compound obtained in the
Example 211 in 5mL of dichloromethane were added 54uL (0 .572mmol) of acetic
anhydride and 123uL (1.53mmol) of pyridine, and the mixture was stirred
for 1 hour at room temperature. Then, 54uL (0.572mmol) of acetic anhydride
andl23uL (1.53mmol) of pyridine were further added to the reaction mixture,
and the mixture was stirred for 1 hour at room temperature. Water was
added to the ireaction mixture and the mixture was extracted with
dichloromethane, and the organic layer was dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure, and the residue
was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 30/1) togivel20mg (87%) of the title compound.
[0431]
Example 213:
l-Cyclohexyl-3-methyl-N-{2-[methyl (methylsulfonyl) amino]ethyl}-1H-
thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
To a solution of 150mg (0.381mmol) of the compound obtained in the
Example 211 in 5mL of dichloromethane were added 44uL (0.572mmol) of
methanesulfonyl chloride and 212uL (1.53mmol) of triethylamine, and the
mixture was stirred for 1 hour at room temperature. After the reaction,
water was added to the reaction mixture and the mixture was extracted
with dichlorome~;hane. The organic layer was dried over with anhydrous
sodium sulfate and the solvent was removed under reduced pressure. The
resulting residue was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 40/1), and the eluate was treated with
4N-HCl/dioxane ~o give 128mg (77%) of the title compound.
[0432]

Example 214:
Ethyl (4-{[(l-cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)-
carbonyl]amino}-1-piperidinyl)acetate
To a solution of 250mg (0.722mol) of the compound obtained in the
Example 134 in 6r.iL of dichloromethane were added 88uL (0.794mmol) of ethyl
bromoacetate and 151uL (1.082mmol) of triethylamine, and the mixture was
stirred for 3 days at room temperature. Then, water was added to the reaction
mixture and the mixture was extracted with dichloromethane. The organic
layer was dried over with anhydrous sodium sulfate and the solvent was
removed, under reduced pressure. The resulting residue was purified by
silicci gel column chromatography (eluent: dichloromethane/methanol = 40/1)
to give 237mg (76%) of the title compound.
[0433]
Example 215:
(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}-1-piperidinyl)acetic acid
The title compound 176mg (86%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 214,
instead of the compound obtained in the Example 40.
[0434]
Example 216:
Ethyl 2-(4-{ [ (l--cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}--1-piperidinyl)-2-methylpropanoate
To a solution of 252mg (0.727mmol) of the compound obtained in the
Example 134 in 5mL of N,N-dimethylformamide were added 128uL (0 . 873mmol)
of ethyl 2-bromoisobutyrate and 152uL (1.09mmol) of triethylamine, and
the mixture was stirred for over night at 70°C. Then, water was added
to the reaction mixture and the mixture was extracted with dichloromethane.
The organic layer was dried over with anhydrous sodium sulfate and the
solvent was removed under reduced pressure. The resulting residue was
purified by silica gel column chromatography (eluent: dichloromethane/
methanol = 40/1) to give 115mg (34%) of the title compound.
[0435]

Example 217:
2-(4-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-1-piperidinyl)-2-methypropanoic acid
The title compound 65mg (69%) was obtained in a manner similar to
the Example 41 by use of the compound obtained in the Example 216, instead
of the compound obtained in the Example 40.
[04361
Example 218:
N-[4-(4-Hydroxy-l-piperidinyl)phenyl]-3-methyl-l-tetrahydro-2H-
pyran--4-yl-lH-thieno [2, 3-c]pyrazole-5-carboxamide
The title compound 198mg (90%) was obtained in a manner similar
to the Example 7 by use of 1- (4-aminophenyl) -4-piperidinol and the compound
obtained in the Example 195, instead of benzylamine and the compound obtained
in the Example 6, respectively.
[0437]
Example 219:
1-Cyclohexyl-N-[2-(5,5-dimethyl-2, 4-dioxo-l,3-oxazolidin-3-yl)-
ethyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.488mol) of the compound obtained in the
Example 122 in 5mL of tetrahydrofuran were added 75.6mg (0.586mmol) of
5,5-dimethyloxazolidine-dione, 154mg (0.586mmol) of triphenylphsophine
and267uL (0 . 586]timol) of diethyl azodicarboxylate (40% toluene solution) ,
and the mixture was stirred for 2 hours at room temperature. After the
reaction, water was added to the reaction mixture and the mixture was
extracted with dichloromethane. The organic layer was dried over with
anhydrous sodium sulfate and the solvent was removed under reduced pressure.
The resulting residue was purified by silica gel column chromatography
(eluent: dichloromethane /acetone = 2/1 for first trial, and hexane/ethyl
acetate = 2/1 for second trial) to give 133mg (65%) of the title compound.
[0438]
Example 220:
l-Cyclohexyl-3-methyl-N-{[methyl(4-moprpholinylcarbonyl)amino]ethyl}
-lH-thieno[2,3-c]pyrazole-5-carboxamide

The title: compound 164mg (99%) was obtained in a manner similar
to the Example 214 by use of the compound obtained in the Example 211
and 4-morpholinylcarbonyl chloride, instead of the compound obtained in
the Example 134 and ethyl bromoacetate, respectively.
[0439]
Example 221:
l-Cyclohexyl-N-{2-[[(dimethylamino)carbonyl] (methyl) amino]ethyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 119mg (80%) was obtained in a manner similar
to the Example 214 by use of the compound obtained in the Example 211
and dimethylaminocarbonyl chloride, instead of the compound obtained in
the Example 134 and ethyl bromoacetate, respectively.
[0440]
Example 222:
Methyl 2-{ [ (l-cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)-
carbonyl]amino}ethyl(methyl)carbamate
To a solution of 150mg (0.381mmol) of the compound obtained in the
Example 211 in 5mL of dichloromethane and 5mL of water were added 158mg
(1.14mmol) of potassium carbonate and 44uL (0.572mmol) of ethyl
chlorocarbonate, and the mixture was stirred for over night at room
temperature. Then, water was added to the reaction mixture and the mixture
was extracted with dichloromethane . The organic layer was dried over with
anhydrous sodium sulfate and the solvent was removed under reduced pressure .
The resulting residue was purified by silica gel column chromatography
(eluent: dichloromethane/methanol = 40/1) togivel20mg (83%) of the title
compound.
[0441]
Example 223:
1-Cyclohexyl-N- •' 2- [ (methoxyacetyl) (methyl) amino] ethyl} -3-methyl-
IH-thieno[2,3-c' pyrazole-5-carboxamide
The title compound 124mg (83%) was obtained in a manner similar
to the Example 214 by use of the compound obtained in the Example 211
and methoxyacetyl chloride, instead of the compound obtained in the Example

134 and ethyl bromoacetate, respectively.
[0442]
Example 224:
1-Cyclohexyl-N-{2-[glycoloyl (methyl) amino]ethyl}-3-methyl-lH-
> thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0 .38lmmol) of the compound obtained in the
Example 211 in bmL of dichloromethane were added 34.8mg (0.458mmol) of
hydroxyaceticacid, 186uL (1.335mmol) oftriethylamine, 61.8mg (0.458mmol)
of N-hydroxybenzotriazole and 80.4mg (0.419mmol) of l-ethyl-3-(3'-di-
) methylaininopropyl) carbodiimide, and the mixture was stirred for 3 hours
at room temperature. Then, water was added to the reaction mixture and
the mixture was extracted with dichloromethane. The organic layer was
dried over with anhydrous sodium sulfate and the solvent was removed under
reduced pressure. The resulting residue was purified by silica gel column
) chromatography (eluent: dichloromethane/methanol = 40/1) to give 87mg
(60%) of the ti~le compound.
[0443]
Example 225:
1-Cyclohexyl-N-(4-{[(2-hydroxyethyl) (methyl)amino]carbonyl}-
) cyclohexyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 128mg (74%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 205
and 2-N-methylaminoethanol, instead of the compound obtained in the Example
211 and hydroxyacetic acid, respectively.
) [0444]
Example 226:
Methyl (lS,3S)-3-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}cyclopentanecarboxylate
The title compound 565mg (97%) was obtained in a manner similar
) to the Example 7 by use of methyl (IS, 35) -3-aminocyclopentanecarboxylate,
instead of benzylamine.
[0445]
Example 227:

(IS,3S)-3-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclopentanecarboxylic acid
The title compound 542mg (quantitative) was obtained in a manner
similar to the Eixample 41 by use of the compound obtained in the Example
226, instead of the compound obtained in the Example 40.
[0446]
Example 228:
l-Cyclohexyl-3-methyl-N-[2-(4-methyl-2, 3-dioxo-l-piperazinyl)ethyl]-
lH-thie.no [2, 3-c] pyrazole-5-carboxamide
The title compound 88mg (35%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Example 37, instead
of benzylamine.
[0447]
Example 229:
l-Cyclohexyl-N-{(IS,3S)-3-[(dimethylamino)carbonyl]cyclopentyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 176mg (91%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 227
and 2M-dimethylamine tetrahydrofuran solution, instead of the compound
obtained in the Example 211 and hydroxyacetic acid, respectively.
[0448]
Example 230:
1-Cyclohexyl-N-1(IS, 3S)-3-[(dimethylamino)carbonyl]cyclopentyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide HC1 salt
The title compound 137mg (84%) was obtained in a manner similar
to the Example 125 by using the compound obtained in the Example 229,
instead of the compound obtained in the Example 124.
[0449]
Example 231:
Methyl (1R,3R)-3-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-
yl)carbonyl]amino}cyclopentanecarboxylate
The title compound 772mg (99%) was obtained in a manner similar
to the Example 7 by use of methyl (1R, 3R) -3-aminocyclopentanecarboxylate,

instead of benzylamine.
[0450]
Example; 232:
(1R,3R)-3-{[(l-Cyclohexyl-3-merhyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}cyclopentanecarbcxylic acid
The title compound 822mg (quantitative) was obtained in a manner
similar to the E,xample 41 by use of the compound obtained in the Example
231, instead of the compound obtained in the Example 40.
[0451]
Example 233:
l-Cyclohexyl-N-{(1R,3R)-3-[(dimethylamino)carbonyl]cyclopentyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 153mg (79%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 232
and 2M-dimethylamine tetrahydrofuran solution, instead of the compound
obtained in the Example 211 and hydroxyacetic acid, respectively.
[0452]
Example 234:
l-Cyclchexyl-N-{(1R,3R)-3-[(dimethylamino)carbonyl]cyclopentyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 80mg (54%) was obtained in a manner similar to
the Example 125 by use of the compound obtained in the Example 233, instead
of the compound obtained in the Example 124.
[0453]
Example 235:
1-Cyclohexyl-N-[1[(dimethylamino)carbonyl]-4-piperidinyl}-3-methyl-
lH-thieno[2,3-cjpyrazole-5-carboxamide
The title compound 241mg (95%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 39, instead of benzylamine.
[0454]
Example 236:
l-Cyclohexyl-3-methyl-N-[4-(4-morpholinylcarbonyl)cyclohexyl]-1H-

thieno [2, 3-c] pyrazole-5-carboxamide
The title: compound 236mg (96%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 205
and morpholine, instead of the compound obtained in the Example 211 and
hydroxyacetic acid, respectively.
[0455]
Example 237:
l-Cyclohexyl-3-:nethyl-N-{4-[(methylamino)carbonyl]cyclohexyl}-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 122mg (79%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 205
and methylamine (30% ethanol solution) , instead of the compound obtained
in the Example 211 and hydroxyacetic acid, respectively.
[0456]
Example 238:
l-Cyclohexyl-N-{4-[(cyclopropylamino)carbonyl]cyclohexyl}-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 115mg (64%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 205
and cyclopropyl£tmin, instead of the compound obtained in the Example 211
and hydroxyacetic acid, respectively.
[0457]
Example 239:
1-Cyclohexyl-N-[4-[(4-hydroxy-l-piperidinyl)carbonyl]cyclohexyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 157mg (86%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 205
and 4-hydroxypiperidine, instead of the compound obtained in the Example
211 and hydroxyacetic acid, respectively.
[0458]
Example 240:
l-Cyclohexyl-N-;i-[(dimethylamino)sulfonyl]-4-piperidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide

The title compound 257mg (99%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 41, instead of benzylamine.
[0459]
Example 241:
tert-Butyl 4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-1-piperidinecarboxylate
The title compound 2.57g (98%) was obtained in a manner similar
to the Example 7 by use of 4-amino-l-Boc-piperidine, instead of benzylamine.
[0460]
Example 242:
l-Cyclohexyl-3-methyl-N-(4-piperidinyl)-IH-thieno[2,3-c]pyrazole-5-
carboxamide di-HCl salt
The title compound 2.29g (97%) was obtained in a manner similar
to the Manuf acturing Example 4 by using the compound obtained in the Example
241, instead of the compound obtained in the Manufacturing Example 3.
[0461]
Example 243:
N-[(3S)-1-Benzylpyrrolidinyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxaraide
The title compound 2.32g (97%) was obtained in a manner similar
to the Example 7 by use of (3S)-l-benzyl-3-aminopyrrolidine, instead of
benzylamine.
[0462]
Example 244:
l-Cyclohexyl-3-methyl-N-[(3S)-pyrrolidinyl]-IH-thieno[2,3-c]-
pyrazole-5-carboxamide
To a solution of 2.26g (5.35mmol) of the compound obtained in the
Example 243 in 50mL of 1,2-dichloroethane was added 721pL (6.68mmol) of
1-chloroethyl chloroformate, and the mixture was refluxed for 2 hours.
Then, 239uL (2.67mmol) of 1-chloroethyl chloroformate was further added
to this mixture and the mixture was refluxed for 1 hour under stirring.
The solvent was removed under reduced pressure and 50mL of methanol was

added to the residue, and the mixture was refluxed for 30 minutes. The
solvent was removed under reduced pressure and the residue was treated
with saturated sodium bicarbonate aqueous solution, and the mixture was
extracted with dichloromethane. The organic layer was dried over with
anhydrous sodium sulfate, and the solvent was removed under reduced pressure.
The residue was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 20/l) togive0.83g (47%) of the title compound.
[0463]
Example 245:
l-Cyclohexyl-N-{(3S)-l-[(dimethylamino)carbonyl3pyrrolidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 155mg (85%) was obtained in a manner similar
to the Example 214 by use of the compound obtained in the Example 244
and dimethylaminocarbonyl chloride, instead of the compound obtained in
the Example 134 and ethyl bromoacetate, respectively.
[0464]
Example 246:
1-Cyclchexyl-N-{(3S)-1-[(dimethylamino)carbonyl]pyrrolidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 155mg (85%) was obtained in a manner similar
to the Example 125 by use of the compound obtained in the Example 245,
instead of the compound obtained in the Example 124.
[0465]
Example 247:
1-Cyclohexyl-N-[4-[(2,5-dioxo-l-imidazolidinyl)methyl]cyclohexyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
To a solution of 136mg (0.362mmol) of the compound obtained in the
Example 206 in lOmL of tetrahydrofuran were added 72mg (0.724mmol) of
hydantoin, 135uL (0.543mmol) of tri-n-butylphosphineandl, 1 '-azobis (N,N-
dimethylformamide) , and the mixture was stirred for 3 hours at 60°C. The
reaction mixture; was cooled to room temperature, treated with water, and
extracted with ethyl acetate. The organic layer was dried over with
anhydrous sodium sulfate and removed under reduced pressure. The residue

was purified by silica gel column chromatography (eluent: ethyl acetate)
to give 96mg (58%) of the title compound.
[0466]
Example 248:
Ethyl 1-[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]-4-piperidinecarboxylate
The title compound 2.73g (98%) was obtained in a manner similar
to the Example 7 by using ethyl isonipecotic acid, instead of benzylamine.
[0467]
Example 249:
1-[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-4-
piperidinecarboxylic acid
The title compound 1. Ig (99%) was obtained in a manner similar to
the Example 41 by use of the compound obtained in the Example 248, instead
of the compound obtained in the Example 40.
[0468]
Example 250:
1- [ (l-Cyclohexy_"_-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl) carbonyl] -N-
methyl-4-piperidinecarboxamide
The title compound 195mg (94%) was obtained in a manner similar
to the Example 224 by use of methylamine (30% ethanol solution) and the
compound obtained in the Example 249, instead of the compound obtained
in the Example 211 and hydroxyacetic acid, respectively.
[0469]
Example 251:
Ethyl (3S)-1-[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]-3-piperidinecarboxylate
The title compound 2.29g (quantitative) was obtained in a manner
similar to the Example 7 by use of ethyl (R)-nipecotic acid, instead of
benzylamine.
[0470]
Example 252:
N-[(6S,7aS)-1,3--Dioxohexahydro-lH-pyrrolo[1,2-c]imidazol-6-yl]-1-

cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carbxamide
The title compound 595mg (74%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 45, instead of benzylamine.
[0471]
Example 253:
N-[ (6,3,7aS)-2-Methyl-l,3-dioxohexahydro-lH-pyrrolo[1,2-c] imidazol-
6-yl]-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
HC1 salt
To a solution of 150mg (0.374mmol) of the compound obtained in the
Example 252 in lOmL of tetrahydrofuran were added 30uL (0.747mmol) of
methanol, 122mg (0.476mmol) of triphenylphosophine and 213uL (0.467mmol)
of diethylazodicarboxylate (40% toluene solution), and the mixture was
stirred for 1 hour at room temperature. Then, the solvent was removed
under reduced pressure and the residue was purified by silica gel column
chromatography (eluent: hexane/acetone = 2/1 for first trial;
dichlorome thane/ethyl acetate = 1/1 for second trial) , and obtained product
was converted to the HC1 salt by treating with lOOuL of 4N-HCl/dioxane
solution and recrystallized from methanol-ethanol (1/1) to give 23 mg
(15%) of the title compound.
[0472]
Example 254:
(±)-{l-[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]-3-piperidinyl}methanol
The title compound 595mg (74%) was obtained in a manner similar
to the Example 7 by use of (±)-3-hyrdoxymethylpiperidine, instead of
benzylamine.
[0473]
Example 255:
N-{4-[(Dimethylamino)carbonyl]phenyl}-3-methyl-l-tetrahydro-2H-
pyran~4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 123mg (80%) was obtained in a manner similar
to the Example 7 by use of 4-(dimethylaminocarbonyl)aniline, instead of

benzylamine.
[0474]
Example 256:
l-Cyclohexyl-3-methyl-N-[6-(2-oxo-l-imidazolidinyl)-3-pyridinyl]-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 199mg (83%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 46, instead of benzylamine.
[0475]
Example 257:
1-Cyclohexyl-N-[(IS,3S)-3-(hydrcxymethyl)cyclopentyl]-3-methyl-
lH-tieno[2,3-c]pyrazole-5-carboxamide
The title compound 462mg (quantitative) was obtained in a manner
similar to the Example 206 by use of the compound obtained in the Example
226, instead of the compound obtained in the Example 204.
[0476]
Example 258:
l-Cyclohexyl-N-{(lS,3S)-3-[(2,5-dioxo-l-imidazolidinyl)methyl]-
cyclopentyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 74mg (40%) was obtained in a manner similar to
the Example 247 by use of the compound obtained in the Example 257, instead
of the: compound obtained in the Example 206.
[0477]
Example 259:
1-Cyclchexyl-N-[4-(2,5-dioxo-l-imidazolidinyl)phenyl]-3-methyl-
lH-thieno[2, 3-c1pyrazole-5-carboxamide
The title compound 54mg (27%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example
47, instead of benzylamine.
[0478]
Example 260:
3-Methyl-N-[4-(3-methyl-2,5-dioxo-l-imidazolidinyl)phenyl]-1-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide

The title compound 104mg (61%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 48 and the compound obtained in the Example 195, instead of
benzylamine and the compound obtained in the Example 6, respectively.
[0479]
Example 261:
3-Methyl-N-[6-(2-oxo-l-imidazolidinyl)-3-piperidinyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound lOlmg (63%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 46 and the compound obtained in the Example 195, instead of
benzylamine and the compound obtained in the Example 6, respectively.
[0480]
Example 2 62:
l-Cyclohexyl-N-{4-[(3R)-3-hydroxypyrrolidinyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 308mg (64%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 49, instead of benzylamine.
[0481]
Example 2 63:
1-Cyclohexyl-N-(3-fluoro-4-[(3R)-3-hydroxypyrrolidinyl]phenyl}-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 397mg (79%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 51, instead of benzylamine.
[0482].
Example 264:
1-Cyclchexyl-N-{3-[(4-hydroxy-l-piperidinyl)sulfonyl]phenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 80mg (35%) was obtained in a manner similar to
the Example 7 by use of the compound obtained in the Manufacturing Example.
53, instead of benzylamine.

[0483]
Example 2 65:
N-{4-[4-{[tert-Butyl(dimethyl)silyl]oxy}-l-piperidinyl]sulfonyl}-
phenyl}-l-cyclchexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title; compound 243mg [69%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 56, instead of benzylamine.
[0484]
Example 266:
l-Cyclohexyl-N-{4-[(4-hydroxy-l-piperidinyl)sulfonyl]phenyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 231mg (0.374mmol) of the compound obtained in the
Example 265 in 5mL of tetrahydrofuran was added 562uL (0.562mmol) of
tetrabutylammoniumfluoride (iM-tetrahydrohfuran solution), and the
mixtuire was stirred for over night at room temperature. Then, the reaction
mixture was tree.ted with ethyl acetate, and the organic layer was washed
with water, saturated saline solution and then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
hexane/ethyl acetate = 1/2) to give 176mg (94%) of the title compound.
[0485]
Example 2 67:
1-Cyclohexyl-N-[4-(2-hydroxyethyl)phenyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 139mg (64%) was obtained in a manner similar
to the Example 7 by use of 4-aminophenethy1alcohol, instead of benzylamine.
[0486]
Example 268:
N-[3-Fluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 161mg (96%) was obtained in a manner similar
to the: Example 7 by use of the compound obtained in the Manufacturing
Example 62 and the compound obtained in the Example 195, instead of

benzylamine and the compound obtained in the Example 6, respectively.
[0487]
Example 269:
l-Cyclchexyl-3-methyl-N-[4-(4-methyl-l-piperazinyl)-3-(trifluoro-
methyl)phenyl]-IH-thieno[2,3-clpyrazole-5-carboxamide
The title compound 229mg (80%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 58, instead of benzylamine.
[0488]
Example 270:
l-Cyclohexyl-3-methyl-N-[trans-4-(2-oxo-l,3-oxazoliclin-3-yl)-
cyclohexyl]-lH-~hieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 150mg (0.416mmol) of the compound obtained in
the Example 132 in 2 . 5mL of tetrahydrofuran were added 52uL (0. 5Ommol)
of 2-chloroethyl chloroformate and 87uL (0.624mmol) of triethylamine,
and the mixture was stirred for 3 hours at room temperature. Saturated
sodium bicarbonate aqueous solution was added to the reaction mixture
and the mixture was extracted with chloroform. The organic layer was washed
with water and saturated saline solution and dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure to give
urethane intermediate compound.
Next, to a mixture solution of the urethane intermediate compound
obtained above in 2mL of ethanol and 4mL of tetrahydrofuran was added
2mL of 4M-NaOH aqueous solution, and the mixture was stirred for 4 0 hours
at room temperature. The solvent was removed under reduced pressure and
the residue was treated with water, and the mixture was extracted with
chloroform. The organic layer was washed with water and saturated saline
solution and dried over with anhydrous sodium sulfate. The solvent was
removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: chloroform/methanol = 10/1) to give
180mg (quantita-;ive) of the title compound.
[0489]
Example 271:

l-Cyclohexyl-3-methyl-N-[trans-A-(2-oxo-l-imidazolidinyl)-
cyclohexyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 150mg (0.416mmol) of the compound obtained in
the Example 132 in 4mL of tetrahydrofuran was added 71uL (0.832mmol) of
2-chloroethyisocyanate, and the mixture was stirred for 3.5 hours at room
temperature. 2niL of lM-NaOH aqueous solution was added to the reaction
mixture, and the mixture was stirred. Then, further 5mL of 4M-NaOH aqueous
solution and 15mL of tetrahydrofuran were added to the mixture, and the
mixture was stirred for 2 hours. Next, 5uL of 15-crown-5 was added to
the reaction mixture and the mixture was further stirred for 43 hours
at room temperature, then, 5mL of ethanol was added to the reaction mixture
and stirred for 6 hours at 80°C. The solvent was removed under reduced
pressure and the residue was treated with water. The mixture was extracted
with chloroform and the organic layer was washed with water and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: chloroform/methanol = 10/1)
to give 106mg (55%) of the title compound.
[0490]
Example 272:
4- [ (trans-4-{ [ (I_-Cyclohexyl-3-methyl-lH-thieno [2, 3-c] pyrazol-5-yl) -
carbonyl]amino}cyclohexyl)amino]-4-oxobutanoic acid
To a suspension of 150mg (0.416mmol) of the compound obtained in
the Example 132 in 5mL of xylene was added 62mg (0.624mmol) of succinic
anhydride, and the mixture was refluxedfor 5 hours . The solvent was removed
under reduced pressure and the residue was treated with ether. The appeared
precipitates were collected to give 178mg (93%) of the title compound.
[0491]
Example 273:
1-Cyclohexyl-N-\trans-A-(2,5-dioxo-l-pyrrolidinyl)cyclohexyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
Amixtureof 141mg (0.306mmol) of the compound obtained in the Example
272, 2mL of acetic anhydride and 33mg of sodium acetate was stirred for

3 hours at 60°C and for 14 hours at 30°C, then, 2mL of acetic anhydride
was further added to the reaction mixture, and the mixture was stirred
for 6 hours at 100°C. After the reaction, ice water was added to the reaction
mixture and the mixture was neutralized by adding saturates sodium
bicarbonate aqueous solution, and extracted with chloroform. The organic
layer was washed with water and saturated saline solution, and dried over
with anhydrous sodium sulfate. The solvent was removed under reduced
pressure and the residue was treated with ethanol to give 59mg (49%) of
the title compound.
[0492]
Example 274:
1-Cyclohexyl-N-[trans-4-(1,l-dioxide-2-isothiazolidinyl)cyclohexyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.416mmol) of the compound obtained in the
Example 132 in lOmL of dichloromethane were added 87uL (0.624mmol) of
triethylamine and 61uL (0.50mmol) of 3-chloropropanesulfonyl chloride,
and the mixture was stirred for 1.5 hours at room temperature. Water was
added to the reaction mixture and the mixture was extracted with chloroform.
The organic layer was washed with water and saturated saline solution
and dried over with anhydrous sodium sulfate. The solvent was removed
under reduced pressure to give sulfonamide intermediate compound.
Next, to a mixture solution of the sulfonamide intermediate compound
obtained above in 5mL of ethanol was added 2mL of 4M-NaOH aqueous solution,
and the mixture was stirred for 1.5 hours at room temperature and for
3 hours at 80C° . The reaction mixture was cooled and treated with water,
and then, extracted with chloroform. The organic layer was washed with
water and saturated saline solution and dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was recrystallized from ethanol to give 112mg (58%) of the title compound.
[0493]
Example 275:
Benzyl [{[{trans-4-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl] amino}cyclohexyl) amino]carbonyl}(methyl)amino]acetate

To a solution of 200mg (0.555mmol) of the compound obtained in the
Example 132 in 4mL of tetrahydrofuren were added 66mg (0.22mmol) of
tri-phosgene and 232uL (1.66mmol) of triethylamine, and the mixture was
stirred fori hour: at room temperature. Then, 195mg (0.55mmol) ofp-toluene
sulfonic acid sarcosine benzyl ester and 77uL (0.555mmol) of triethylamine
were added to the reaction mixture, and the mixture was stirred for 5
hours at room temperature. Water was added to the reaction mixture and
the mixture was extracted with chloroform, and the organic layer was washed
with water and saturated saline solution, then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
chloroform/methanol =15/1) to give 227mg (72%) of the title compound.
[0494]
Example 276:
l-Cyclohexyl-3-methyl-N-[trans-4-(3-methyl-2,5-dioxo-l-
imidazolidinyl)cyclohexyl]-lH-thieno[2, 3-c]pyrazole-5-carboxamide
To a solution of 207mg (0.366mmol) of the compound obtained in the
Example 275 in 5mL of ethanol was added 0.5mL of 6M-HC1 aqueous solution
and the mixture was refluxed for 4 hours. After the reaction, the mixture
was neutralized oy adding saturated sodium bicarbonate aqueous solution,
and extracted with chloroform. The organic layer was washed with water
and saturated saline solution and dried over with anhydrous sodium sulfate .
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: chloroform/methanol = 15/1)
to give 169mg (quantitative) of the title compound.
[0495]
Example 277:
l-Cyclohexyl-3-iaethyl-N-[2-(3-methyl-2,5-dioxo-l-imidazolidinyl)-
ethyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.487mmol) of the compound obtained in the
Example 122 and 55.6mg (0.487mmol) of 1-methylhydantoin 4mL of
tetrahydrofuran were added 121uL (0 . 487mmol) of n-butylphosphine and 83. 8mg
(0.487mmol) of 1,1'-azobis(N,N-dimethylformamide), and the mixture was

stirred for 5hours at room temperature. The reaction mixture was treated
with waiter and extracted with chloroform. The organic layer was washed
with water and saturated saline solution, and dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent: ethyl
acetate) to give 113mg (58%) of the title compound.
[0496]
Example 278:
l-Cyclohexyl-3-methyl-N-[3-(3-methyl-2,5-dioxo-l-imidazolidinyl)-
propyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title: compound 147mg (75%) was obtained in a manner similar
to the Example 277 by use of the compound obtained in the Example 123,
instead of the compound obtained in the Example 122.
[0497]
Example 279:
1-Cyclohexyl-N-[trans-[4-({[(2-hydroxyethyl) (methyl)amino]carbonyl}-
aminocyclohexyl]-3-methyl-lH-thienc[2, 3-c]pyrazole-5-carboxamide
To a suspension of 200mg (0.555mmol) of the compound obtained in
the Example 132 in 4mL of tetrahydrofuran were added 66mg (0.22mmol) of
triphosgene and 232uL (1.66mmol) of triethylamine and the mixture was
stirrec. for 1 hour at room temperature. Then, 54uL (0.66mmol) of
2- (methylamino)ethanol was added to ^he reaction mixture and the mixture
was stirred for 3 hours at room temperature. The reaction mixture was
treated with water and extracted with chloroform, washed with water and
saturated saline solution, and then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent:
chloroform/methanol = 15/1) to give 190mg (74%) of the title compound.
[0498]
Example 280:
l-Cyclohexyl-3-methyl-N-[trans-[4-(3-methyl-2-oxo-l-imidazolidinyl)-
cyclohexyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 187mg (0.519mmol) of the compound obtained in

the Example 279 in 6mL of tetrahydrofuran was added 140mg (1.25mmol) of
potassium tert-butoxide and the mixture was cooled to 0°C. Then, a solution
of 119mg (0.623mmol) of p-toletnesulfonyl chloride in 2mL of
tetrahydrofuran was added gradually to the reaction mixture and the mixture
was stirred for 30 minutes at room temperature. The reaction mixture was
treated with water and extracted with chloroform. The organic layer was
washed with water and saturated saline solution and dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
chloroform/methanol = 20/1) to give 115mg (64%) of the title compound.
[0499]
Example 281:
Ethyl 3-{[(l-cyclohexyl-3-methyi-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}propanoate
The title compound 716mg (98%) was obtained in a manner similar
to the Example 7 by use of [3-alanine ethyl ester HC1 salt, instead of
benzylamine.
[0500]
Example 282:
N-[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-yl)carbonyl]-
ft-alanine
The title compound 620mg (99%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 281,
instead of the compound obtained in the Example 40.
[0501]
Example 283:
tert-Butyl {[(l--cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}acetate
The title compound 663mg (88%) was obtained in a manner similar
to the Example 7 by use of glycine tert-butyl ester HC1 salt, instead
of benzylamine.
[0502]
Example 284:

{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}cicetic acid
A mixture: solution of 637mg (1.68mmol) of the compound obtained
in the Example 2 83 and 5mL of 4M-HCl/dioxane was stirred for 5 hours at
room temperature, and after the reaction, the solvent was removed under
reduced pressure. The residue was treated with water and extracted with
chloroform, and the organic layer was washed with water and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure to give 556mg (quantitative)
of the title compound.
[0503]
Example 285:
l-Cyclohexyl-3-methyl-N-[3-(4-morphonyl)-3-oxopropyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
A suspension solution of 85mg (0.253mmol) of the compound obtained
in the Example 232, 246mg (0.337mmol) of PS-carbodiimide (Argonaut Co.) ,
and 39mg (0.287mmol) of 1-hydroxybenzotriazole in 4mL of dichloromethane
was stirred for 10 minutes at room temperature. To the reaction mixture
was added 20uL (0.228mmol) of morpholine, and the mixture was stirred
for 20 hours at room temperature. Then, 267mng (0.861mmol) of MP-carbonate
(Argonaut Co.) was added to the reaction mixture and the mixture was stirred
for 3 hours at room temperature. The reaction mixture was filtrated and
the filtrate was condensed under reduced pressure. The residue was
recrystallized from ethyl acetate/hexane to give 80mg (78%) of the title
compound.
[0504]
Example 286:
tert-Butyl 2-{[(l-cyclohexyl-3-raethyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbony1]amino}ethylcarbamate
The title compound 2.23g (97%) was obtained in a manner similar
to the Example 7 by use of N- (2-aminomechyl) carbamic acid tert-butyl ester,
instee.d of benzylamine.
[0505]

Example 287:
N-(2-Aminoethyl)-l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
To a solution of 2.18g (5.36mmol) of the compound obtained in the
Example 286 in 20mL of dichloromethane was added 5mL of 4M-HCl/dioxane,
and the mixture was stirred for 18 hours at room temperature. After reaction,
the solvent was removed under reduced pressure and the residue was
neutralized with saturated sodium bicarbonate aqueous solution, and
extracted with chloroform. The organic layer was washed with water and
saturated saline solution, then, dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was treated
with ethanol to give 670mg (41%) of the title compound.
[0506]
Example 288:
1-Cyclchexyl-N-[3-(dimethylamino)-3-oxopropyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 52mg (57%) was obtained in a manner similar to
the Example 285 by use of 2.OM-dimethylamine/tetrahydrofuran, instead
of morpholine.
[0507]
Example 289:
l-Cyclohexyl-3-methyl-N-{3-[methyl(l-methyl-4-piperidinyl)amino]-3-
oxopropyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 79mg (70%) was obtained in a manner similar to
the Example 285 by use of 1-methyl-4-(methylamino)piperidine, instead
of morpholine.
[0508]
Example 290:
1-Cyclohexyl-N-[3-(4-hydroxy-l-piperidinyl)-3-oxopropyl]-3-methyl-
IH-thieno[2,3-c|pyrazole-5-carboxamide
The title compound 74mg (70%) was obtained in a manner similar to
the Example 285 by use of 4-hydroxypiperidine, instead of morpholine.
[0509]

Example 291:
l-Cyclohexyl-3-methyl-N-[2-(4-morpholinyl)-2-oxoethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 62mg (63%) was obtained in a manner similar to
the Example 285 by use of the compound obtained in the Example 284, instead
of the compound obtained in the Example 282.
[0510]
Example 292:
1-Cyclohexyl-N-[2-(dimethylamino)-2-oxoethyl]-3-methyl-lH-
thieno [2, 3-c] pyrazole-5-carboxarnide
The title compound 63mg (71%) was obtained in a manner similar to
the Example 285 by use of the compound obtained in the Example 284 and
2. OM-dimethylamine/tetrahydrofuran, instead of the compound obtained in
the Example 282 and morpholine, respectively.
[0511]
Example 293:
l-Cyclohexyl-3-methyl-N-[2-(4-rnethyl-l-piperazinyl)-2-oxoethyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 68mg (67%) was obtained in a manner similar to
the Example 285 by use of the compound obtained in the Example 284 and
N-methylpiperazine, instead of the compound obtained in the Example 282
and morpholine, respectively.
[0512]
Example 294:
1-Cyclohexyl-N-[2-(4-hydroxy-l-piperidinyl)-2-oxoethyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 75mg (73%) was obtained in a manner similar to
the Example 285 by use of the compound obtained in the Example 284 and
4-hydroxypiperidine, instead of the compound obtained in the Example 282
and morpholine, respectively.
[0513]
Example 295:
l-Cyclohexyl-3-methyl-N-[3-(4-methyl-l-piperazinyl)-3-oxopropyl]-

lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 84mg (80%) was obtained in a manner similar to
the Example 285 by use of N-methylpiperazine, instead of morpholine.
[0514]
Example 296:
l-Cyclohexyl-3-methyl-N-{3-[4-methyl-l-piperidinyl]-3-oxopropyl}-
lH-thieno[2,3-c]pyrazole-5-carboxamide fumarate
The title compound 41mg (41%) was obtained in a manner similar to
the Example 191 by use of the compound obtained in the Example 295, instead
of the compound obtained in the Example 144.
[0515]
Example 297:
l-Cyclohexyl-3-methyl-N-{2-[methyl(l-methyl-4-pireridinyl)amino]-2-
oxoethyl}-lH-thieno[2,3-c]pyrazple-5-carboxamide
The title compound 81mg (74%) was obtained in a manner similar to
the Example 285 by use of the compound obtained in the Example 284 and
l-methyl-4- (methylamino)piperidine, instead of the compound obtained in
the Example 282 and morpholine, respectively.
[0516]
Example 298:
l-Cyclohexyl-3-methyl-N-{2-[methyl(l-methyl-4-piperidinyl)amino-2-
oxoethyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide fumarate
The title compound 74mg (79%) was obtained in a manner similar to
the Example 191 by use of the compound obtained in the Example 297, instead
of the compound obtained in the Example 144.
[0517]
Example 299:
l-Cyclchexyl-3-methyl-N-[2-(2-oxo-l,3-oxazolidin-3-yl)ethyl]-1H-
thieno[2/3-c]pyrazole-5-carboxamide
To a suspension of 150mg (0.490mmol) of the compound obtained in
the Example 287 in 3mL of tetrahydrofuran were added 102uL (0.735mmol)
of triethylamine and 61uL (0.590mmol) of 2-chloroethyl chloroformate,
and the mixture was stirred for 2 hours at room temperature. Then, 210mg

(1.08inmol) of 28%-sodium methoxide/methanol solution was added to the
reactionmixture: and the mixture was stirred for 2 hours at room temperature,
and further 130mg (0.674mmol) of 28%-sodium methoxide/methanol solution
was added to the reaction mixture and the resulting mixture was stirred
for 15 hours at room temperature. Then, the reaction mixture was treated
with water and extracted with chloroform. The organic layer was washed
with water and saturated saline solution, then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was recrystallized from ethyl acetate to give 107mf (58%) of the
title compound.
[0518]
Example 300:
l-Cyclohexyl-N-[2-(1,l-dioxide-2-isothiazolidinyl)ethyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 125mg (62%) was obtained in a manner similar
to the Example 274 by use of the compound obtained in the Example 287,
instead of the compound obtained in the Example 132.
[0519]
Example 301:
1-Cyclohexyl-N-[2-({[(2-hydroxyethyl) (methyl) amino]carbonyl}amino)-
ethyl]-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 160mg (60%) was obtained in a manner similar
to the Example 279 by use of the compound obtained in the Example 287,
instead of the compound obtained in the Example 132.
[0520]
Example 302:
l-Cyclohexyl-3-methyl-N-[2-(3-methyl-2-oxo-l-imidazolidinyl)ethyl]-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound HOmg (80%) was obtained in a manner similar
to the Example 280 by use of the compound obtained in the Example 301,
instead of the compound obtained in the Example 279.
[0521]
Example 303:

Ethyl 4-{ [ (l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}butanoate
The title; compound 763mg (67%) was obtained in a manner similar
to the Example 7 by use of ethyl 4-aminobutyrate HC1 salt, instead of
benzylamine.
[0522]
Example 304:
4-{[ (l--Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
aminojbutanoic acid
The title compound 690mg (quantitative) was obtained in a manner
similar to the Example 41 by use of the compound obtained in the Example
303, instead of the compound obtained in the Example 40.
[0523]
Example 305:
l-Cyclohexyl-N-[2-(2,5-dioxo-l-imidazolidinyl)ethyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 98mg (67%) was obtained in a manner similar to
the Example 7 by use of 3- (2-aminoethyl) -2, 4-imidazolidinedione, instead
of benzylamine.
[0524]
Example 306:
1-Cyclohexyl-N-[4-(dimethylamino)-4-oxobutyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound lOlmg (85%) was obtained in a manner similar
to the Example 285 by use of the compound obtained in the Example 304
and 2 . OM-dimethylamine/tetrahydrofuran solution, instead of the compound
obtained in the Example 282 and morpholine, respectively.
[0525]
Example 307:
l-Cyclchexyl-3-methyl-N-[2-(3,4,4-trimethyl-2,5-dioxo-l-
imidazclidinyl)ethyl]-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.487mmol) of the compound obtained in the
Example 122 in 5mL of tetrahydrofuran were added 90mg (0.634mmol) of

1,5,5-trimethylhydantoin, 166mg (0.634mmol) of triphenylphosphine and
289uL (0.634mmol) of 40%-diethyl azodicarboxylate/toluene solution, and
the mixture was stirred for 30 minutes at room temperature. After the
reaction, the reaction mixture was treated with water and extracted with
dichloromethane. The organic layer was washed with water and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 1/2)
to give 146mg (69%) of the title compound.
[0526]
Example 308:
1-Cyclohexyl-N-[2-(2,4-dioxo-l,3-thiazolidine-3-yl)ethyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 106mg (53%) was obtained in a manner similar
to the Example 307 by use of 2,4-thiazolidinedione, instead of
1,5,5-tirmethyInydantoin.
[0527]
Example 309:
1-Cyclohexyl-N-[1-(hydroxymethyl)cyclopropyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 766mg (93%) was obtained in a manner similar
to the Example 7 by use of (1-aminocyclopropyl) methanol, instead of
benzylamine.
[0528]
Example 310:
l-Cyclohexyl-3-methyl-N-{l-[(3-methyl-2, 5-dioxo-l-imidazolidinyl)-
methyl]cyclopropyl}-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound lllmg (58%) was obtained in a manner similar
to the Example 307 by use of the compound obtained in the Example 309
and 1-methylhydantoin, instead of the compound obtained in the Example
122 and 1,5,5-trimethylhydantoin, respectively.
[0529]
Example 311:

Methyl [(2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}ethyl) amino]acetate
To a solution of 170mg (0 .555mmol) of the compound obtained in the
Example 287 in 5mL of acetonitrile were added 52.5uL (0.555mmol) of methyl
bromoacetate and 153mg (l.llmmol) of potassium carbonate, and the mixture
was refluxed foi: 3 hours. The reaction mixture was cooled and filtrated.
The filtrate was treated with water and extracted with ethyl acetate.
The organic layer was washed with water and saturated saline solution,
then, dried over with anhydrous sodium sulfate. The solvent was removed
under reduced pressure and the residue was purified by silica gel column
chromatography (eluent: dichloromethane/methanol = 20/1 to 10/1) to give
93mg (44%) of the title compounc.
[0530]
Example 312:
Methyl [ (aminocarbonyl) (2-{[(l-cyclohexyl-3-methyl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}ethyl)amino]acetate
To a solution of 78.8mg (0.208mmol) of the compound obtained in
the Example 311 in 1. 5mL of dioxane and 1.5mL of water were added 25.3mg
(0.312mmol) of potassium cyanate and 36uL of acetic acid, and the mixture
was stirred for 1.5 hours at room temperature. The reaction mixture was
treated with water and extracted with ethyl acetate. The organic layer
was washed with water and saturated saline solution, then, dried over
with anhydrous sodium sulfate. The solvent was removed under reduced
pressure and the residue was purified by silica gel column chromatography
(eluent: ethyl acetate/methanol = 20/1 to 10/1) to give 73mg (84%) of
the title compound.
[0531]
Example 313:
1-Cyclohexyl-N-[2-(2,4-dioxo-l-imidazolidinyl)ethyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 68mg (0.161mmol) of the compound obtained in the
Example 312 in 6mL of methanol was added 13mg (60% oily; 0.323mmol) of
sodium hydride, find the mixture was stirred for 1. 5 hour at room temperature.

The solvent was removed and the residue was treated with water and extracted
with ethyl acetate. The organic layer was washed with water and saturated
saline solution, and then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was
recrystallized from ethanol to give 20mg (32%) of the title compound.
[0532]
Example 314:
1-Cyclohexyl-N-[2-(4,4-dimethyi-2,5-dioxo-l-imidazolidinyl)ethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole~5-carboxamide
The title compound 195mg (96%) was obtained in a manner similar
to the Example 307 by use of 5,5-dimethylhydantoin, instead of
1,5,5-trimethylhydantoin.
[0533]
Example' 315:
l-Cyclohexyl-3-methyl-N-[2-(5-methy1-1,1-dioxide-l,2,5-thia-
diazolidin-2-yl)ethyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 227mg (94%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 60, instead of benzylamine.
[0534]
Example 316:
l-Cyclohexyl-N-[2-(3-ethyl-2,4-dioxo-l-imidazolidinyl)ethyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 84mg (65%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 313 and
ethanol, instead of 1, 5, 5-trimethylhydantoin and the compound obtained
in the Example 122, respectively.
[0535]
Example 317:
l-Cyclohexyl-3-methyl-N-[2-(3-methyl-2, 4-dioxo-l-imidazolidinyl)-
ethyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 82mg (66%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 313 and

methanol, instead of 1, 5, 5-trimethylhydantoin and the compound obtained
in the Example 122, respectively.
[0536]
Example 318:
1-Cyciohexyl-N-[(IS)-2-hydroxy-l-methylethylJ-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 170mg (56%) was obtained in a manner similar
to the Example 7 by use of (S) - ( + ) -2-amino-l-propanol, instead of
benzylamine.
[0537]
Example 319:
1-Cyclohexyl-N-[(IS)-2-(2,5-dioxo-l-imidazolidinyl)-1-methylethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 46mg (24%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 318 and
hydantoin, instead of the compound obtained in the Example 122 and
1,5,5-trimethyrnydantoin, respectively.
[0538]
Example 320:
N- [ (3R) -1-Benzylpyrrolidinyl]-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 2.32g (97%) was obtained in a manner similar
to the Example 7 by use of (3R)-(-)-l-benzyl-3-aminopyrrolidine, instead
of benzylamine.
[0539]
Example 321:
l-Cyclohexyl-3-methyl-N-[(3R)-pyrrolidinyl]-lH-thieno[2,3-c]-
pyrazole-5-carboxamide
To a solution of 2.28g (5.40mmol) of the compound obtained in the
Example 32 0 in 15mL of dichloromethane was added gradually 1.16mL (10. 8mmol)
of l-chloroethy.'L formate at 0C°, and the mixture was stirred for 1 hour
at the same temperature and for 2 hours at room temperature. The solvent
was removed under reduced pressure and 25mL of ethanol was added to the

residue, then, the mixture was refluxed for 2.5 hours. After cooling,
the solvent was removed under reduced pressure, and the residue was treated
with 6M-HC1 aqueous solution. Water layer was washed with ether, and
neutralizedby 4M-NaOH aqueous solution, and extracted with dichloromethane.
The organic layer was washed with water and saturated saline solution,
then, cried over with anhydrous sodium sulfate. The solvent was removed
under reduced pressure and the residue was purified by alkaline silica
gel column chromatography (eluent: dichloromethane/methanol = 50/1 to
30/1) to give 1.06g (59%) of the title compound.
[0540]
Example 322:
l-Cyclohexyl-N-{(3R)-1-[(dimethylamino)carbonyl]pyrrolidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.451mmol) of the compound obtained in the
Example 321 in 5mL of dichloromethane were added 50uL (0.541mmol) of
N,N-dimethylcaroamoyl chloride and 94uL of (0. 677mmol) of triethylamine,
and the mixture was stirred for 4 hours at room temperature. The reaction
mixture was treated with saturated sodium bicarbonate aqueous solution
and extracted with dichloromethane. The organic layer was washed with
water and saturated saline solution, then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by alkaline silica gel column chromatography (eluent:
dichloromethane/methanol = 30/1 to 10/1) to give 177mg (97%) of the title
compound.
[0541]
Example 323:
1-Cyclohexyl-N-{(3R)-1-[(dimethylamino)carbonyl]pyrrolidinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HCl salt
O.llmL (0.44mmol) of 4M-HCl/ethyl acetate was added to a solution
of 150rog (0.372mmol) of the title compound in lmL of ethyl acetate, and
the mixture was treated with ether, then, stirred for 2 hours. The
precipitates were collected to give 152mg (93%) of the title compound.
[0542]

Example 324:
1-Cyclohexyl-N-[(1R)-2-hydroxy-l-methylethyl]-3-methyl-lH-
thieno[2, 3-c]py::azole-5-carboxamide
The title compound 357mg (98%) was obtained in a manner similar
to the Example 7 by use of (R) - (-) -2-amino-l-propanol, instead of
benzylamine.
[0543]
Example 325:
1-Cyclohexyl-N-[(1R)-2-(2,5-dioxo-l-imidazolidinyl)-1-methylethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 67mg (18%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 324 and
hydantbin, instead of the compound obtained in the Example 122 and
1,5,5-trimethylhydantoin, respectively.
[0544]
Example 326:
1-Cyclohexyl-N-[(2S)-2-hydroxypropyl]-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide
The title compound 343mg (94%) was obtained in a manner similar
to the Example 7 by use of (S) - (-)-l-amino-2-propanol, instead of
benzylamine.
[0545]
Example 327:
1-Cyclohexyl-N-[(2R)-2-(2, 5-dioxo-l-imidazolidinyl)propyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 57mg (15%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 326 and
hydantcin, instead of the compound obtained in the Example 122 and
1,5,5-trimethylhydantoin, respectively.
[0546]
Example 328:
1-Cyclohexyl-N-[(2R)-2-hydroxypropyl]-3-methyl-lH-thieno[2,3-c]-
pyrazole-5-carboxamide

The title compound 338mg (93%) was obtained in a manner similar
to the Example 7 by use of (R) - (+) -l-amino-2-propanol, instead of
benzylamine.
[0547]
Example 329:
1-Cyclohexyl-N-[(2S)-2-(2,5-dioxo-l-imidazolidinyl)propyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 42mg (11%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 328 and
hydantoin, instead of the compound obtained in the Example 122 and
1,5,5-trimethylhydantoin, respectively.
[0548]
Example 330:
1-Cyclohexyl-N-[(1R)-1-(hydroxymethyl)propyl]-3-methyl-lH-
thieno [ 2, 3-c] py3:azole-5-carboxamide
The title compound 355mg (94%) was obtained in a manner similar
to the Example 7 by use of (R) - (-) -2-mino-l-butanol, instead of benzylamine.
[0549]
Example 331:
1-Cyclohexyl-N-{(1R)-1-[(2,5-dioxo-l-imidazolidinyl)methyl]propyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 66mg (18%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 330 and
hydantoin, instead of the compound obtained in the Example 122 and
1,5,5-trimethylhydantoin, respectively.
[0550]
Example 332:
1-Cyclohexyl-N- ■' (1R) -1- (hydroxymethyl) -2-methylpropyl] -3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 392mg (99%) was obtained in a manner similar
to the Example "i by use of D-valinol, instead of benzylamine.
[0551]
Example 333:

1-Cyclohexyl-N-{(1R)-1-[(2,5-dioxo-l-imidazolidinyl)methyl]-2-
methylpropyl}-3-methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 97mg (22%) was obtained in a manner similar to
the Example 307 by use of the compound obtained in the Example 332 and
hydantoin, instead of the compound obtained in the Example 122 and
1,5,5-trimethylhydantoin, respectively.
[0552]
Example 334:
tert-Butyl 2-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-2-methylpropylcarbamate
The title compound 493mg (quantitative) was obtained in a manner
similar to the Example 7 by use of tert-butyl 2-amino-2-methylpropyl-
carbamate, instead of benzylamine.
[0553]
Example 335:
N-(2-Amino-1,1-dimethylethyl)-l-cyclohexyl-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
A mixture solution of 470mg (1.08mmol) of the compound obtained
in the Example 334 in 2mL of 4M-HCl/dioxane was stirred for 3 hours at
room temperature. Then, the solvent was removed under reduced pressure
and the residue was treated with ether and the resultant precipitates
were collected. The collected precipitates were dissolved in water and
the mixture was neutralized with saturated sodium bicarbonate aqueous
solution, and extracted withdichiorome thane. The organic layer was washed
with water and saturated saline solution and dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure to give
344mg (92%) of the title compound.
[0554]
Example 336:
1-Cyclohexyl-N-|2-(2, 5-dioxo-l-imidazolidinyl)-1,1-dimethylethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 304mg (0.882mmol) of the compound obtained in the
Example 335 in 5mL of ethanol was added gradually a solution of 114mg

(0. 882mmol) of ethyl isocyanatoacetate in 5mL of ethanol, and the mixture
was stirred for 3 hours at room temperature . The solvent was removed under
reduced pressure and the residue was dissolved in 5mL of ethanol, then,
5mL of 6M-HC1 aqueous solution was added to the mixture. The mixture was
refluxed for 3 hours, and the solvent was removed under reduced pressure.
The residue was neutralized with saturated sodium bicarbonate aqueous
solution and the mixture was extracted with ethyl acetate. The organic
layer was washed with water and saturated saline solution and then, dried
over with anhydrous sodium sulfate .. The solvent was removed under reduced
pressure and the residue was purified by silica gel column chromatography
(eluent: ethyl acetate) to give 336mg (91%) of the title compound.
[0555]
Example 337:
1-Cyclohexyl-N-[2-(2,5-dioxo-l-imidazolidinyl)-1,1-dimethylethyl]-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide HC1 salt
The title compound 227mg (70%) was obtained in a manner similar
to the Example 323 by use of the compound obtained in the Example 336,
instead of the compound obtained in the Example 322.
[0556]
Example 338:
N-(3-Amino-2,2-dimethylpropyl)-l-cyclohexyl-3-methyl-lH-
thieno [ 2, 3-c] pyrazole-5-carboxanrLde
The title compound 162mg (41%) was obtained in a manner similar
to the Example 7 by use of 2,2-dimethyl-l, 3-propanediamine, instead of
benzylamine.
[0557]
Example 339:
1-Cyclohexyl-N- ]3-(2,5-dioxo-l-imidazolidinyl)-2, 2-dimethylpropyl]-
3-methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 123mg (72%) was obtained in a manner similar
to the Example 336 by use of the compound obtained in the Example 338,
instead of the compound obtained in the Example 335.
[0558]

Example 340:
(±)-1-Cyclohexyl-N-[trans-2-(hydroxymethyl)cyclopropyl]-3-methyl-
lH-thiemo[2, 3-c]pyrazole-5-carboxamide
The title: compound 280mg (42%) was obtained in a manner similar
to the Example 7 by use of (±) -trans- (2-aminocyclopropyl) methanol, instead
of benzylamine.
[0559]
Example 341:
l-Cyclohexyl-3-methyl-N-[4-(3-oxo-l-piperazinyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 215mg (87%) was obtained in a manner similar
to the; Example 7 by use of the compound obtained in the Manufacturing
Example 66, instead of benzylamine.
[0560]
Example 342:
3-Methyl-N-[4-(3-oxo-l-piperazinyl)phenyl]-l-tetrahydro-2H-pyran-
4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 152mg (77%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 66 and the compound obtained in the Example 195, instead of
benzylamine and the compound obtained in the Example 6, respectively.
[0561]
Example 343:
Methyl 3-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}benzoate
The title compound 1.78g (95%) was obtained in a manner similar
to the Example 7 by use of methyl m-aminobenzoate, instead of benzylamine.
[0562]
Example 344:
3-{[(l-Cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl]-
amino}benzoic ac:id
The title compound 1.67g (quantitative) was obtained in a manner
similar to the Example 41 by use of the compound obtained in the Example

343, instead of the compound obtained in the Example 40.
[0563]
Example 345:
1-Cyclohexyl-N-{3-[(dimethylamino)carbonyl]phenyl}-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 145mg (90%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 344
and 2M-dimethylamine/tetrahydrofuran solution, instead of the compound
obtained in the Example 211 and hydroxyacetic acid, respectively.
[0564]
Example; 346:
l-Cyclohexyl-3-methyl-N-[3-(4-morpholinylcarbonyl)phenyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 167mg (94%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 344
and morpholine, instead of the compound obtained in the Example 211 and
hydroxyacetic acid, respectively.
[0565]
Example 347:
Methyl trans-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexanecarboxylate
"he title compound 605mg (99%) was obtained in a manner similar
to the Example 7 by use of methyl trans-4-aminocyclohexanecarboxylate
HC1 salt and the compound obtained in the Example 195, instead of benzylamine
and the compound obtained in the Example 6., respectively.
[0566]
Example 348:
trans-4-{[(3-Me:hyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexanecarboxylic acid
The title compound 540mg (98%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 347,
instead of the compound obtained in the Example 40.
[0567]

Example 349:
N-{trans-4-[(Dimethylamino)carbonyl]cyclohexyl}-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 117mg (91%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 34 8
and 2M-dimethylanime/tetrahydrofuran solution, instead of the compound
obtained in the Example 211 and hydroxyacetic acid, respectively.
[0568]
Example 350:
3-Methyl-N-[trans-4-(4-morpholinylcarbonyl)cyclohexyl]-1-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 132mg (93%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 348
and morpholine, instead of the compound obtained in the Example 211 and
hydroxyacetic acid, respectively.
[0569]
Example 351:
N-{trans-A-[(4-Hydroxy-l-piperidinyl)carbonyl]cyclohexyl}-3-methyl-
l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 137mg (94%) was obtained in a manner similar
to the Example 224 by use of the compound obtained in the Example 348
and 4-hydroxypiperidine, instead of the compound obtained in the Example
211 and hydroxyacetic acid, respectively.
[0570]
Example 352:
3-Methyl-N-{trans-4-[(4-methyl-l-piperazinyl)carbonyl]cyclohexyl}-
l-tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 97mg (76%) was obtained in a manner similar to
the Example 224 by use of the compound obtained in the Example 348 and
1-methylpiperazine, instead of the compound obtained in the Example 211
and hydroxyacetic acid, respectively.
[0571]
Example 353:

l-Cyclohexyl-3-methyl-N-[3-(4-morpholinyl)propyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 199mg (90%) was obtained in a manner similar
to the Example 7 by use of N- (3-aminopropyl)morpholine, instead of
benzylamine.
[0572]
Example 354:
l-Cyclohexyl-3-methyl-N-[2-(4-morpholinyl)ethyl]-1H-
thieno[2, 3-c]py::azole-5-carboxamide
The title compound 174mg (82%) was obtained in a manner similar
to the Example 7 by use of N-(2-aminoethyl)morpholine, instead of
benzylamine.
[0573]
Example 355:
l-Cyclohexyl-3-methyl-N-[2-(1-piperidinyl)ethyl]-1H-
thieno [2, 3-c]py:razole-5-carboxamide
The title compound 148mg (70%) was obtained in a manner similar
to the Example 7 by use of N- (2-aminoethyl)piperidine, instead of
benzylanime.
[0574]
Example 356:
N-[trans-A-(Hyd::oxymethyl)cyclohexyl]-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 628mg (96%) was obtained in a manner similar
to the Example 206 by use of the compound obtained in the Example 347,
instead of the compound obtained in the Example 204.
[0575]
Example 357:
{trans-A-{{(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)ca::bonyl]amino}cyclohexyl)methyl p-toluenesulfonate
To a suspension solution of 510mg (1.35mmol) of the compound obtained
in the Example 356 in 20mL of dichloromethane and 20mL of chloroform were
added 270mg (1.42mmol) of p-toluenesulfonyl chloride and 131uL (1.62mmol)

r
of pyricine, and i;he mixture was stirred for over night at room temperature.
Then, further 27 0mg (1.42mmol) of p-toluenesulfonyl chloride and 131uL
(1.62mmol) of pyridine were added twice to the reaction mixture at 50C°,
and the mixture was stirred for ever night. Further, 270mg (1.42mmol)
of p-toluenesulfonyl chloride, 131uL (1.62mmol) of pyridine and 226uL
(1.62mmol) of triethylamine were added twice to the reaction mixture,
and the mixture was stirred for over night. Then, the reaction mixture
was washed with water and dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: hexane/ethyl acetate = 1/1
to ethyl acetate only) to give 402mg (56%) of the title compound.
[0576]
Example 358:
3-Methyl-N-[trans-A-(4-morpholinylmethyl)cyclohexyl]-1-tetrahydro-
2H-pyran-4-yi-fH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 120mg (0.226mrnol) of the compound obtained in the
Example 357 in 5mL of N,N-dimethylfcrmamide was added 79uL (0.903mmol)
of morpholine, and the mixture was stirred for 12 hours at 100°C. Then,
the reaction mixture was cooled to room temperature, and treated with
20mL of ethyl acetate. The organic layer was washed with water and saturated
saline solution, and dried over with anhydrous sodium sulfate. The solvent
was removed under reduced pressure and the residue was purified by silica
gel column chromatography (eluent: dichloromethane/methanol = 40/1) to
give 52mg (52%) of the title compound.
[0577]
Example 359:
N-{trans-4-[(Diraethylamino)methyl]cyclohexyl}-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 92mg (quantitative) was obtained in a manner
similar to the Example 358 by use of 2M-dimethylamine/tetrahydrofuran
solution, instead of morpholine.
[0578]
Example 360:

N-{trans-4-[(4-&cetyl-l-piperazinyl)methyl]cyclohexyl}-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 82mg (87%) was obtained in a manner similar to
the Example 358 by use of 1-acetylpiperazine, instead of morpholine.
[0579]
Example 361:
N-{3-[(Dimethylamino)sulfonyl]phenyl}-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 133mg (66%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 61 and the compound obtained in the Example 195, instead of
benzylamine and the compound obtained in the Example 6, respectively.
[0580]
Example 362:
3-Methyl-N-[3-(methylsulfonyl)phenyl]-l-tetrahydro-2H-pyran-4-yl-
lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 74mg (39%) was obtained in a manner similar to
the Example 7 by use of 3-methylsulfonylaniline HC1 salt and the compound
obtained in the Example 195, instead of benzylamine and the compound obtained
in the Example 6, respectively.
[0581]
Example 363:
N-{3-[(2-{[tert-Butyl(dimethyl)silyl]oxy}ethyl)sulfonyl]phenyl}-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 135mg (53%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 68 and the compound obtained in the Example 195, instead of
benzylamine and the compound obtained in the Example 6, respectively.
[0582]
Example 364:
N-[3-[(2-Hydroxyethyl)sulfonyl]phenyl]-3-methyl-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide

The title compound 61mg (60%) was obtained in a manner similar to
the Example 266 by use of the compound obtained in the Example 363, instead
of the compounc. obtained in the Example 265.
[0583]
Example 365:
1-Cyclohexyl-N-[3-fluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide dimethanesulfonate
A mixture solution of 456.5mg (l.OOmmol) of the compound obtained
in the Example 159 and 142.8uL (2.20mmol) of methanesulfonic acid in 4mL
of ethanol was condensed under reduced pressure. The residue was treated
with 5mL of ethanol and the residue was solved in the solution by heating
and refluxing. Then, 2mL of isopropyl ether was added and the mixture
was cooled gradually to room temperature. The resulting precipitates were
collected by filtration to give 383mg (59%) of the title compound.
[0584:
Example 366:
1-Cyclohexyl-N-[3-fluoro-4-(4-hydrcxy-l-piperidinyl)phenyl]-3-methyl
-lH-thieno[2/3-c]pyrazole-5-carboxamide p-toluenesulfonate
To a solution of 228.3mg (0.50mmol) of the compound obtained in
the Example 159 in 2mL of ethanol was added 104.6mg (0.55mmol) of
p-toluenesulf onic acid monohydrate a~ 50 °C, and the mixture was condensed
under reduced pressure. Then, 1. 5mL of isopropanol was added to the residue
and the residue was solved in the mixture by heating at 70C°, and the
mixture was cooled gradually to room temperature. The resulting
precipitates were collected by filtration to give 281mg (89%) of the title
compound.
[0585]
Example 367:
1-Cyclohexyl-N-[4-(4-hydroxy-l-piperidinyl)phenyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide methanesulfonate
To a solution of 438. 6mg (l.OOmmol) of the compound obtained in
the Example 114 in 4mL of ethanol was added 71.4uL (l.lOmmol) of
methanesulfonic acid, and further 0.8mL of ethyl acetate was added to

the mixture. After refluxing the mixture, then, the mixture was cooled
gradually to room temperature. The resulting precipitates were collected
by filtration to give 424mg (79%) of the title compound.
[0586]
Example 368:
1-Cyclohexyl-N-[4-(4-hydroxy-l-piperidinyl)phenyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide p-toluenesulfonate
To a suspension of 219. 3mg (0.50mmol) of the compound obtained in
the Example 114 in 3mL of ethanol was added 104.6mg (0.55mmol) of
p-toluenesulfonic acid monohydrate, and the mixture was refluxed. Then,
the separated precipitates were dissolved by adding 0.6mL of water and
the mixture was cooled gradually to 0DC. The resulting precipitates were
collected by filtration to give 244mg (80%) of the title compound.
[0587]
Example 369:
3-Methyl-N-[trans-A-(4-morpholinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 120mg (0.45mmol) of the compound obtained in
the Example 195 in 2mL of 1,2-dichloroethane was added 66uL (0.90mmol)
of thionyl chloride and the mixture was refluxed for 2 hours . After cooling
the reaction mixture and the solvent removed under reduced pressure to
give acid chloride intermediate compound.
314uL (2.25mmol) of triethylamine and 139mg (0.54mmol) of the
compound obtained in the Manufacturing Example 64 were added to the solution
of the acid chloride intermediate compound in 5mL of anhydrous
di chl or ome thane,, and the mixture was stirred for 3 hours at room temperature.
The reaction mixture was treated with saturated sodium bicarbonate aqueous
solution and extracted with dichloromethane. The organic layer was washed
with water and saturated saline solution, then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure and the
residue was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 20/1 to 10/1) to give 172mg (88%) of the title
compound.

[0588]
Example 370:
1-Cyclohexyl-N-[6-(4-hydroxy-l-piperidinyl)-3-pyridinyl]-3-methyl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title: compound 216mg (quantitative) was obtained in a manner
similar to the Example 7 by use of the compound obtained in the Manufacturing
Example 74, instead of benzylamine.
[0589]
Example 371:
1-Cyclohexyl-N-[2/3-difluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 177mg (82%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 76, instead of benzylamine.
[0590]
Example 372:
1-Cyclohexyl-N-[4-(4-hydroxy-l-piperidinyl)-3-methylphenyl]-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 189mg (92%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 78, instead of benzylamine.
[0591]
Example 373:
N-[3-Cyano-4-(4-hydroxy-l-piperidinyl)phenyl]-l-cyclohexyl-3-
methyl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 209mg (99%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 80, instead of benzylamine.
[0592]
Example 374:
Methyl 5-{[(l-cyclohexyl-3-methyl-lH-thieno[2,3-c]pyrazol-5-yl)-
carbonyl]amino}-2-(4-hydroxy-l-piperidinyl)benzoate
The title compound 224mg (99%) was obtained in a manner similar

to the Example 7 by use of the compound obtained in the Manufacturing
Example 82, instead of benzylamine.
[0593]
Example 375:
5-{[(l-Cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazol-5-yl)carbonyl]-
amino}-2-(4-hydroxy-l-piperidinyl)benzoic acid
The title compound 167mg (81%) was obtained in a manner similar
to the Example 41 by use of the compound obtained in the Example 374,
instead of the compound obtained in the Example 40.
[0594J
Example 376:
N-[6-(4-Hydroxy-1-piperidinyl)-3-pyridinyl]-3-methyl-l-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 202mg (quantitative) was obtained in a manner
similar to the Example 369 by use of the compound obtained in the
Manufacturing Example 74, instead of the compound obtained in the
Manufacturing Example 64.
[0595]
Example 377:
3-Methyl-l-tetrahydro-2H-pyran-4-yl-N-(l-tetrahydro-2H-pyran-4-yl-
4-piperidinyl)-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 187mg (96%) was obtained in a manner similar
to the Example 369 by use of the compound obtained in the Manufacturing
Example 84, instead of the compound obtained in the Manufacturing Example
64.
[0596]
Example 378:
1-Cyclohexyl-N-{6-[(4-hydroxy-l-piperidinyl)carbonyl]-3-pyridinyl}-
3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of lOOmg (3.26mmol) of the compound obtained in
the Example 103 in 5mL of anhydrous dichloromethane were added 39.4mg
(0.39mmol) of 4-hydroxypiperidine, 53mg (0.39mmol) of 1-hydroxy-
benzotriazole, 74.8mg (0.39mmol) of l-ethyl-3-(3-dimethylamino-

propyl; carbodiimide HC1 salt and 72. 5uL (0.52mmol) of triethylamine, and
the mixture was stirred for 17 hours at room temperature. The reaction
mixture was treated with saturated sodium bicarbonate aqueous solution,
and extracted with dichloromethane. The organic layer was washed with
water and saturated saline solution, then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 10/l) togivel02mg (84%) of the title compound.
[0597]
Example 379:
1-Cyclohexyl-N-(6-{[(2-hydroxyethyl)amino]carbonyl}~3-pyridinyl)-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 76mg (68%) was obtained in a manner similar to
the Example 378 by use of 2-aminoethanol, instead of 4-hydroxypiperidine.
[0598]
Example 380:
l-Cyclohexyl-3-methyl-N-{6-[(4-methyl-l-piperazinyl)carbonyl]-3-
pyridinyl}-IH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 87mg (72%) was obtained in a manner similar to
the Example 378 by use of N-methylpiperazine, instead of
4-hydroxypiperidine.
[0599]
Example 381:
l-Cyclohexyl-N-[6-({[2-(dimethylamino)ethyl]amino}carbonyl-3-
pyridinyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 71mg (60%) was obtained in a manner similar to
the Example 378 by use of N,N-dimethylethylenediamine, instead of
4-hydroxypiperidine.
[0600]
Example 382:
1-Cyclohexyl-N-(6-{[(tran.s-4-hydroxycyclohexyl)amino]carbonyl}-3-
pyridinyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 50mg (39%) was obtained in a manner similar to

the Example 37E: by use of trans-4-aminocyclohexanaol, instead of
4-hydroxypiperidine.
[0601]
Example 383:
l-Cyclohexyl-3-methyl-N-{6-[(4-methyl-l,4-diazepam-l-yl)carbonyl]-
3-pyridinyl}-1H-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 105mg (84%) was obtained in a manner similar
to the Example 378 by use of N-methylhomopiperazine, instead of
4-hydroxypiperidine.
[0602]
Example 384:
tert-Butyl 4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno [2,3-c] -
pyrazol-5-yl)carbonyl] amino}-l-piperidinecarboxylate
The title compound 1.86g (92%) was obtained in a manner similar
to the Example 3 69 by use of 4-amino-l-Boc-piperidine, instead of the
compound obtained in the Manufacturing Example 64.
[0603]
Example 385:
3-Methyl-N-(4-piperidinyl)-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazole-5-carboxamide
A mixture solution of 1.81g (4.03mmol) of the compound obtained
in the Example 334 in lOmL of 4M-ECl/dioxane was stirred for 30 minutes
at room temperature and for 2 hours at 60°C. After cooling the reaction
mixture,, the solvent was removed under reduced pressure and the residue
was treated with saturated sodium bicarbonate aqueous,solution, then,
the mixture was extracted with chloroform. The organic layer was washed
with water and saturated saline solution and then, dried over with anhydrous
sodium sulfate. The solvent was removed under reduced pressure to give
1.22g (87%) of the title compound.
[0604]
Example 386:
N-{1-[(Dimethylamino)carbonyl]-4-piperidinyl}-3-methyl-l-tetra-
hydro-2H-pyran-4 -yl-lH-thieno [2, 3-c." pyrazole-5-carboxamide

The title compound 132mg (91%) was obtained in a manner similar
to the Example 322 by use of the compound obtained in the Example 385,
instead of the compound obtained in the Example 321.
[0605]
Example 387:
tert-Bu-yl 4-{4~{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl] amino}piperidin-l-yl}-l-piperidine-
carboxylate
To a suspension of 220mg (0.63mmol) of the compound obtained in
the Example 385 in 5mL of 1,2-dichloroethane were added 15 uL of acetic
acid and 151mg (0.757mmol) of l-Boc-4-piperidone, and the mixture was
stirred for 30 minutes at room temperature. Then, 200mg (0.95mmol) of
sodium triacetoxyborohydride was added to the reaction mixture, and the
mixture was stirred for 6 hours at room temperature. The reaction mixture
was treated with saturated sodium bicarbonate aqueous solution and
extracted with dichloromethane. The organic layer was washed with water
and saturated saline solution, then, dried over with anhydrous sodium
sulfate. The solvent was removed under reduced pressure and the residue
was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 10/1) to give 230mg (69%) of the title compound.
[0606]
Example 388:
3-Methyl-N-(piperidin-4-yl-4-piperidinyl)-l-tetrahydro-2H-pyran-
4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 165mg (98%) was obtained in a manner similar
to the Example 385 by use of the compound obtained in the Example 387,
instead of the compound obtained in the Example 384.
[0607]
Example 389:
3-Methyl-N-(l-acetylpiperidin-4-yl-4-piperidinyl)-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 51mg (62%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example

388, instead of the compound obtained in the Manufacturing Example 2.
[0608]
Example 390:
3-Methyl-N-(l-methanesulfonylpiperidin-4-yl-4-piperidinyl)-1-tetra-
hydro--2H-pyran-4-yl-lH-thieno [2, 3-c] pyrazole-5-carboxamide
The title compound 68mg (77%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example
388 and methanesulfonyl chloride, instead of the compound obtained in
the Manufacturing Example 2 and acetyl chloride, respectively.
[0609]
Example 391:
tert-Butyl 4-(trans-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-1-piperazine-
carboxylate
The title compound 456mg (46%) was obtained in a manner similar
to the Example 3 69 by use of the compound obtained in the Manufacturing
Example 8 6, instead of the compound obtained in the Manufacturing Example
64.
[0610]
Example 392:
tert-Butyl 4-(cis-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]py::azol-5-yl)carbonyl] amino}cyclohexyl)-1-piperazine-
carboxylate
523mg (52%) of the title compound was obtained as by-product in
the Example 391.
[0611]
Example 393:
3-Methyl-N-[trans-A-(1-piperazinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide di-HCl salt
Amixtureof 419mg (0.817mmol) of the compound obtained in the Example
391 in 3mL of 4M-HCl/dioxane and ImL of methanol was stirred for 5 hours
at room temperature. The solvent was removed under reduced pressure and
the residue was treated with ethanol. The resulting precipitates were

collected by filtration to give 343mg (83%) of the title compound.
[0612]
Example 394:
3-Methyl-N-[cis-4-(1-piperazinyl)cyclohexyl]-l-tetrahydro-2H-pyran-
4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide di-HCl salt
The title compound 234mg (51%) was obtained in a manner similar
to the Example 393 by use of the compound obtained in the Example 392,
instead of the compound obtained in the Example 391.
[0613]
Example 395:
N-[trans-4-(4-Acetyl-l-piperazinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound lOOmg (70%) was obtained in a manner similar
to the Manufacturing Example 3 by use of the compound obtained in the
Example 388 and acetic anhydride, instead of the compound obtained in
the Manufacturing Example 2 and acetyl chloride, respectively.
[0614]
Example 396:
3-Methyl-N-{ trar.s-4- [4- (methylsulfonyl) -1-piperazinyl] cyclohexyl}-
l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 109mg (71%) was obtained in a manner similar
to the Manufacturing Example 3 by use of the compound obtained in the
Example 393 andmethanesulfonyl chloride, instead of the compound obtained
in the Manufacturing Example 2 and acetyl chloride, respectively.
[0615]
Example 397:
N-[cis-4-(4-Acetyl-l-piperazinyl)cyclohexyl]-3-methyl-1-tetrahydro-
2H-pyran-4-yl-lE-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 113mg (66%) was obtained in a manner similar
to the Manufacturing Example 3 by use of the compound obtained in the
Example 394 and acetic anhydride, instead of the compound obtained in
the Manufacturing Example 2 and acetyl chloride, respectively.
[0616]

Example 398:
3-Methyl-N-[1-(4-morpholinylcarbonyl)-4-piperidinyl]-1-tetrahydro-
2H-pyran-4-yl-lK-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 109mg (69%) was obtained in a manner similar
to the Manufacturing Example 3 by use of the compound obtained in the
Example 385 and 4-morpholinyl chloride, instead of the compound obtained
in the Manufacturing Example 2 and acetyl chloride, respectively.
[0617]
Example 399:
3-Methyl-N-{1-[(4-methyl-l-piperazinyl)carbonyl]-4-piperidinyl}-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 92mg (56%) was obtained in a manner similar to
the Manufacturing Example 3 by use of the compound obtained in the Example
385 and 4-methyl-1-piperazinecarbonyl chloride HC1 salt, instead of the
compound obtained in the Manufacturing Example 2 and acetyl chloride,
respectively.
[0618]
Example 400:
N-(traiis-4-Hydroxycyclohexyl)-3-methyl-l-tetrahydro-2H-pyran-4-yl-
lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 843mg (52%) was obtained in a manner similar
to the Example 396 by use of trans-4-aminocyclohexanol, instead of the
compound obtained in the Manufacturing Example 64.
[0619]
Example 401:
3-Methyl-N-(4-oxocyclohexyl)-l-tetrahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 828mg (2.28mmol) of the compound obtained in the
Example 400 in 30mL of dichloromethane were added 983mg (4.56mmol) of
pyridinium chlorocromate and 2g of Molecular sieves 4A, and the mixture
was stirred for 4 hours at room temperature. The reaction mixture was
filtrated by Celite®, and the filtrate was removed under reduced pressure.
The residue was purified by silica gel column chromatography (eluent:

dichlorome thane /ethyl acetate) and further purified by silica gel column
chromatography (eluent: ethyl acetate) to give 668mg (81%) of the title
compound.
[0620]
Example 402:
N-[trans-4-(cis-2,6-Dimethylmorpholinyl)cyclohexyl]-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a solution of 150mg (0.415rrmol) of the compound obtained in the
Example 401 in 3mL of 1,2-dichloroethane were added 103uL (0.83mmol) of
cis-2, 6-dimethylmorpholine and 15uL of acetic acid, and the mixture was
stirred for 30 minutes at room temperature. Then, 132mg (0.623mmol) of
sodium triacetoxyborohydride was added to the reaction mixture and the
mixture was stirred for 4 hours at room temperature. The reaction mixture
was treated wi-;h saturated sodium bicarbonate aqueous solution and
extracted with tiichloromethane. The organic layer was washed with water
and saturated saline solution, then, dried over with anhydrous sodium
sulfate. The organic layer was removed under reduced pressure and the
residue was purified by alkaline silica gel column chromatography (eluent:
ethyl acetate/hexane = 1/1) to give 132mg (69%) of the title compound.
[0621]
Example 403:
N-[cis-4-(cis-2,6-Dimethylmorpholinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 4 6mg (24%) was obtained in the Example 402 as
by-product.
[0622]
Example 404:
1-Cyclchexyl-N-[6-(hydroxymethyl)-3-pyridinyl]-3-methyl-lH-
thieno[2,3-c]pyrazole-5-carboxamide
The title compound 215mg (58%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 87, instead of benzylamine.
[0623]

Example 405:
Methyl 5-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl) carbonyl] amino} -2-pyriclinecarboxylate
To a suspension of 700mg (2.63mmol) of the compound obtained in
the Example 195 in 6mL of 1,2-dichloroethane was added 384uL (5.26mmol)
of thionyl chloride, and the mixture was refluxed for 2 hours. After
reaction mixture was cooled, the solvent was removed under reduced pressure
to give acid chloride intermediate compound.
Then, to a solution of the acid chloride intermediate compound
obtained above in 8mL of pyridine was added 400mg (2.63mmol) of methyl
5-amino-2-pyridinecarboxylate, and the mixture was stirred for 2 hours
at room temperature. The reactionmixture was treated with saturated sodium
bicarbonate aqueous solution and extracted with dichloromethane. The
organic layer was washed with water and saturated saline solution, then,
dried over with anhydrous sodium sulfate. The solvent was removed under
reduced pressure: and the residue was purified by silica gel column
chromatography (eluent: ethyl ace~ate) to give 956mg (91%) of the title
compound.
[0624]
Example 406:
5-{[(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazol-
5-yl)carbonyl]amino}-2-pyridinecarboxylic acid
To a solution of 923mg (2.30mmol) of the compound obtained in the
Example 405 in 5mL of methanol was added 5mL of lM-NaOH aqueous solution,
and the mixture was stirred for 1.5 hours at 60°C. After cooling the reaction
mixture, the solvent was removed under reduced pressure and the residue
was neutralized by adding 2 . 5mL of 2M-HC1 aqueous solution. The resulting
precipitates were collected to give 870mg (98%) of the title compound.
[0625]
Example 407:
N-(6-{[(trans-4-Hydroxycyclohexyl)amino]carbonyl}-3-pyridinyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide

The title; compound 118mg (94%) was obtained in a manner similar
to the Example 378 by use of the compound obtained in the Example 406
and trcms-4-amiriocyclohexanol, instead of the compound obtained in the
Example 103 and 4-hydroxypiperidine, respectively.
[0626]
Example 408:
N-[6-({[2-(Dimethylamino)ethyl]amino}carbonyl)-3-pyridinyl]-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 108mg (91%) was obtained in a manner similar
to the Example 378 by use of the compound obtained in the Example 406
and N,N-dimethylethylenediamine, instead of the compound obtained in the
Example 103 and 4-hydroxypiperidine, respectively.
[0627]
Example 409:
3-Methyl-N-(6-{[(l-methyl-4-piperidinyl) amino]carbonyl}-3-
pyridinyl)-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxemide
The title compound 35.6mg (36%) was obtained in a manner similar
to the Example 378 by use of the compound obtained in the Example 406
and 4-amino-l-methylpiperidine, instead of the compound obtained in the
Example 103 and 4-hydroxypiperidine, respectively.
[0628]
Example 410:
N-(6-{[(l-Acetyl-4-piperidinyl) amino]carbonyl]-3-pyridinyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-
carboxamide
The title compound 109mg (82%) was obtained in a manner similar
to the Example 378 by use of the compound obtained in the Example 406
and 4-amino-l-acetylpiperidine, instead of the compound obtained in the
Example 103 and 4-hydroxypiperidine, respectively.
[0629]
Example 411:

l-Cyclohexyl-3-rnethyl-N-[6-(4-morpholinylmethyl)-3-pyridinyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 120mg (0.324mmol) of the compound obtained in
the Example 404 in 3mL of ethyl acetate were added 90uL (0.648mmol) of
triethylamine and 38uL (0.486mmol) of methanesulfonyl chloride, and the
mixture was stirred for 30 minutes at room temperature. The react ionmixture
was treated with ethyl acetate, and the organic layer was washed with
saturated sodium bicarbonate aqueous solution, water and saturated saline
solution, respectively, then, dried over with anhydrous sodium sulfate.
Sodium sulfate was removed off by filtration, and the filtrate was treated
with lmL of 4M-HCl/dioxane, and the solvent was removed to give (5-{[
(l-cyclohexyl-3-methyl-lH-thieno[2, 3-c]pyrazole-5-yl)carbonyl]amino}
-2-pyridinyl)methyl methanesulfonate HC1 salt as the intermediate
compound.
To a suspension of the intermediate compound obtained above in 3mL
of acetonitrile were added 162mg (1.17inmol) of potassium carbonate, 28.8uL
(0.33mmol) of morpholine and 5.8mg (0.035mmol) of potassium iodide, and
then, the mixture was stirred for 2 hours at 70°C and for 15 hours at
room temperature. Then, the reaction mixture was treated with water and
extracted with ethyl acetate. The organic layer was washed with water
and saturated saline solution, and dried over with anhydrous sodium sulfate.
The solvent was removed under reduced pressure and the residue was purified
by silica gel column chromatography (eluent: dichloromethane/methanol
=10/1) to give 114mg (80%) of the title compound.
[0630]
Example 412:
l-Cyclohexyl-3-methyl-N-[6-(4-morpholinylmethyl)-3-pyridinyl]-1H-
thieno[2,3-c]pyrazole-5-carboxamide methanesulfonate
To a solution of lOOmg (0.227mmol) of the compound obtained in the
Example 411 in 2mL of ethanol was added 14.8uL of methanesulfonic acid
and the solvent, was removed. The residue was recrystallized from
isopropanol to give 77mg (63%) of the title compound.
[0631]

Example 413:
1-Cyclohexyl-N-{6-[(4-hydroxy-l-piperidinyl)methyl]-3-pyridinyl}-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 104mg {71%) was obtained in a manner similar
to the Example 411 by use of 4-hydroxypiperidine, instead of morpholine.
[0632]
Example 414:
N-{6-[(4-Acetyl-l-piperazinyl)methyl]-3-pyridinyl}-l-cyclohexyl-3-
methyl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title: compound 102mg (66%) was obtained in a manner similar
to the Example 411 by use of 1-acetylpiperazine, instead of morpholine.
[0633]
Example 415:
3-Methyl-N-[trans-4-(4-metyl-2-oxo-l-piperazinyl)cyclohexyl]-1-
tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 124mg (72%) was obtained in a manner similar
to the Example 369 by use of the compound obtained in the Manufacturing
Example 91, instead of the compound obtained in the Manufacturing Example
64.
[06341
Example 416:
l-Cyclohexyl-3-methyl-N-[trans-4-(4-methyl-2-oxo-l-piperazinyl)-
cyclohexyl]-IH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 130mg (75%) was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 91, instead of benzylamine.
[0635]
Example 417:
3-Methyl-N-[trans-4-(3-oxo-l-piperazinyl)cyclohexyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 115mg (62%) was obtained in a manner similar
to the Example 402 by use of 2-piperazine, instead of cis-2,6-dimethyl-
morpholine.

[0636]
Example 418:
3-Methyl-N-[cis-4-(3-oxo-l-piperazinyl)cyclohexyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
i The title compound 43mg (23%) was obtained in the Example 471, as
by-product.
[0637]
Example 419:
3-Methyl-N-[trans-4-(4-methyl-3-oxo-l-piperazinyl)cyclohexyl]-1-
I tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
To a suspension of 150mg (0.415mmol) of the compound obtained in
the Example 401 in 3mL of 1,2-dichloroethane were added 125mg (0.83mmol)
of l-methyl-2-piperazinoneHClsalt, 15uL of acetic acid, and82mg (l.Ommol)
of sodium acetate, and the mixture was stirred for 30 minutes at room
» temperature. Then, 132mg (0. 623mmol) of sodium triacetoxyborohydride was
added to the reaction mixture, and the mixture was stirred for 1 hour
at room temperature. The reaction mixture was diluted by saturated sodium
bicarbonate aqueous solution and extracted with dichloromethane. The
organic layer was washed with water and saturated saline solution, then,
) dried over with anhydrous sodium sulfate. The solvent was removed under
reduced pressure and the residue was purified by silica gel column
chromatography (eluent: dichloromethane/methanol = 10/1) to give 131mg
(69%) of the title compound.
[0638]
i Example 420:
3-Methyl-N-[cis-4-(4-methyl-3-oxo-l-piperazinyl)cyclohexyl]-1-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 21ng (11%) was obtained in the Example 419, as
by-prcduct.
) [0639]
Example 421:
Ethyl l-{trans-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidine-

carboxylate
The title: compound 690mg (37%) was obtained in a manner similar
to the Example 369 by use of the compound obtained in the manufacturing
Example 93, instead of the compound obtained in the Manufacturing Example
64.
[0640]
Example 422:
Ethyl 1-(cis-4-{[(3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno-
[2,3-c]pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidine-
carboxylate
The title compound 1.10g (58%) was obtained in the Example 421,
as by-product.
[0641]
Example 423;
N-{trans-4-[4-(Hydroxymethyl)-1-piperidinyl]cyclohexyl}-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2, 3-c]pyrazole-5-carboxamide
The title compound 59mg (54%) was obtained in a manner similar to
the Example 206 by use of the compound obtained in the Example 421, instead
of the compound obtained in the Example 204.
[0642]
Example 424:
N-{ ci-9-4- [4- (Hydroxymethyl) -1-piperidinyl] cyclohexyl}-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 61mg (55%) was obtained in a manner similar to
the Example 206 by use of the compound obtained in the Example 422, instead
of the compound obtained in the Example 204.
[0643]
Example 425:
N-[trans-4-(4-Hydroxy-l-piperidinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 76mg (42%) was obtained in a manner similar to
the Example 402 by use of 4-hydroxypiperidine, instead of cis-2,6-di-
methylmorpholine.

[0644]
Example 426:
N-(cis-4-{4-[(Dimethylamino)carbonyl]-l-piperidinyl}cyclohexyl)-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
A mixture solution of 400mg (0.795mmol) of the compound obtained
in the Example 422 in 8mL of 6M-HC1 aqueous solution was refluxed for
2.5 hours. After cooling the reaction mixture, the solvent was removed
under reduced pressure to give 1-(cis-4-{[(3-methyl-l-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazol-5-yl)carbonyl] amino}cyclohexyl
)-4-piperidinecarboxylic acid HC1 salt as intermediate compound.
Then, to a suspension of the intermediate compound obtained above
in dichloromethane were added 0.60mL (1.2mmol) of 2M-dimethylamine/
tetrahydrofuran, 229mg (1.19mmol) of l-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide HC". salt, 746uL (5.35mmol) of triethylamine and 182mg
(1.19mmol) of 1-hydroxybenzotriazole, and the mixture was stirred for
95 hours at room temperature. The saturated sodium bicarbonate aqueous
solution was added to the reaction mixture, and the mixture was extracted
with dichloromethane. The organic layer was washed water and saturated
saline solution, then, dried over with anhydrous sodium sulfate. The
solvent was removed under reduced pressure and the residue was purified
by alkaline silica gel column chromatography (eluent: ethyl acetate) to
give 196mg (49%) of the title compound.
[0645]
Example 427:
1-(tran.s-4-{[(3-Methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]-
pyrazol-5-yl)carbonyl]amino}cyclohexyl)-4-piperidinecarboxylic acid
HC1 salt
A mixture solution of 400mg (C.795mmol) of the compound obtained
in the Example ^21 in 6M-HC1 aqueous solution was stirred for 2 hours
at70°C. The solvent was removed to give 465mg (quantitative) of the title
compound.
[0646]

Example 428:
N-(traus-4-{4-[(Dimethylamino)carbonyl]-l-piperidinyl}cyclohexyl)-
3-methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxcimide
The title compound 195mg (78%) was obtained in a manner similar
to the Example 378 by use of the compound obtained in the Example 427
and 2M-dimethylamine/tetrahydrofuran, instead of the compound obtained
in the Example 103 and 4-hydroxypiperidine, respectively.
[0647]
Example 429:
N'-(Dihydro-2H-oyran-3(4H)-ilidene)benzohydrazide
To a solution of 3.48g (34.1mmol) of tetrahydro-2H-pyran-3-ol in
350mL of dichloromethane were added 11.lg (51.2mmol) of pyridinium
chlorochromate, 3.16g (38.5mmol) of sodium acetate, and 30g of molecular
sieve 4A, and the mixture was stirred for 4 hours at room temperature.
Then, the reaction mixture was filtrated by Celite® and the filtrate was
condensed under reduced pressure. The residue was purified by silica
gel column chromatography (eluent: hexane/ethyl acetate = 2/1) to give
dihydrc-2H-pyran-3(4H)-one as intermediate compound.
A mixture solution of the intermediate compound obtained above and
4.6g (34.1mmol) of benzoylhydrazine in 20mL of methanol was stirred for
4 hours at 60 °C. After cooling the react ion mixture, the solvent was removed
and the residue was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 30/1) togivel.75g (24%) of the title compound.
[0648]
Example 430:
N'-Tetrahydro-2H-pyran-3-ylbenzohydrazide
To a solution of 1.64g (7.51mmol) of the compound obtained in the
Example 429 in methanol was added 257mg (6.76mmol) of sodium borohydride
at 0°C, and the mixture was stirred for 3 hours at the same temperature.
The solvent was removed and the residue was treated with water and the
mixture was extracted with dichloromethane. The organic layer was washed
with water and saturated saline solution, then, dried over with anhydrous

sodium sulfate. The solvent was removed and the residue was purified by
silica gel column chromatography (eluent: dichloromethane/methanol = 30/l)
to give 1.46g (88%) of the title compound.
[0649]
Example 431:
5-Methyl-2-tetrahydro-2H-pyran-3-yl-2/4-dihydro-3H-pyrazol-3-one
To a solution of 1.44g (6.53mmol) of the compound obtained in the
Example 430 in lOmL of water was added 20mL of cone. HC1, and the mixture
was stirred for 24 hours at 100°C. After cooling the reaction mixture,
the insoluble substances were removed off by filtration, and the filtrate
was condensed to give 1- (tetrahydro-2H-pyran-3-yl) hydrazine HC1 salt as
intermediate compound.
A mixture of the intermediate compound obtained above and 705uL
(6.53mmol) of methyl acetoacetate was stirred for 2 hours at 110°C. The
reaction mixture was cooled and diluted with water and ethyl acetate,
then, neutralized by IM-NaOH aqueous solution. The solvent was removed
and the residue was purified by silica gel column chromatography (eluent:
dichloromethane/methanol = 20/1) togive793mg (67%) of the title compound.
[0650]
Example 432:
5-Chloro-3-methyl-l-tetrahydro-2H-pyran-3-yl-lH-pyraxzole-4-
carboaldehyde
The title compound 452mg (47%) was obtained in a manner similar
to the Example 193 by use of the compound obtained in the Example 431,
instead of the compound obtained in the Example 192.
[0951]
Example 433:
Ethyl 3-methyl-l-tetrahydro-2H-pyran-3-yl-lH-thieno[2,3-c]pyrazole-
5-carboxylate
To a solution of 259uL (2.36mmol) of ethyl thioglycolate in 4mL
of tetrahydrofuran was added 94mg (2.36mmol) of sodium borohydride (60%
oily) at 0°C, and the mixture was stirred for 30 minutes at room temperature.
Then, the reaction mixture was cooled to 0°C and 415mg (1.81mmol) of the

compound obtained in the Example 432 in 4mL of tetrahydrofuran was added
gradually to thi.s mixture, and the mixture was stirred for 2 hours at
room temperature. Then, the reaction mixture was cooled to 0°C and 94mg
(2.36mmol) of scdium borohydride (60% oily) was added to this mixture,
and the mixture was stirred for 30 minutes at room temperature. The reaction
mixture was treated with ice water and extracted with ethyl acetate. The
organic layer was washed with water and saturated saline solution, then,
dried over with anhydrous sodium sulfate. The solvent was removed under
reduced pressure and the residue was purified by silica gel column
chromatography (eluent: hexane/ethyl aceteta = 3/1) to give 413mg (78%)
of the title compound.
[0652]
Example 434:
3-Methyl-l-tetrahydro-2H-pyran-3-yl-lH-thieno[2,3-c]pyrazole-5-
carboxylic acid
The title compound 320mg (89%) was obtained in a manner similar
to the Example 6 by use of the compound obtained in the Example 433, instead
of the compound obtained in the Example 5.
[0653]
Example 435:
3-Methyl-N-[trans-4-(4-morpholinyl)cyclohexyl]-l-tetrahydro-2H-
pyran-3-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 185mg (95%) was obtained in a manner similar
to the Example 369 by use of the compound obtained in the Example 434,
instead of the compound obtained in the Example 195.
[0654]
Example 436:
N-[trans-4-(4-Ethyl-3-oxo-l-piperazinyl)cyclohexyl]-3-methyl-l-
tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The title compound 140mg (71%) was obtained in a manner similar
to the Example 419 by use of l-ethyl-2-piperazinone HC1 salt, instead
of l-methyl-2-p^.perazinone HC1 salt.
[0655]

Example 437:
N-[cis-4-(4-Ethyl-3-oxo-l-piperazinyl)cyclohexyl]-3-methyl-l-tetra-
hydro-2H-pyran-4-yl-lH-thieno[2/3-c]pyrazole-5-carboxamide
The title compound 41mg (21%) was obtained in the Example 436, as
by-product.
[0656]
Example 438:
N-{trans-4-[(4-Ethyl-3-oxo-l-piperazinyl)methyl]cyclohexyl}-3-
methyl-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
To a solution of 150mg (0.282mmol) of the compound obtained in the
Example 357 in 3mL of N,N-dimethylformamide were added 93mg (0.564mmol)
of l-ethyl-2-piperazinone HCl salt, and236uL (1.7mmol) of triethylamine,
and the mixture was stirred for 5 hours at 100°C. Then, 43mg (0.282mmol)
of sodium iodide was added to the reaction mixture and the mixture was
stirred for 40 hours at 100°C. Further, lOOmg (0.61mmol) of
l-ethyl~2-piperazinone HCl salt and 50mg (0.33mmol) of sodium iodide were
added to the reaction mixture, and the mixture was stirred for 15 minutes
at 120°C using microwave. After the reaction, water was added to the
reaction mixture and the mixture was extracted with dichloromethane. The
organic layer was washed with water and saturated saline solution, then,
dried over with anhydrous sodium sulfate. The solvent was removed under
reduced pressure and the residue was purified by silica gel column
chromatography (eluent: dichloromethane/methanol = 20/1 to 15/1), and
further alkaline silica gel column chromatography (eluent: ethyl acetate)
to give 63mg (46%) of the title compound.
[0657]
Example 439:
3-Methyl-N-{trans-4-[(4-methyl-3-oxo-l-piperazinyl)methyl]-
cyclohexyl}-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-
carboxamide
The title compound 24mg (18%) was obtained in a manner similar to
the Example 438 by use of l-methyl-2-piperazinone HCl salt, instead of

l-ethyl-2-piperazinone HC1 salt.
[0658]
Example 440:
3-Methyl-N-[4-(4-methyl-2-oxo-l-piperazinyl)phenyl]-1-tetrahydro-
2H-pyran-4-yl-lH-thieno[2,3-c]pyrazole-5-carboxamide
The free base of the title compound was obtained in a manner similar
to the Example 7 by use of the compound obtained in the Manufacturing
Example 72 and the compound obtained in the Example 195, instead of
benzylamine and the compound obtained in the Example 6, respectively.
Then, 30.7uL (0. 473mmol) of methanesulfonic acid was added to a solution
of the free base of the compound obtained above in 2.5mL of isopropanol,
and the mixture was re fluxed. The reaction mixture was cooled to room
temperature and the resultant precipitates were collected to give 206mg
(83%) of the title compound.
[0659]
Chemicla structure and physicochemical data of the compounds
obtained by the above-mentioned Manufadturing Examples and Examples are
summarized in the following Tables.













































































































































































































































































Industrial Applicability
[0794]
The present invention provides thienopyrazole derivatives having
selective PDE 7 (phosphodiesterase VII) inhibiting effect. These
5 compounds are effective compounds for treating various kinds of diseases
such as allergic diseases, inflammatory diseases and immunologic diseases .

WE CLAIM:
1. Thienopyrazole compounds represented by the following formula (I):

[wherein,
R1 is a C3-C8 cycloalkyl group or substituted or unsubstituted heterocycloalkyl group;
R2 is a C1-C3 alkyl group;
R3 is a hydrogen atom;
R4 is a group -CONR5R6;
R5 and R6 are, same or different from each other, a hydrogen atom; C1-C6 alkyl group which
may be substituted by a halogen atom, substituted or unsubstituted aryl group, substituted or
unsubstituted heteroaryl group, substituted or unsubstituted heterocycloalkyl group, substituted or
unsubstituted cycloalkyl group, a group -NR7COR8, -COR8, -NR9R10; substituted or unsubstituted
cycloalkyl group; substituted or unsubstituted heterocycloalkyl group; substituted or unsubstituted aryl
group; substituted or unsubstituted heteroaryl group; or substituted or unsubstituted heterocycloalkyl
group in which the ring is formed together with the nitrogen atom binding R5 and R6;
R7 is a hydrogen atom, or substituted or unsubstituted C1-C3 alkyl group;
R8 is substituted or unsubstituted heterocycloalkyl group, or a group -OH, -OR7 or -NR9R10;
R9 and R10 are, same or different from each other, a hydrogen atom, substituted or
unsubstituted CrC3 alkyl group, substituted or unsubstituted heterocycloalkyl group; substituted or
unsubstituted acyl group; a group -SO2R7, or substituted or unsubstituted heterocycloalkyl group in
which the ring is formed together with the nitrogen atom binding R5 and R6]
or pharmaceuticaly acceptable salts or solvates thereof.
2. The compound as claimed in claim 1, wherein R1 is cyclohexyl group.
3. The compound as claimed in claim 1, wherein R1 is tetrahydropyranyl group.
4. The compound as claimed in any one of claims 1 to 3, wherein R2 is methyl group.
5. The compound as claimed in any one of claims 1 to 4, wherein any one of R5 and R6 is a
hydrogen atom.
6. The compound as claimed in any one of claims 1 to 4, wherein any one of R5 and R6 is
substituted or unsubstituted C3-C8 cycloalkyl group.

7. The compound a as claimed in any one of claims 1 to 4, wherein any one of R5 and R6 is
a cyclohexyl group which is substituted by heterocycloalkyl group selected from piperidinyl,
pyrrolidinyl, piperazinyl, tetrahydrofuryl, tetrahydropyranyl, morphorinyl, azetidinyl, imidazolidinyl,
oxazolidinyl, hexahydropyrrolidinyl, octahydroindolidinyl, octahydroquinolidinyl, octahydroindolyl,
and oxo-derivative thereof which may be substituted.
8. The compound as claimed in any one of claims 1 to 4, wherein any one of R5 and R6 is a.
phenyl group which may be substituted.
9. The compound as claimed in any one of claims 1 to 4, wherein any one of R5 and R6 is a
phenyl group which is substituted by heterocycloalkyl group selected from piperidinyl, pyrrolidinyl,
piperazinyl, tetrahydrofuryl, tetrahydropyranyl, morphorinyl, azetidinyl, imidazolidinyl, oxazolidinyl,
hexahydropyrrolidinyl, octahydroindolidinyl, octahydroquinolidinyl, octahydroindolyl, and oxo-
derivative thereof which may be substituted.
10. The compound as claimed in claim 1, wherein any one of R5 and R6 is a C1-C6 alkyl
group.

11. The compound as claimed in claim 1, wherein any one of R5 and R6 is a pyridinyl group.
12. The compound as claimed in claim 1, which is selected from
l-Cyclohexyl-N-{4-[(dimethylamino)carbonyl]phenyl}-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide,
l-Cyclohexyl-N-[(4-(4-hydroxy-l-piperidinyl)phenyl)-3-methyl-lH-thieno[2,3-c]pyrazole-5-
carboxamide,
l-Cyclohexyl-N-[3-fluoro-4-(4-hydroxy-l-piperidinyl)phenyl]-3-methyl-lH-thieno[2,3-
c]pyrazole-5-carboxamide,
l-Cyclohexyl-3-methyl-N-[6-(2-oxo-l-imidazolidinyl)-3-pyridinyl]-lH-thieno[2,3-c]pyrazole-
5-carboxamide,
3-Methyl-N-[6-(2-oxo-l-imidazolidinyl)-3-piperidinyl]-l-tetrahydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazole-5-carboxamide,
1 -Cyclohexyl-N- [(1 R)-2-(2,5 -dioxo-1 -imidazolidinyl)-1 -methylethy 1] -3-methy 1-1H-
thieno[2,3-c]pyrazole-5-carboxamide,
1 -Cyclohexyl-N-[3-(2,5-dioxo-1 -imidazolidinyl)-2,2-dimethylpropyl]-3-methyl- 1H-
thieno[2,3-c]pyrazole-5-carboxamide,
3-Methyl-N-[trans5-4-(4-morpholinyl)cyclohexyl]-l-tetrahydro-2H-pyran-4-yl-lH-thieno[2,3-
c]pyrazole-5-carboxamide,

1 -Cyclohexyl-N-[6-(4-hydroxy-1 -piperidinyl)-3-pyridinyI]-3-methyl-1 H-thieno[2,3-
c]pyrazole-5-carboxamide, and
N-[trans-4-(4-Acetyl-l-piperazinyl)cyclohexyl]-3-methyl-l-tetra-hydro-2H-pyran-4-yl-lH-
thieno[2,3-c]pyrazole-5-carboxamide.
13. A compound as claimed in any one of claims 1 to 12 exhibiting PDE7 -
inhibiting property with beneficial therapeutic efficacy in the diseases, like allergic diseases,
inflammatory disease or an immunologic diseases.
14. A pharmaceutical composition comprising a compound as claimed in any one of claims
1 to 12, or a pharmaceutically acceptable salt or a solvate thereof, as an active ingredient and
pharmaceutically acceptable excepients.
15. A method for preparing the thienopyrazole compounds represented by the formula (I):

(wherein, R1, R2, R3 and R4 have the same meanings as defined in claim 1), comprising by reacting
pyrazole derivative of formula (IV):

(wherein, R1, R2 and R3 have the same meanings as defined in claim 1);
with the compound of the formula (III) in the presence of base:

(wherein, R4 has the same meanings as defined in claim 1);
to give the compound of the formula (II):


(wherein, R1, R2, R3 and R4 have the same meanings as defined in claim 1);
and then, treating the resulting compound of formula (II) with base to give thienopyrazole compound of
the formula (I).
16. The method for preparing thienopyrazole compound represented by the formula (I) as
claimed in claim 15, wherein the conversion of the compound of formula (IV) to the compound of
formula (I) is carried out in one pot synthesis without separation of the compound of the frormula (TI).


To provide thienopyrazole derivatives inhibiting PDE 7 selectively,
and therefore, enhance cellular cAMP level. Consequently, the compound
is useful for treating various kinds of disease such as allergic diseases,
inflammatory diseases or immunologic diseases. The compound is
thienopyrazole compound represented by the following formula (I):

[wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a
tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is
a group: -CONR5R6 (in which any one of R5 and R6 is a hydrogen atom) ] .

Documents:

00332-kolnp-2007-assignment-1.1.pdf

00332-kolnp-2007-assignment.pdf

00332-kolnp-2007-correspondence-1.1.pdf

00332-kolnp-2007-correspondence-1.2.pdf

00332-kolnp-2007-form 3-1.1.pdf

00332-kolnp-2007-g.p.a.pdf

0332-kolnp-2007-abstract.pdf

0332-kolnp-2007-claims.pdf

0332-kolnp-2007-correspondence others.pdf

0332-kolnp-2007-description (complete).pdf

0332-kolnp-2007-form1.pdf

0332-kolnp-2007-form3.pdf

0332-kolnp-2007-form5.pdf

0332-kolnp-2007-international publication.pdf

0332-kolnp-2007-pct form.pdf

332-KOLNP-2007-(29-08-2012)-CORRESPONDENCE.pdf

332-KOLNP-2007-(29-08-2012)-OTHERS.pdf

332-KOLNP-2007-(29-08-2012)-PA-CERTIFIED COPIES.pdf

332-KOLNP-2007-ABSTRACT 1.1.pdf

332-KOLNP-2007-AMANDED CLAIMS.pdf

332-KOLNP-2007-ASSIGNMENT.pdf

332-KOLNP-2007-CERTIFIED COPIES(OTHER COUNTRIES).pdf

332-KOLNP-2007-CORRESPONDENCE 1.1.pdf

332-KOLNP-2007-CORRESPONDENCE OTHERS 1.3.pdf

332-KOLNP-2007-CORRESPONDENCE-1.2.pdf

332-KOLNP-2007-CORRESPONDENCE-1.3.pdf

332-KOLNP-2007-CORRESPONDENCE.pdf

332-KOLNP-2007-DESCRIPTION (COMPLETE) 1.1.pdf

332-KOLNP-2007-EXAMINATION REPORT.pdf

332-KOLNP-2007-FORM 1-1.2.pdf

332-KOLNP-2007-FORM 13.pdf

332-KOLNP-2007-FORM 18.pdf

332-KOLNP-2007-FORM 2.pdf

332-KOLNP-2007-FORM 3.pdf

332-KOLNP-2007-FORM 5.pdf

332-KOLNP-2007-GPA 1.1.pdf

332-KOLNP-2007-GPA.pdf

332-KOLNP-2007-GRANTED-ABSTRACT.pdf

332-KOLNP-2007-GRANTED-CLAIMS.pdf

332-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf

332-KOLNP-2007-GRANTED-FORM 1.pdf

332-KOLNP-2007-GRANTED-FORM 2.pdf

332-KOLNP-2007-GRANTED-SPECIFICATION.pdf

332-KOLNP-2007-MARKED COPY-1.1.pdf

332-KOLNP-2007-OTHERS.pdf

332-KOLNP-2007-PA.pdf

332-KOLNP-2007-PETITION UNDER RULE 137.pdf

332-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf

332-KOLNP-2007-SEQUENCE LISTING.pdf

abstract-00332-kolnp-2007.jpg


Patent Number 252786
Indian Patent Application Number 332/KOLNP/2007
PG Journal Number 22/2012
Publication Date 01-Jun-2012
Grant Date 30-May-2012
Date of Filing 29-Jan-2007
Name of Patentee DAIICHI SANKYO CO., LTD.
Applicant Address 9-11, AKASAKA 2-CHOME, MINATO-KU, TOKYO 1078541 JAPAN
Inventors:
# Inventor's Name Inventor's Address
1 MURAFUJI HIDENOBU C/O BIOMEDICAL RESEARCH LABORATORIES, DAIICHI ASUBIO PHARMA CO. LTD., 1-1, WAKAYAMADAI 1-CHOME, SHIMAMOTO-CHO, MISHIMA-GUN, OSAKA 618-8513
2 INOUE HIDEKAZU C/O BIOMEDICAL RESEARCH LABORATORIES, DAIICHI ASUBIO PHARMA CO. LTD. 1-1, WAKAYAMADAI 1-CHOME, SHIMAMOTO-CHO, MISHIMA-GUN, OSAKA 618-8513
3 HAYASHI YASUHIRO C/O BIOMEDICAL RESEARCH LABORATORIES, DAIICHI ASUBIO PHARMA CO. LTD., 1-1, WAKAYAMADAI 1-CHOME, SHIMAMOTO-CHO, MISHIMA-GUN, OSAKA 618-8513
PCT International Classification Number A61K31/4162; A61K31/4164; A61K31/422
PCT International Application Number PCT/JP2005/012208
PCT International Filing date 2005-07-01
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 2004-195836 2004-07-01 Japan